Establishment of a good manufacturing practice-compliant procedure for expansion of therapeutic doses of genetically modified, CAR expressing NK-92 cells for the treatment of ErbB2-positive malignancies by Nowakowska, Paulina
 Establishment of a good manufacturing practice-compliant 
procedure for expansion of therapeutic doses of genetically 
modified, CAR expressing NK-92 cells for the treatment of 
ErbB2-positive malignancies 
 
 
Vom Fachbereich Biologie der Technischen Universität Darmstadt 
zur Erlangung des akademischen Grades 
eines Doctor rerum naturalium 
genehmigte Dissertation von 
Master of Science Paulina Nowakowska 
aus Malbork 
 
1. Referent: Prof. Dr. Beatrix Süß 
2. Referent: Prof. Dr. Adam Bertl 
3. Referent: Prof. Dr. Torsten Tonn 
 
Tag der Einreichung: 13. September 2016 
Tag der mündlichen Prüfung: 18. November 2016 
Darmstadt 2016 
D17 
 
i 
 
Table of contents 
Table of contents ................................................................................................................ i 
1 Introduction ........................................................................................................ 1 
1.1 Natural killer cells .............................................................................................. 1 
1.1.1 Function and distribution .................................................................................... 1 
1.1.2 Maturation of NK cells ....................................................................................... 2 
1.1.3 Target recognition and mechanisms of killing ................................................... 3 
1.1.4 NK cells in cancer immunosurveillance ............................................................. 5 
1.1.5 NK cell lines ....................................................................................................... 6 
1.2 NK-92 ................................................................................................................. 7 
1.2.1 Establishment of the NK-92 cell line ................................................................. 7 
1.2.2 Immunotherapy with parental NK-92 cells ........................................................ 8 
1.2.3 Genetically engineered NK-92 variants ............................................................. 9 
1.2.4 CAR expressing NK -92 cells for cancer immunotherapy ............................... 10 
1.3 Chimeric antigen receptors (CARs) ................................................................. 11 
1.3.1 Design of chimeric antigen receptors ............................................................... 11 
1.3.2 Clinical experience with CAR-modified immune cells .................................... 14 
1.4 ErbB2 ................................................................................................................ 16 
1.4.1 ErbB2 in tumorigenesis .................................................................................... 16 
1.4.2 ErbB2 overexpressing malignancies ................................................................ 17 
1.4.3 ErbB2 as a therapeutic target ............................................................................ 18 
1.5 ErbB2-CAR expressing NK-92 cell line: NK-92/5.28.z .................................. 20 
1.6 Aim of the study ............................................................................................... 22 
2 Materials and Methods ..................................................................................... 24 
2.1 Chemicals ......................................................................................................... 24 
2.2 Cell culture reagents ......................................................................................... 24 
2.3 Buffers .............................................................................................................. 25 
2.4 Antibodies and kits ........................................................................................... 26 
2.5 Cell culture methods ......................................................................................... 27 
  
2.5.1 Cell lines and culture conditions ...................................................................... 27 
2.5.2 Culture media and supplements for expansion of NK-92 and NK-92/5.28.z ... 27 
2.5.3 Cryopreservation solutions ............................................................................... 28 
2.5.4 Gamma irradiation ............................................................................................ 29 
2.5.5 Shipment/injection solutions ............................................................................ 30 
2.5.6 Clinical scale expansion of NK-92/5.28.z ........................................................ 31 
2.6 Establishment of a GMP-compliant master cell bank of NK-92/5.28.z ........... 31 
2.6.1 Cell expansion and cryopreservation ................................................................ 31 
2.7 Potency assays .................................................................................................. 33 
2.7.1 Verification of identity and stability of chimeric antigen receptor expression 33 
2.7.2 FACS-based cytotoxicity assay ........................................................................ 34 
2.7.3 Europium TDA (EuTDA) cytotoxicity assay ................................................... 35 
2.7.4 Cytometric bead array ...................................................................................... 36 
2.7.5 Isolation of human primary NK cells ............................................................... 37 
2.7.6 Human stem cell colony formation assay after NK-cell treatment .................. 38 
2.7.7 Enumeration of ErbB2 molecules on target cells ............................................. 39 
2.7.8 Effect of corticosteroids on cytotoxicity .......................................................... 40 
2.8 Statistical analysis ............................................................................................. 40 
3 Results .............................................................................................................. 41 
3.1 Development of a GMP-compliant manufacturing processes .......................... 41 
3.1.1 GMP-grade culture media ................................................................................ 41 
3.1.2 Serum/plasma-free culture ................................................................................ 42 
3.1.3 Impact of IL-2 concentration on cell proliferation and functionality ............... 44 
3.1.4 Influence of human platelet lysate on NK-92/5.28.z proliferation and 
functionality ...................................................................................................... 45 
3.1.5 Establishment of cryopreservation protocols ................................................... 48 
3.1.6 Impact of gamma irradiation on proliferation and potency of NK-92/5.28.z ... 51 
3.2 Qualification of a GMP-compliant master cell bank of NK-92/5.28.z............. 54 
3.2.1 Testing of manufacturing related parameters ................................................... 54 
3.3 Manufacturing and release testing of therapeutic patient doses, expanded from 
the master cell bank .......................................................................................... 56 
3.3.1 Establishment of shipment/injection solution (excipient) ................................ 56 
  
3.3.2 Stability of NK-92/5.28.z at high cell densities ................................................ 58 
3.3.3 Generation of a therapeutic doses of NK-92/5.28.z ......................................... 59 
3.4 Patient related issues in the context of clinical application .............................. 61 
3.4.1 Impact of corticosteroid treatment on NK-92/5.28.z cytotoxicity .................... 61 
3.4.2 Analysis of soluble factors secreted by target stimulated NK-92 cells, 
NK-92/5.28.z and primary NK cells ................................................................. 62 
3.4.3 NK-92/5.28.z activation depends on ErbB2 expression on target cells. .......... 68 
3.4.4 Impact of NK-92/NK-92/5.28.z on colony forming capacity of peripheral blood 
stem cells .......................................................................................................... 69 
4 Discussion ......................................................................................................... 71 
5 Summary ........................................................................................................... 79 
5.1 Abstract ............................................................................................................. 79 
5.2 Zusammenfassung ............................................................................................ 81 
6 Addendum ........................................................................................................ 84 
6.1 Abbreviations .................................................................................................... 84 
6.2 List of figures .................................................................................................... 87 
6.3 List of tables ..................................................................................................... 88 
7 References ........................................................................................................ 90 
8 Acknowledgements ........................................................................................ 104 
9 Word of honor ................................................................................................ 105 
10 Curriculum Vitae ............................................................................................ 106 
11 Publications and congress contributions ......................................................... 107 
11.1 Publications .................................................................................................... 107 
11.2 Congress contributions ................................................................................... 108 
11.2.1 Oral presentation ............................................................................................. 108 
11.2.2 Poster .............................................................................................................. 108 
1 Introduction 1 
1 Introduction 
1.1 Natural killer cells 
1.1.1 Function and distribution 
Natural killer cells are an important component of the innate immune system; as such, 
they are responsible for the elimination of virally infected, malignant or otherwise 
stressed cells. They do not require prior stimulation to efficiently lyse target cell in 
MHC-independent manner.  In addition, they provide a link between innate and 
adaptive immunity by robust secretion of immunomodulatory cytokines (e.g. IFN-γ and 
TNF-α) and by interacting with dendritic cells. Natural killer cells are large granular 
lymphocytes derived, like all hematopoietic cells, from lineage-undetermined CD34+ 
hematopoietic progenitor cells. They constitute 10 % of peripheral blood lymphocytes 
and can be phenotypically separated from T and B lymphocytes by the absence of 
T- and B-lineage determining surface antigens, such as CD3 and surface Ig and B cell 
receptor expression, respectively. In humans, two major NK cell subsets can be 
distinguished based on the surface markers expression, namely CD56dimCD16+ and 
CD56brightCD16- [1]. The first constitutes the majority of circulating NK cells (> 90 %) 
and possesses robust cytolytic properties, whereas the CD56bright subtype secretes 
abundant amounts of cytokines and is significantly enriched in uterus, liver and 
lymphoid tissue (lymph nodes, spleen, bone marrow, tonsil) where it acquires 
a tissue-specific phenotype and function (tissue-resident CD56bright population) [2] 
(Figure 1.1).  
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Figure 1.1 Distribution of NK cell populations. Adapted from Melsen et al. [2] 
1.1.2 Maturation of NK cells 
Natural killer cells are part of the hematopoietic system and are produced in bone 
marrow; however, the maturation of NK cells is complex and does not occur completely 
in this organ. It has been hypothesized that the CD56bright population is less mature than 
the CD56dim and is highly enriched in secondary lymphoid tissue (SLT) (lymph nodes 
and tonsils). Activation of the SLT-derived CD56bright subsets induced expression of 
receptors characteristic to CD56dim NK cells [3]. Furthermore, a population of pre-NK 
cells described as 34+CD45RA+ was found to be selectively enriched in SLT when 
compared to peripheral blood and bone marrow. High frequencies of these two 
immature NK cell populations, together with IL-15 expression on antigen presenting 
cells (APC), suggest SLT as a site of NK-cell development [4]. Based on recent 
findings the maturation of NK cells may be divided into 5 phases: pro-NK cells from 
bone marrow circulate in the peripheral blood (1) and via high endothelial venules enter 
the lymph node (2) where in the parafollicular space they become activated by APC and 
mature through pro-, pre and iNK cell intermediate stages followed by CD56bright and 
CD56dim (3). Next, mature CD56dim population returns to the periphery via the efferent 
lymph (4) providing the pool of circulating NK cells, whereas the majority of CD56bright 
cells support the tissue-resident population (5) [1] (Figure 1.2). 
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Figure 1.2 Model of human NK cell maturation [1] 
1.1.3 Target recognition and mechanisms of killing 
Natural killer cells express a wide spectrum of inhibitory and activating receptors 
in a germline configuration that enable them to distinguish stressed cells (malignant, 
infected or otherwise injured cells) from normal cells. The leading mechanism 
preventing the elimination of healthy cells is MHC class I induced self-tolerance, where 
inhibitory killer immunoglobulin like receptors (KIRs) recognize and bind classical 
MHC class I molecules (HLA-A, B and C) expressed on every cell in the body except 
RBCs. Upon ligand binding, the KIR sends a strong inhibitory signal that overcomes 
activating ones and prevents NK cell from killing [5]. Upon malignant transformation, 
MHC class I molecules are often downregulated leading to the lack of KIR-mediated 
NK cell inhibition and hence, target cell lysis, in a mechanism called missing-self 
recognition. However, downregulation of MHC class I molecules on the target cell 
in the absence of an activating signal is not sufficient to activate NK cell. 
Conversely, if activating signals derived from stress ligands are strong enough to 
overcome KIR-induced inhibition, the presence of MHC class I molecules on malignant 
cells is not sufficient to inhibit NK cell activation (Figure 1.3), in other words, the 
suppressive action of KIRs is relative [6]. In addition to KIRs, NK cells bear other 
receptors with inhibitory function, namely C-type lectin-like receptors: heterodimeric 
CD94/NKG2A which binds non-classical MHC class Ib ligand (HLA-E) and NKR-P1A 
(CD161) which recognizes non-MHC ligand lectin-like transcript-1. Moreover, a lack 
of inhibition is not sufficient to activate NK cell, implying that the predominant signal 
derived from activating receptors is indispensable for NK cell mediated target cell lysis 
[7,8]. There are numerous NK-cell activating receptors described to date including 
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NKG2D, the group of NCR (NKp30, NKp44, NKp46), NKp80 and DNAM1 [9-12]. 
NKG2D is the best characterized activating receptor and plays a crucial role in cancer 
immunosurveillance via a mechanism called stress-induced self-recognition [13,14]. 
NKG2D recognizes self-proteins selectively upregulated by cells which have undergone 
various forms of stress, e.g. infection with intracellular pathogens, transformation 
or DNA damage. These stress-ligands include MHC class I chain-related proteins A and 
B (MICA and MICB) and a family of UL16-binding proteins (ULBP1-6) both of which 
are not detectable on healthy cells [15,16]. Ligands for natural cytotoxicity receptors 
(NCR) are still poorly characterized, with the exception of B7-H6 which was identified 
as a tumor-specific ligand interacting with NKp30 [17]. In addition to aforementioned 
activating receptors, the mature population of CD56dim NK cells bears FcγRIII (CD16), 
the low affinity receptor binding the Fc portion of IgG bound to opsonized target cells. 
The FcγRIII-IgG interaction initiates a process called antibody-dependent cell-mediated 
cytotoxicity (ADCC), where the NK cell becomes activated and kills the target cell via 
the cytolytic granule-dependent mechanism [7]. Exocytosis of cytolytic granules 
containing perforin and granzymes is the major killing mechanism of NK cells. Upon 
NK cell activation and degranulation, perforin acts as a membrane-disrupting protein 
and forms holes in the membrane of a target cell enabling diffusion of granzyme B. 
Granzyme B is a serine protease, which induces apoptosis via the activation of cellular 
caspases or by direct DNA fragmentation. An alternative mechanism of NK cell 
mediated killing is through surface expression of apoptosis-inducing ligands (FasL, 
TRAIL, TNF-α) for death receptors expressed on the target cell. Death ligand-receptor 
interaction leads to the activation of the caspase-dependent extrinsic apoptosis pathway 
[18]. 
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Figure 1.3 Balance between activating and inhibitory signals regulates the interaction between NK cell 
and target cell. Adapted from Raulet et al [6].  
1.1.4 NK cells in cancer immunosurveillance 
Natural killer cells demonstrate natural innate cytotoxicity against malignant cells 
without the need for prior stimulation or immunization [19,20]. NK cells can eradicate 
tumor cells directly upon stimulatory receptor-mediated activation (discussed in the 
previous chapter) via several mechanisms including: (1) release of perforin/granzyme 
containing granules, (2) expression of ligands for death-receptors, (3) FcγRIII 
associated ADCC and (4) release of effector molecules (e.g. IFN-γ) [21]. 
In addition, abundant production of cytokines, chemokines and growth factors 
by activated NK cells contributes to the development of antitumor adoptive immunity 
by the stimulation of T, B and dendritic cells [7,22]. NK-derived IFN-γ promotes 
tumor-specific antibody production by B cells, activates CD8+ T lymphocytes 
to develop into cytotoxic T cells (CTLs) and stimulates CD4+ T cells to secrete Th1 
cytokines which further supports CTL differentiation and B cell induction [23,24]. 
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Moreover, NK induced tumor cell lysis leads to the release of tumor antigens, which are 
taken up by dendritic cells leading to their maturation and antigen presentation to CTL 
(Figure 1.4) [25]. 
 
 
Figure 1.4 Role of NK cells in antitumor immunity. Adapted from Smyth et al. [13] 
1.1.5 NK cell lines  
There are seven human natural killer cell lines established hitherto: HANK-1, KHYG-1,  
NK-92, NK-YS, NKL, SNK-6, YT, all of which are derived from patients suffering 
from NK/NKT neoplasms (Table 1.1). The cells have a large granular lymphocyte 
(LGL) morphology with pronounced azurophilic granules. Characterization of their 
immunophenotype revealed the immaturity of tested cell lines, defined 
as CD16- CD56+. Only KHYG-1 and NK-92 show significant and reproducible NK 
activity against the MHC-I-negative K562 target cell line. This discrepancy might be 
due to the fact that the other NK-lines have yet reached the maturity stage at which they 
acquire the typical NK cytotoxicity. Five of seven NK cell lines were found to be 
positive for EBV in PCR testing, excluding KHYG-1 and NKL [26]. This could be 
explained by the recent finding showing that, while primary NK cells are an early target 
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for EBV, [27] they may not be necessarily associated with the pathogenesis of the 
malignant disease. 
 
Table 1.1 NK cell lines 
NK-cell line Original disease NK activity against K562 
HANK-1 Nasal-type NK/T-cell lymphoma – 
KHYG-1 Aggressive NK-cell leukemia + 
NK-92 NHL with LGL cells ++ 
NK-YS Nasal NK-cell lymphoma – 
NKL NK-LGL leukemia – 
SNK-6 Nasal NK/T-cell lymphoma – 
YT ALL + thymoma – 
Adapted from Matsuo et al. [26] ALL, acute lymphoblastic leukemia; LGL, large granular lymphocytes; 
NHL, non-Hodgkin’s lymphoma; NK, natural killer-cell; T, T-cell; (−) < 10 % lysis; (+) 
10–50 % lysis; (++) > 50 % lysis. 
1.2 NK-92 
1.2.1 Establishment of the NK-92 cell line 
NK-92 is a continuously growing, IL-2 dependent cell line with the characteristics 
of activated natural killer cells. It was established and further characterized in 1992 
by the Dr. H. Klingemann’s laboratory. The cells were isolated from a 50-year-old male 
patient suffering from an aggressive non-Hodgkin’s NK cell lymphoma. The cells have 
an LGL morphology and the following immunophenotype: CD2+, CD7+, CD11a+, 
CD28+, CD45+, CD54+, CD56++ and CD1-, CD3-, CD4-, CD5-, CD8-, CD10-, CD14, 
CD16-, CD19-, CD20-, CD23-, CD34-, HLA-DR-. The expression of CD25 
(the α subunit of IL-2 receptor) correlates inversely with the IL-2 concentration in the 
culture medium [28]. NK-92 is highly cytotoxic against a broad range of established 
solid (neuroblastoma, ovarian and prostate cancer cell-lines) and hematologic tumor cell 
lines. NK-92 is also cytotoxic against freshly isolated malignant cells of the B- and 
T-lineage [29-31]. High cytolytic activity of NK-92 cells is due to their unique 
repertoire of expressed receptors (Figure 1.5). They express only a few inhibitory 
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receptors (NKG2A/B and ILT-2 ) and lack almost all of the killer-cell immunoglobulin-
like receptors (KIRs) except KIR2DL4, which, unlike other KIR-DL-receptors, has 
activating potential and according to recent findings plays a role in the remodeling 
of the maternal uterine vasculature in the early phase of pregnancy [32,33]. 
Conversely, NK-92 cells express a whole range of activating and co-stimulatory 
receptors (NKp30, NKp46, 2B4, NKG2D/E, CD28) and high levels of perforin and 
granzyme, as well as effector molecules of the TNF-superfamily (FasL, TRAIL, 
TWEAK and TNF-α). However, the lack of CD16 (FcγRIII) expression deprives them 
of the capacity for ADCC (antibody-dependent cell-mediated cytotoxicity), which 
is one of the major NK-cell killing mechanisms. In addition, the absence of CD16 
which is normally expressed by mature peripheral blood NK cells together with lack of 
KIRs, confirms the relative immaturity of NK-92 cells [32]. 
 
 
Figure 1.5 Lack of KIR expression increases the cytolytic activity of NK-92 cells. Based on  Raulet et al. 
[6] and Maki et al. [32] 
1.2.2 Immunotherapy with parental NK-92 cells 
NK-92 is the only natural killer cell line ever to enter clinical trials for in-vivo 
anti-cancer therapy. Two phase I studies with intravenous infusions of up to 1 x 1010/m² 
of body surface area of gamma-irradiated NK-92 cells in patients with advanced 
malignancies have been completed to date. One clinical trial, conducted in Chicago 
(USA) by Arai et al., included 11 patients with renal cell carcinoma (RCC) and 1 patient 
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with melanoma [34]. Another trial, performed in Frankfurt, Germany by Tonn et al., 
recruited a heterogeneous group comprising 15 patients suffering from end-stage solid 
tumors and hematologic malignancies (medulloblastoma, PNET, SCLC, NSCLC, 
colorectal cancer, sarcoma, rhabdomyosarcoma, osteosarcoma, adrenal carcinoma, CLL 
and B-NHL) [35,36]. None of the 27 patients treated in the above mentioned clinical 
trials showed severe toxicity and there was also no evidence of prolonged persistence 
of NK-92 cells. Both initial studies confirmed the feasibility of clinical scale expansion 
and the safety of administrating high numbers of parental NK-92 cells  
(up to 1010 cells/m² BSA). Due to the early phase of the trials, definitive conclusions 
regarding the effectiveness of NK-92 treatment are limited. The impression of some 
beneficial effect was gained in a group of patients, with a partial tumor regression 
reported in 1 patient, stable disease in 5 patients, and a mixed response in 3 more 
patients. Despite the allogenic character of NK-92 cells, antibody formation against 
NK-92 HLA was observed only in a small group of patients; however, this can be 
explained by their immunocompromised status. These are encouraging results 
considering the presumably advanced stages of the targeted diseases and the extensive 
pretreatment of enrolled individuals where NK-92 cell therapy might be considered. 
However, further strategies improving the efficacy of parental NK-92 are necessary. 
1.2.3 Genetically engineered NK-92 variants 
Unlike primary NK cells, NK-92 can be sufficiently engineered, not only with viral 
vectors, but also with physical methods like transfection with mRNA. Post-modification 
cultivation and serial cell sorting allows obtaining highly purified population 
of genetically modified NK-92 cells with the expression of desired transgene [37]. 
To date, NK-92 cells were engineered in a number of ways in order to make them more 
attractive and feasible for cancer immunotherapy. As mentioned previously, NK-92 
cells lack expression of FcγRIII (CD16). Therefore, they are not able to kill via ADCC. 
This issue was solved by Campbell et al. who engineered NK-92 cells by means 
of retroviral transduction to express a high affinity CD16 Fc receptor (NK-92.26.5 cells) 
[38]. Taking into account the limited therapeutic efficacy of monoclonal antibodies 
in the majority of patients with intermediate or low affinity variants of FcγRIII receptor 
[39], therapy combining high affinity NK-92Fc with therapeutic antibodies 
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(e.g. Rituximab and Ofatumumab) might be a promising strategy to fight the cancer 
[40,41]. Currently, the Fc expressing NK-92 variant is successfully being used as 
an effector in a commercialized bioassay panel for screening of monoclonal antibodies 
to determine their contribution to ADCC. Another interesting approach of NK-92 
engineering was presented by Tam et al. and Sahm et al. [42,43]. Both groups 
introduced the ectopic expression of cytokines essential for NK-92 cell proliferation and 
function, namely IL-2 and IL-15 respectively, which resulted in the generation 
of NK-92 variants independent from the exogenous supply of these cytokines.  
1.2.4 CAR expressing NK -92 cells for cancer immunotherapy 
While NK-92 cells seemed to be well tolerated after systemic infusion in early clinical 
trials, the activity of parental NK-92 cells appears to be restricted to certain tumor 
entities and their potency limited. NK-92 cells showed efficacy in vitro and in animal 
models against NK cell sensitive hematologic malignancies, such as AML, B-ALL and 
T-ALL. However, most solid tumors are resistant to NK cell mediated killing [44]. 
It has prompted further development of NK-92 with grafted specificity to tumor 
associated antigens by virtue of expressing chimeric antigen receptors (CAR). 
CAR expressing NK-92 cells specific against tumor antigens, like CD38, CD19, CD20, 
epithelial cell adhesion molecule (EPCAM), GD2, EGFRvIII and ErbB2 (HER2), 
have been generated and proved to be specific and highly cytotoxic against otherwise 
resistant tumor cells [41,45-48].   
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1.3 Chimeric antigen receptors (CARs) 
1.3.1 Design of chimeric antigen receptors 
Chimeric antigen receptors are recombinant molecules which were initially designed 
to redirect and improve the specificity and potency of T lymphocytes against virally 
infected or malignant cells. The first functional chimeric receptor was developed 
by Eshhar et al. in 1989. It consisted of TCR constant domains of α and β chains 
recombined with variable region heavy (VH) and light (VL) chains of anti-TNP 
(2,4,6-trinitrophenyl) antibody (Sp6). Expression of chimeric TCR (cTCR) in cytotoxic 
T cell hybridoma cells resulted in specific antigen recognition in an MHC-independent 
manner and in efficient T-cell activation [49]. Over the past 3 decades, chimeric 
receptors have gained great attention from researchers and a huge amount of effort has 
been invested to make them more attractive for immunotherapy. Currently, there are 
two leading strategies for antigen specific activation of immune effector cells: 
recombinant T-cell receptors (TCRs) and chimeric antigen receptors (CARs). 
The first, however, is associated with serious limitations like patient specific 
HLA-restriction and a risk of mispairing with the endogenous TCRs and thus severe 
autoimmune reactions [50]. In contrast, CARs recognize the specific antigen directly. 
A downside of CARs is their inability to target intracellular targets. 
Historically, the development of CAR has gone through three phases, or generations, 
thus far, determined by the number of signaling molecules included in the receptor 
construct. First generation CARs comprised of an antigen recognition/binding domain, 
hinge region (spacer) and CD3-ζ or FcRγ as a signaling domain. Second generation 
CARs included an intracellular costimulatory domain (e.g. CD28, CD134 or CD137), 
while chimeric antigen receptors of the third generation are equipped with two 
costimulatory molecules in order to further enhance the stimulatory potential  
(Figure 1.6). 
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Figure 1.6 Generations of chimeric antigen receptors. Modified from Abate-Daga et al. [51] 
 
Binding domains 
The most commonly used antigen-binding domain is a scFv (single chain variable 
fragment) molecule. It is generated by joining the light (VL) and heavy chain (VH) 
variable regions of a monoclonal antibody with a linker (Figure 1.7). The major role of 
the antigen binding domain is that it determines CAR specificity and affinity, which is 
consistent with the specificity and affinity of the original monoclonal antibody from 
which the light and heavy chain have been derived. Moreover, positioning of a binding 
epitope within the antigen and its distance from the cell membrane may have an impact 
on the potency of CAR-equipped effector cells. It was observed that CAR-T cells 
recognizing membrane-proximal epitopes of CD22 on malignant B-cells had superior 
anti-leukemic potency than those binding to membrane-distal epitopes [52]. The affinity 
of the scFv binding domain may determine the functional properties of a CAR in the 
context of safety. CARs equipped with low affinity scFv mediate killing of tumor cells 
exhibiting target antigen overexpression, while healthy human tissues expressing low 
or intermediate levels of the same antigen remain intact [53]. 
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Hinge region (Spacer) 
The hinge region can be derived from IgG Fc (CH2-CH3) (Figure 1.7), CD8α or CD28 
and together with transmembrane domains anchors the CAR in the cell membrane and 
provides the link between the antigen-binding domain and intracellular signaling 
domains. Length and flexibility of the hinge region may play an important role in spatial 
orientation of CAR during antigen binding. However, finding an optimal spacer 
is difficult, as the optimal length and structure are unpredictable and can only be 
approached experimentally. To a significant degree, which spacer will work 
is determined by the position of the binding epitope and its proximity 
to the cell membrane which may assist spacer design, provided the two are known [54]. 
 
                            Figure 1.7 Immunoglobulin-derived regions utilized in CAR construct 
 
Signaling domains 
ITAMs (immunoreceptor tyrosine based activation motifs)-containing cytoplasmic 
portions of CD3-ζ or FcRγ are typically used as signaling domains and have been 
shown to be sufficient (first generation CAR) to trigger T and NK cell cytotoxicity and 
cytokine secretion upon antigen binding to the scFv region [48]. What is more, in vivo 
animal models showed improved survival and tumor elimination in mice treated with 
scFv- CD3-ζ CAR T cells [55]. However, the therapeutic potency of 1st generation 
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CARs was disappointing, with limited clinical efficacy, in vivo expansion and 
persistence, fueling further CAR development.   
Costimulatory domains 
To improve the potency of 1st generation CARs, additional costimulatory domains were 
introduced resulting in the development of the 2nd (one costimulatory domain) and 
3rd (two costimulatory domain) generations. Molecules typically used to provide 
costimulatory signals play a role in primary T cell activation. The most commonly 
utilized and clinically explored are CD28 and CD137 (4-1BB) derived domains. 
CD134 (OX 40) and ICOS have also been extensively investigated.  
A secondary signal provided from costimulatory molecules significantly improves 
cytotoxicity, cytokine secretion, persistence and proliferation capacity of effector cells. 
In vivo studies showed superior efficacy of ErbB2-specific 2nd generation chimeric 
receptors comprising CD28 when compared to the first generation CARs with the same 
specificity [56]. In a clinical trial performed by Savoldo et al. CD19-redirected T cells 
bearing CD28-comprising CAR showed a higher proliferation rate and longer 
persistence in vivo, when compared to their first generation counterparts [57]. 
Furthermore, CAR constructs containing CD28 moieties induced higher proliferation 
and cytokine secretion (IFN-γ, TNF-α, IL-2 and IL-10), when compared to CARs 
containing other costimulatory domains [58]. In contrast, introduction of CD137 
resulted in a higher percentage of specific target cell lysis and reduced effector cell 
exhaustion [59]. The 3rd generation CARs, combining early costimulatory molecule 
CD28 and late costimulatory molecule OX40 (CD28/OX40) or 4-1BB (CD28/4-1BB) 
exhibited some improvement with regard to in vivo anti-tumor efficacy and effector cell 
persistence. However, disappointing in vivo data, showing only little benefit over 
2nd generation CARs has thus far limited clinical application of 3rd generation variants 
[60]. 
1.3.2 Clinical experience with CAR-modified immune cells 
To date, numerous clinical trials have been conducted with genetically modified 
immune effector cells equipped with chimeric antigen receptors mainly for cancer 
treatment using second generation CARs comprising CD28 or 4-1BB as costimulatory 
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molecules. The largest studies reported hitherto focused on targeting the CD19 antigen 
for the treatment of B-cell hematologic malignancies: adult and pediatric B-ALL  
(B-cell acute lymphoblastic leukemia), CLL (chronic lymphatic leukemia),  
B-NHL (B-cell non-Hodgkin lymphoma). These studies provided encouraging results 
with a high percentage of patients in CR (complete remission) [61]. However, disease 
relapse is still a problem. CD19 targeted therapies seem to promote the outgrowth 
of CD19-negative leukemic variants, which is probably the primary cause for disease 
recurrence [62]. Immunotherapy employing highly activated effector cells is associated 
with the risk of side effects. Indeed, all aforementioned studies reported similar 
treatment related complications such as: cytokine release syndrome (CRS), 
neurotoxicity and B-cell aplasia. The last complication was expected, considering CD19 
expression by normal B cells. Thus CD19-CAR therapies require lifelong intravenous 
plasma donor-derived immunoglobulin replacement [63]. Cytokine release syndrome 
was the most serious toxicity manifested at different grades from mild 
to life-threatening, which has been strongly correlated with tumor burden [64]. 
CRS is caused by the secretion of great amounts of pro-inflammatory cytokines  
(IL-6, IL-2, IFN-γ and TNF-α) after stimulation of CAR-T cells with malignant targets 
and may occur several hours (severe CRS) to several weeks (mild CRS) post CAR-T 
cell injection. In most cases, CRS is fully reversible with corticosteroids and/or 
anti-cytokine therapy with tocilizumab (IL-6 receptor inhibitor) [65]. Although the main 
focus of CAR-based therapies has been on hematologic malignancies due to the 
availability of a sufficiently specific molecular target, i.e. CD19, there are some early 
phase clinical trials targeting solid tumors-associated antigens. To date, 11 clinical 
studies on solid tumors have been completed and published including: HER2-positive 
sarcoma, neuroblastoma, mesothelioma, colon cancer, ovarian cancer and metastatic 
renal cell carcinoma (RCC) [66]. There was some substantial antitumor efficacy 
observed in the clinical trials including neuroblastoma patients where CAR-T cells 
targeting either CD171 or GD2 antigens were employed without any serious 
treatment-related toxicity [67,68]. Conversely, in a small study, including three RCC 
patients subjected to CAR-T cell therapy targeting CAIX tumor associated antigens, all 
individuals experienced hepatotoxicity [69]. Taken together, the above discussed 
clinical experiences employing CAR-based strategies revealed the great potential of this 
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therapeutic approach. However, there are still many issues to be solved concerning 
safety and long-term efficacy. 
1.4 ErbB2 
1.4.1 ErbB2 in tumorigenesis 
ErbB2, also called HER2 (human epidermal growth factor receptor 2), is a 185 kDa 
protein and transmembrane receptor with tyrosine kinase activity [70]. 
Together with ErbB1 (EGFR), ErbB3 and ErbB4 belong to the epidermal growth factor 
receptor family. All four receptors (ErbB1-4) consist of an extracellular ligand-binding 
domain, a transmembrane domain, and an intracellular signaling domain. 
Despite intensive research, the natural external ligand for ErbB2 is unknown. 
ErbB2 exhibits both ligand-dependent and ligand-independent dimerization activity. 
It can heterodimerize with ligand-bound ErbB1, ErbB3 and ErbB4. In addition, it can 
form signaling-active homodimers in a ligand-independent manner; suggesting its 
constitutively active conformation, when overexpressed at the plasma membrane [71]. 
Receptor dimerization and subsequent phosphorylation of tyrosine residues in the 
receptor cytoplasmic tails activate mitogenic and survival signaling pathways such as 
the MAP kinase and the PI3 kinase pathways. Overexpression of ErbB2 disturbs 
homeostatic receptor interactions and preferentially induces the formation of ErbB2 
complexes containing hetero- and homo-dimers. As a consequence, inappropriate 
activation of downstream signaling can lead to dysregulated cell growth, inhibition 
of apoptosis and in turn to oncogenic transformation [72,73]. The best described 
mechanism of ErbB2 mediated tumorigenesis is deregulation of G1/S control 
by degradation of p27 (CDKN1B; cyclin dependent kinase inhibitor 1B) and 
upregulation of c-Myc and D-cyclins involved in sequestration of p27. Binding of p27 
to cyclin E-CDK2 or cyclin D-CDK4 complexes prevents their activation and thus 
controls the cell cycle progression during the G1 phase. Reduction of the free p27 leads 
to activation of the mentioned complexes, and as a consequence to uncontrolled cell 
proliferation [74]. 
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1.4.2 ErbB2 overexpressing malignancies 
ErbB2 is overexpressed by many tumors of epithelial origin including breast, ovarian, 
stomach, colorectal and aggressive forms of uterine cancer (Table 1.2) In a number of 
malignancies such as osteosarcoma and glioblastoma, ErbB2 overexpression 
is associated with increased disease recurrence and poor patient prognosis [75]. 
A large retrospective study, including 149 samples of glioblastoma patients, was 
performed to assess the prognostic value of ErbB2 in this disease. This study showed 
that the median survival of the patients with ErbB2 overexpressing tumors was shorter 
by half compared to the patients without overexpression (4 months versus 8 months) 
[76]. ERBB2 gene amplification is the most common mechanism leading to protein 
overexpression. The most pronounced example of gene amplification-dependent ErbB2 
overexpression is breast cancer, where concordance rates between these two parameters 
measured by FISH and IHC respectively were between 73 %-98 %. The second 
example is gastric cancer showing concordance between ERBB2 gene amplification by 
FISH and protein overexpression in IHC between 58.5 %-88 % [77]. However, analysis 
conducted in early 90’s on gastric cancer patients by Kameda et al. [78] showed, in 
some cases, high ErbB2 protein expression without gene amplification. Furthermore, in 
the study investigating human glioblastoma cases, expression of the ErbB2 protein was 
present in 54 % (20/37) of analyzed tumor specimens. However, no gene amplification 
was detected [79]. Above findings suggest that ErbB2 overexpression is not always 
gene amplification-dependent and may result from different mechanisms like high 
polysomy of chromosome 17, where the ErbB2 encoding gene is located, epigenetic 
changes or dysregulation of transcriptional or post-transcriptional processes [80].  
 
Table 1.2 ErbB2 overexpression in different types of tumors 
Tumor type Frequency of ErbB2 overexpression (%) 
Medulloblastoma 86.5 [81] 
Endometrial carcinoma 14-80 [82] 
Wilms’ tumor 68.5 [83] 
Glioblastoma 15.4-54 [76,79] 
Inflammatory breast cancer 50 [84]  
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Tumor type Frequency of ErbB2 overexpression (%) 
Osteosarcoma 42.6 [75] 
Gastric cancer 8.2-41.3 [85,86] 
Ovarian cancer 9-32 [87] 
Breast cancer 18 [84] 
Lung cancer 7 [84]  
Pancreatic cancer 4 [84]  
Colon cancer 3 [84]  
1.4.3 ErbB2 as a therapeutic target 
The most important feature of the therapeutic target is its selective expression on 
tumors, but not on normal healthy cells, thereby avoiding on-target, off-tumor toxicities. 
ErbB2 is overexpressed by a variety of malignancies, but its presence on normal tissues 
is limited to few tissues across the body (e.g. cardiomyocytes, respiratory epithelial 
cells) where ErbB2 is expressed at low levels [88]. Moreover, the role of ErbB2 
in tumorigenesis and tumor progression was widely demonstrated. 
All these observations make ErbB2 an attractive target for cancer immunotherapies. 
Indeed, a few ErbB2 targeted treatments have been already approved and investigated 
in early and advanced phase clinical studies with promising results. ErbB2-specific 
therapeutic monoclonal antibodies play the leading role in this field, where trastuzumab  
(marked as Herceptin) is the best investigated one. Mechanism of action of trastuzumab 
includes downmodulation of signaling pathways (PI3K/AKT and ras-Raf-MAPK)  
and inhibition of cell cycle progression by induction of the p27 protein which leads to 
Cdk2 inactivation and G1 arrest. Moreover, trastuzumab prevents ErbB2 ectodomain 
(ECD) cleavage, a phenomenon observed in some breast cancers, which is associated 
with constitutive activation of remaining receptor domains resulting in increased signal 
transduction. In vivo, trastuzumab induces host immune responses by recruiting immune 
effector cells carrying Fc receptors (NK cells, monocytes), which leads to ADCC 
and killing of trastuzumab coated tumor cells [89]. Trastuzumab has been approved 
by the Food and Drug Administration for the treatment of ErbB2-overexpressing, early 
stage and metastatic breast cancer and metastatic gastric/gastroesophageal (GE) junction 
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cancers with ErbB2 overexpression or gene amplification. It has been applied as 
a single-agent therapy or in combination with standard chemotherapy, showing 
significant improvement of overall survival and disease-free survival when compared 
with chemotherapy alone [90]. However, except common side effects like flu-like 
symptoms, nausea and diarrhea, cardiac dysfunction was reported in 3 %-7 % 
of the patients receiving trastuzumab as a single-agent [91]. In a large phase 3, 
international ToGA (Trastuzumab for Gastric Cancer) trial, including ErbB2-positive 
gastric/GE junction cancer patients from 24 countries, trastuzumab was investigated 
as a first-line therapy in combination with chemotherapy. Trastuzumab-containing 
regimens significantly improved median overall survival (mOS=13.8 months)  
and progression free survival (PFS=6.7 months) of the patients, when compared to 
the group treated with chemotherapy alone (mOS=11.1 months; PFS=5.5 months). 
As expected, analysis of ErbB2 status suggested that trastuzumab-containing treatment 
was more efficient in patients with high expression of this protein (mOS=16 months). 
Importantly, the incidence rates of cardiac adverse events or grade 3/4 adverse events 
did not differ between the trastuzumab plus chemotherapy and chemotherapy alone 
treated group [92].  
There are more approved therapies under evaluation, specifically targeting ErbB2 
protein, including the monoclonal antibody pertuzumab (trade name Perjeta), the small 
molecule tyrosine kinase inhibitor lapatinib and a novel antibody–drug conjugate 
trastuzumab emtansine (T-DM1; marked as Kadcyla). Pertuzumab binds 
an extracellular dimerization domain of ErbB2 (domain II), a moiety different from that 
of trastuzumab binding (domain IV), by which it prevents dimerization of ErbB 
receptors and inhibits downstream signaling (Figure 1.8A). Like trastuzumab, 
pertuzumab causes ADCC mediated killing of antibody coated tumor cells.  Lapatinib is 
a dual tyrosine kinase inhibitor binding to ATP-binding sites of ErbB1 (EGFR) and 
ErbB2 tyrosine kinase in the cytoplasmic domain, preventing phosphorylation and 
subsequent activation of signaling pathways (Figure 1.8B). T-DM1 is a combination of 
trastuzumab (T) with the cytotoxic agent emtansine (DM-1), which is specifically 
derived to target cells by means of trastuzumab to ErbB2 overexpressing cells and 
subsequent internalization. DM1, once entering the tumor cell, prevents microtubules 
polymerization and thereby inhibits tumor cell division (Figure 1.8C). 
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Currently, efficacy and safety of all mentioned therapeutic agents in combination with 
each other and with standard chemotherapy are under evaluation in numerous clinical 
trials mainly in breast cancer and gastric cancer patients [93]. 
 
 
Figure 1.8 Mechanism of action of ErbB2 targeting therapeutic agents. Modified from Park et al. [93] 
1.5 ErbB2-CAR expressing NK-92 cell line: NK-92/5.28.z 
While T-cells are certainly attractive vehicles to carry CARs in the therapy 
of malignancies, NK cells do offer certain advantages over T cells. The most prominent 
is that NK cells do not cause GvHD and can be used in an allogeneic fashion [94]. 
In the case of the immortalized NK-92 cell line, this feature will enable further 
development of “off-the-shelf” based cell therapies significantly simplifying a complex 
cell therapy process as genetic engineering. The first CAR expressing NK-92 cells were 
generated almost 15 years ago. These cells were highly effective against ErbB2 positive 
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breast and ovarian cancer cells in vitro and in vivo [41]. Based on these promising 
results, ErbB2-CAR expressing NK-92 cells were regenerated, following 
GMP-compliant procedures, in order to make them suitable for clinical evaluation. 
Parental NK-92 cells from a FDA-licensed master cell bank were transduced with 
lentiviral vector encoding a humanized, second generation CAR construct, comprising 
an ErbB2-specific single chain variable fragment (scFv) derived from the FRP5 
monoclonal antibody, CD28 as a costimulatory molecule and the CD3-ζ signaling 
domain (5.28.z) (Figure 1.9) [95]. The thusly generated NK-92/5.28.z cell line exhibited 
high specific cytotoxicity toward ErbB2-expressing tumor targets which were resistant 
to parental NK-92 cells. In vivo antitumor efficacy was extensively tested in several 
established mouse models of orthotopic human GBM, renal cell carcinoma and breast 
carcinoma xenografts, showing specific homing of NK-92/5.28.z cells to tumor sites, 
significant reduction of metastases and, in some cases, complete tumor clearance [96]. 
 
 
 
Figure 1.9 ErbB2 specific 2nd generation CAR expressed by NK-92/5.28.z [95] 
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1.6 Aim of the study 
Treatment of cancer patients with innovative cellular products is preceded by 
the tedious translation of laboratory scale experiments and upgrading research-grade 
procedures to clinically applicable, robust and reproducible processes compliant with 
GMP guidelines and feasible for clinical-scale production. Generation of the cellular 
product of NK-92/5.28.z planned in this study is based on concept applied by 
Tonn et al. for parental NK-92 cells [35], where a qualified GMP-compliant master cell 
bank serves as a platform for further expansion and generation of individual therapeutic 
doses. While NK-92/5.28.z cells were generated under GMP compliant conditions,  
by means of lentiviral transduction, any further development for clinical application will 
involve the establishment and qualification of a GMP-compliant master cell bank. 
One major hurdle in NK-92 based therapies is the general sensitivity of NK-92 cells and 
their derivative to cryopreservation and thawing. Other obstacles are the demand of this 
cell line for complex cell culture media and its IL-2-dependent proliferation and 
potency. Therefore, the overall aim of this thesis was to develop a process which will 
allow the generation of a safe and efficient cellular therapy product of NK-92/5.28.z 
cells following standardized procedures in order to be able to support a subsequent 
phase I/II clinical trials in ErbB2-overexpressing malignancies. The first task of this 
study was the establishment of GMP-grade culture and of cryopreservation protocols 
optimal for efficient growth and satisfactory post-thaw recovery of NK-92/5.28.z cells 
in order to generate a GMP-compliant master cell bank. In addition, it was necessary to 
develop adequate methods to enable determination and monitoring of the identity 
(CD56 expression, lack of CD16 and CAR expression) and functional properties 
(retargeted killing of ErbB2+ targets and natural killing ability against K562 cells)  
of the NK-92/5.28.z cell line to control the quality of the cells during manufacturing 
processes and as a final product. Since the clinical application of NK-92/5.28.z cells 
will most probably include γ-irradiation to prevent in vivo expansion, different 
irradiation doses were analyzed in order to find a dose which will inhibit proliferation 
but retain cell potency. The establishment of a robust manufacturing process yielding 
high numbers (up to 5 x 109) of potent NK-92/5.28.z cells was of major interest. 
In order to achieve this goal, the growth kinetic of CAR-expressing NK-92 cells had to 
be investigated to determine an expansion schedule and optimal harvest point of 
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individual patient doses. Other issues associated with clinical application, including 
final product formulation: the maximal cell density at which effector cells retain their 
viability and potency and optimal shipment/injection solution, were addressed in this 
study in order to obtain a stable cellular therapy product with clinically relevant 
shelf-life. Considering the fact that a patient’s premedication may attenuate natural 
killer cell cytotoxicity [97], it was reasonable to test the impact of corticosteroids used 
in cancer patients on the potency of NK-92/5.28.z cells. Since CAR-T cell therapies 
were associated with cytokine release syndromes [98], it was of importance to 
determine the profile of soluble factors secreted by target stimulated NK-92/5.28.z cells. 
To further explore the safety aspect, the influence of NK-92/5.28.z cells on normal 
human hematopoietic stem cells was tested with colony forming assay. 
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2 Materials and Methods 
2.1 Chemicals 
Table 2.1:  List of chemicals 
Chemicals Company 
7-AAD (7-Amino-Actinomycin D) BD PharmingenTM, San Jose, CA, USA 
Calcein violet AM Molecular Probes Invitrogen, Karlsruhe, 
Germany 
DMSO WAK Chemie Medical, Steinbach, Germany 
Lymphocyte separation medium BioWhittaker, Lonza, Basel, Switzerland 
HEPES Carl Roth, Karlsruhe, Germany 
Probenecid Alfa Aesar, Karlsruhe, Germany 
Recombinant Human ErbB2/Her2 Fc 
Chimera  
R&D systems, Minneapolis, USA 
Hydrogen peroxide Allied Signal, Morristown, USA 
2.2 Cell culture reagents 
Table 2.2: List of cell culture reagents 
Reagents Company 
Accutase GE Healthcare, Pasching, Austria 
CellGro SCGM (Stem Cell Growth 
Medium) 
CellGenix, Freiburg, Germany 
CryoStor CS10 medium BioLife Solutions, STEMCELL 
Technologies, Vancouver, Canada 
DMEM-GlutaMaxTM (Dulbecco’s 
Modified Eagle Medium (High Glucose) 
Gibco Life Technologies, Carlsbad, USA 
 
FBS (Fetal Bovine Serum) Biochrom, Berlin, Germany 
Human plasma German Red Cross, Blood donation 
service, Frankfurt am Main, Germany 
Human serum albumin 200g/L Baxter, Deerfield, Illinois, USA 
PLTMax (hPL 1) Mill Creek Life Sciences, Rochester, USA 
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Reagents Company 
Human platelet lysate 2 (hPL 2) German Red Cross, Blood donation 
service, Frankfurt am Main, Germany 
IL-2 (Proleukin) Novartis Pharma, Nürnberg, Germany 
PBS (Dulbecco’s Phosphate Buffered 
Saline without Ca2+ and Mg2+) 
Gibco Life Technologies, Carlsbad, USA 
 
Penicillin-Streptomycin Gibco Life Technologies, Carlsbad, USA 
RPMI-1640-GlutaMaxTM (Roswell Park 
Memorial Institute Medium) 
Gibco Life Technologies, Carlsbad, USA 
 
StemMACS HSC-CFU lite with Epo MiltenyiBiotec, Bergisch Gladbach, 
Germany 
Trypan blue Sigma-Aldrich, St. Louis, USA 
X-Vivo 10 without Phenol red and 
Gentamicin 
Lonza, Basel, Switzerland 
 
X-Vivo 10 without Phenol red and 
Gentamicin contains recombinant 
transferrin 
Lonza, Basel, Switzerland 
 
2.3 Buffers 
Table 2.3:  List of buffers 
Buffers Composition 
FACS buffer 0.5 % FBS 
in 1x PBS 
EuTDA assay buffer 1 % Probenecid 
2 % HEPES 
in 1x PBS 
HEPES Gibco Life Technologies, Carlsbad, USA 
PAGGS-M based transport buffer 1 % HSA 
in 1 x PAGGS-M 
SAG-M based transport buffer 1 % HAS 
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in 1x SAG-M  
PBS/EDTA based transport buffer 1 % HSA 
in 1x PBS/EDTA 
SSP based transport buffer 1 % HSA 
in 1x SSP  
2.4 Antibodies and kits 
Table 2.4:  List of antibodies 
Antibody Company Clone Dilution factor 
FACS (fluorescence-activated cell sorting) 
FITC-labeled mouse anti-human CD16 BD Biosciences NKP15 1:50 
PE-labeled mouse anti-human CD56 BD Biosciences NCAM16.2 1:100 
APC-conjugated mouse anti-human 
CD56 
BD Biosciences B159 1:30 
V450-labeled mouse anti-human CD3 BD Horizon UCHT1 1:20 
APC-conjugated goat anti-human IgG 
F(ab’)2 
Jackson 
ImmunoResearch 
Polyclonal 1:200 
PE-labeled mouse anti-human ErbB2 R&D Systems 191924 1:20 
Isotype controls    
Mouse IgG2B isotype control-PE R&D Systems 133303 1:20 
Table 2.5:  List of kits 
Kit Company 
QuantiBRITETMPE* Becton Dickinson 
EasySepTM Negative Human NK cell Enrichment kit STEMCELL Technologies 
BD Cytometric Bead Array (CBA) Human Soluble 
Protein Master Buffer Kit 
BD Biosciences 
BD CBA Flex Set (human soluble proteins) 
 CD178 (Fas ligand) Flex Set 
 G-CSF Flex Set 
 GM-CSF Flex Set 
 TNF Flex Set 
 IFN-γ Flex Set 
BD Biosciences 
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Kit Company 
 IL-2 Flex Set 
 IL-6 Flex Set 
 IL-8 Flex Set 
 IL-10 Flex Set 
 MIP-1α Flex Set 
Foxp3/Transcription Factor Fixation/Permeabilization 
Concentrate and Diluent 
eBioscience 
DELFIA EuTDA Cytotoxicity Reagents kit Perkin Elmer 
 
2.5 Cell culture methods 
2.5.1 Cell lines and culture conditions 
Human MDA-MB-453, MDA-MB-468, (DSMZ, Deutsche Sammlung von 
Mikroorganismen und Zellkulturen), MDA-MB-361, HepG2 and G55T2 (ATCC) were 
maintained in DMEM, high glucose, containing GlutaMAX (Life Technologies), 
the erythroleukemic K562 cells (DSMZ) were cultured in RPMI 1640 medium 
containing GlutaMAX (Life Technologies), both media were supplemented with 10 % 
of heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin 
(Life Technologies). For routine maintenance, NK-92 cells as well as NK-92/5.28.z 
were cultured in X-Vivo 10 medium containing recombinant transferrin (Lonza, Basel, 
Switzerland) supplemented with 500 U/ml of IL-2 (Proleukin; Novartis Pharma, 
Nürnberg, Germany) and 5 % of heat-inactivated human plasma (German Red Cross, 
Blood Donation Service, Baden-Württemberg–Hessen, Frankfurt, Germany) unless 
otherwise specified in the respective experiment. NK cells were split twice a week and 
kept in culture at a concentration ranging from 5 x 104 cells/ml, defined as seeding 
concentration, to 5 x 105 cells/ml. 
2.5.2 Culture media and supplements for expansion of NK-92 and NK-92/5.28.z 
To establish optimal culture protocols enabling efficient expansion of NK-92/5.28.z 
cells, the following GMP-grade culture media were tested: 
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 X-Vivo 10 w/o phenol red and Gentamycin containing human holo-Transferrin 
(Lonza #BE04-743Q) 
 X-Vivo 10 w/o phenol red and Gentamycin containing recombinant Transferrin 
(Lonza #BE02-055Q) 
 CellGro (SCGM) (CellGenix) 
In addition, diverse culture conditions (serum-free culture, human serum substitutes, 
and different IL-2 concentrations) were assessed for their capability to optimally 
support proliferation of NK-92/5.28.z cells. To test the above mentioned variables, cells 
were seeded at an initial concentration of 5 x 104/ml in triplicates in vented T75 cell 
culture flasks (Greiner BioOne) in a combination of media supplements as indicated 
in the respective experiment. Large-scale expansion was conducted in gas-permeable 
VueLife750-C1 culture bags (CellGenix). Cell number and viability were measured 
using either Trypan blue exclusion assay or NucleoCounter NC-100 (Chemometec, 
Denmark) according to manufacturer’s protocol. 
2.5.3 Cryopreservation solutions 
Human serum albumin (HSA) (200g/L; Baxter), as well as combination of HSA with 
commercially available CryoStor CS10 medium at 1:1 ratio (BioLife Solutions, 
STEMCELL Technologies) were used as a base cryopreservation solution to freeze 
parental NK-92 and NK-92/5.28.z. Human serum albumin was supplemented with 
various amounts of DMSO to yield final concentrations of 5-15 % DMSO. NK-92 and 
NK-92/5.28.z cells from exponentially growing culture were harvested 
by centrifugation in conical, 50 ml Falcon tubes (Greiner Bio-One, Kremsmünster, 
Austria) at 1800 rpm, for 10 min at RT. Subsequently, supernatant was discarded and 
the cell concentration was adjusted to 1 x 107 cells/ml in respective base medium  
(HSA, CryoStor, HSA + CryoStor). 500 µl of cell suspension (5 x 106 cells) was 
transferred to 1 ml cryovial (Greiner Bio-One, Kremsmünster, Austria) and filled up to 
1 ml with respective cryopreservation base medium supplemented with DMSO. 
Samples were performed in triplicates. Cryovials were transferred into 
isopropanol-based freezing boxes and stored overnight at -80 °C. Next day cells were 
placed in a liquid nitrogen tank and stored in the vapor phase at < -145 °C. 
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After 3 weeks, cells were thawed rapidly in a water bath pre-warmed to 37 °C. Next, the 
content of each cryovial was gently resuspended in 10 ml of heat inactivated human 
plasma pre-cooled to 4 °C and centrifuged at 2000 rpm, for 10 min at RT. Supernatant 
was discarded and cell pellet was resuspended in 20 ml of pre-warmed, complete 
culture medium and transferred to a T75 culture flask (Greiner Bio-One, Kremsmünster, 
Austria). Subsequently, cell concentration and viability were determined using trypan 
blue exclusion assay according to manufacturer’s protocol. Measurement was repeated 
after 24 hours. Additionally, the influence of cryopreservation solution supplemented 
with 20 % of conditioned medium on post-thaw recovery and cell growth of 
NK-92/5.28.z was investigated. NK-92/5.28.z cells were seeded at a concentration of 
7 x 104 cells/ml in complete X-Vivo 10 rTF medium and cultured for 72 hours. 
After this time, the cell suspension was transferred to a 50 ml falcon tubes and 
centrifuged at 4000 rpm for 15 min at RT. Supernatant was harvested, supplemented 
with IL-2 to a final concentration of 500 U/ml and used as conditioned medium in 
subsequent experiments. NK-92/5.28.z cells from exponentially growing culture were 
harvested and frozen in triplicates at a concentration of 5 x 106 cells/ml in 1 ml 
cryovials. Cryopreservation medium consisted of human serum albumin supplemented 
with 20% of conditioned medium and 7.5 % of DMSO. NK-92/5.28.z cells were frozen 
using the ThermoForma computer controlled freezing device with a temperature drop 
rate of 1 Kelvin/min down to -100 °C and subsequently placed in a cryostorage tank. 
After 7 days, cells were thawed and viability and cell concertation were analyzed as 
described above. 
2.5.4 Gamma irradiation 
Cells were exposed to various irradiation doses ranging from 0-30 Gy (0 Gy, 2 Gy, 
5 Gy, 10 Gy and 30 Gy) using a cesium source with a dose rate of 3.75 Gy/min 
(IBL 437C blood irradiator). After exposure, cells were centrifuged (1800 rpm, 10 min, 
RT) and washed in 20 ml of complete X-Vivo 10 rTF medium. After centrifugation, 
supernatant was discarded and cells were seeded in 20 ml of complete X-Vivo 10 rTF 
medium at an initial concentration of 1 x 105/ml and cultured for 120 hours in a cell 
culture incubator. Cell proliferation, viability, specific cytotoxicity and natural killing 
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ability of parental and genetically modified NK-92 cells were tested at indicated time 
points post-irradiation. 
2.5.5 Shipment/injection solutions 
Stability of NK-92/5.28.z was investigated in 6 buffered solutions. Testing included 4 
solutions routinely used for storage/preparation of blood products: saline-adenine-
glucose-mannitol hypertonic solution (SAG-M; 376 mOsm/l; Fresenius Kabi, 
Bad Homburg, Germany) and phosphate-adenine-glucose-guanosin-saline-mannitol 
isotonic solution (PAGGS-M; 285 mOsm/l; Fresenius Kabi, Bad Homburg, Germany) 
both erythrocyte storage buffers, SSP (Macopharma, Langen, Germany) a thrombocyte 
additive solution and PBS/EDTA (MiltenyiBiotec, Bergisch Gladbach, Germany) used 
for preparation of stem cell products, all buffers were supplemented with 1 % of human 
serum albumin. In addition, pure HSA (200 g/1L) and X-Vivo 10 rTF medium as pure 
or complete (supplemented with 5% heat inactivated human plasma and 500 U/ml IL-2) 
formulation were included in the analysis. Cells were expanded in VueLife 750-C1 
culture bags prefilled with complete culture medium, harvested by centrifugation and 
irradiated with 10 Gy. After irradiation, the cell suspension was centrifuged (2000 rpm, 
10 min, RT) and washed with 20 ml of pure X-Vivo 10 rTF medium. 
After centrifugation, supernatant was discarded and cell concentration was adjusted to 
5 x 106 cells/ml in respective buffer. Non-irradiated cells stored in complete 
X-Vivo 10 rTF were included as controls. Cell suspension was transferred to 
CryoMACS bags and stored under ambient conditions (temperature range: 22-22.5 °C) 
for 48 hours. Viability and pH measurements were performed in duplicates over the 
storage period using the NucleoCounter NC-100 (Chemometec) device and 
Microprocessor pH Meter pH 211 (Hanna instruments), respectively. Samples were 
analyzed in duplicates in 3 independent experiments. Subsequently, the analysis of 
stability was extended to cell potency. Specific cytotoxicity of NK-92/5.28.z cells in 
suspensions prepared as described above in pure X-Vivo 10, pure HSA and PAGGS-M 
+ 1 % HSA was analyzed in quintuplicates using EuTDA assay (described in chapter 
2.7.3) after 6-hour storage under ambient conditions. 
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2.5.6 Clinical scale expansion of NK-92/5.28.z 
Clinical scale expansion was conducted in gas-permeable VueLife 750-C1 culture bags 
(CellGenix), which proved to be optimal (data not shown). NK-92/5.28.z cells were 
inoculated into culture bags prefilled with 1000-2000 ml of X-Vivo 10 medium 
containing recombinant transferrin, supplemented with 5 % of heat inactivated human 
plasma and 500 U/ml of IL-2 at a concentration of 5 x 104 cells/ml. After 5 days, cells 
were harvested at a concentration of 5-6 x 105/ml by centrifugation (2000 rpm, 20 min 
RT, R9 acceleration/R3 breaks) in 400-ml transfer bags (Fenwal), γ-irradiated with 
10 Gy, washed with fresh X-Vivo 10 rTF + 100 U/ml IL-2 medium, concentrated by 
centrifugation and transferred to CryoMACS bag (MiltenyiBiotec, Bergisch Gladbach, 
Germany) serving as a final bag. After cell counting performed with Sysmex XT-1800i 
(Sysmex, Kobe, Japan), cell concentration in the final product was adjusted to 
5 x 107/ml in X-Vivo 10 containing recombinant transferrin, supplemented with 
100 U/ml of IL-2. Three independent final products were generated and tested in terms 
of cell viability, CAR expression and potency. Additionally, sterility testing for aerobic 
and anaerobic bacteria was performed using the BacT/ALERT system, presence of 
mycoplasma was tested using the PCR-based Intego Mycoplasma Detection Kit and 
endotoxin level was measured by Endosafe PTS, all used for routine testing of blood 
products. 
2.6 Establishment of a GMP-compliant master cell bank of NK-92/5.28.z 
2.6.1 Cell expansion and cryopreservation 
Generation of master cell bank (MCB) was performed in a class 100 cleanroom in the 
GMP facility of the Institute for Transfusion Medicine in Frankfurt, with qualified 
starting materials only. The manufacturing process consisted of three main phases:  
(i) thawing and recovery, (ii) expansion in cell culture bags, (iii) harvesting and 
freezing. Genetically modified NK-92 cells were thawed and after recovery and 
a pre-expansion phase seeded at a concentration of 1-3 x 104 cells/ml in 10 
VueLife 750-C1 culture bags prefilled with 1.5 L of X-Vivo 10 containing recombinant 
transferrin supplemented with 5 % of heat inactivated human plasma and 500 U/ml of 
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IL-2. Sterility testing for aerobic and anaerobic bacteria was performed using 
the BacT/ALERT system. After 50 days NK-92/5.28.z cells were harvested with 
the concentrations of 7-13 x 105 cells /ml considered as optimal and confluent cell 
density. 10 VueLife 750-C1 bags were connected one by one with 4 transfer bags 
(Fresenius Kabi, Bad Homburg, Germany) using a sterile tubing welder (TSCD II; 
Terumo, Tokio, Japan) and 15 liters of cell suspension were transferred by means of 
a peristaltic pump (ISMATEC). Transfer bags containing cell suspension were 
centrifuged (1800 rpm, 20 min RT, R9 acceleration/R9 breaks) and supernatant was 
pressed out using a manual plasma extractor (Baxter laboratories) into an empty transfer 
bag. One bag with supernatant was kept to serve as a conditioned medium in the end of 
procedure. Transfer bags were connected using a sterile tubing welder (Terumo TSCD 
II) and cell pellets were pooled into 1 transfer bag. Cells were resuspended in 100 ml of 
PBS/EDTA solution and incubated in the refrigerator for 15 min in order to avoid 
clumping. Subsequently, the cell suspension was centrifuged (1800 rpm, 20 min RT, 
R9 acceleration/R9 breaks) and resuspended in conditioned medium. 500 µl of cell 
suspension was transferred into 1 ml cryovial (Greiner Bio-One) to which were added 
500 µl of HSA supplemented with 15% of DMSO. 200 vials containing in total 
5 x 109 cells (approximately 2.5 x 107cells/vial) were frozen in cryopreservation 
solution consisting of 50 % HSA, 50% of conditioned medium and DMSO at a final 
concentration of 7.5 %. Freezing was performed using a ThermoForma computer 
controlled freezing device with a temperature drop rate of 1 Kelvin/min down to 
-100 °C (Figure 2.1). Subsequently, the vials were placed into the vapor phase of liquid 
nitrogen at < -145 °C.  
 
Figure 2.1 Generation of a master cell bank 
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2.7 Potency assays 
2.7.1 Verification of identity and stability of chimeric antigen receptor expression 
Identity and CAR expression stability of NK-92/5.28.z cells, which were kept in 
maintenance culture for up to 12 months, were monitored monthly using a two-step 
FACS staining. Parental NK-92 cells were included as a control. 1 x 105 cells/sample 
from an exponentially growing culture were transferred to FACS tubes and centrifuged 
(1500 rpm, 5 min, RT). Supernatant was discarded and 2 ml of PBS + 0.5 % FCS were 
added to each tube and centrifuged again. After discarding the supernatant 1 µg/sample 
of rhErbB2/Fc fusion protein (R&D Systems) was added and samples were 
incubated for 30 min on ice. Afterwards, cells were washed twice with 2 ml of FACS 
wash buffer (PBS + 0.5 % FCS) and 5 µl/sample of goat anti-human IgG F(ab’)2-APC 
(Jackson ImmunoResearch) was added forming FACS-detectable complexes with 
fusion protein bound to CAR expressed by NK-92/5.28.z cells (Figure 2.2). 
To confirm an immunophenotype characteristic for NK-92 cell line 
(CD16neg, CD56bright) and to estimate cell viability, 1µl/sample of anti-human CD56-PE 
(BD Biosciences), 2 µl/sample of anti-human CD16-FITC (BD Biosciences) and 
5 µl/sample of 7-AAD (BD Pharmingen) were included into the staining. Samples were 
incubated for 15 min on ice and washed twice with 2 ml per tube of FACS wash buffer. 
After the last centrifugation, supernatant was discarded and the pellet was resuspended 
in 250 µl of Cytofix solution (BD Bioscience). Samples were incubated for 15 min 
at 4 °C protected from light and washed with 2 ml of FACS wash buffer. 
After centrifugation and decantation of supernatant, the cell pellet was resuspended in 
400 µl of FACS wash buffer. Analysis was performed in triplicates. Measurement and 
data analysis were performed using FACSCanto II flow cytometer equipped with 
FACSDiva software. 
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Figure 2.2 Principle of CAR staining 
2.7.2 FACS-based cytotoxicity assay 
Cytotoxicity of NK-92/5.28.z and parental NK-92 cells toward tumor targets  
(MDA-MB-453, MDA-MB-468 and K562) was analyzed using a FACS-based killing 
assay. Adherent target cells were harvested using Accutase solution (GE Healthcare, 
Pasching, Austria) and washed in complete DMEM culture medium  
(centrifugation 1400 rpm, 5min, RT). The supernatant was discarded and the 
concentration of target cells was adjusted to 1 x 106 cells/ml for subsequent staining 
with calcein violet AM (Molecular Probes, Invitrogen, Karlsruhe, Germany). 
Briefly, calcein violet AM powder was resuspended in DMSO and 1.5 µl of calcein 
violet solution per 1 ml of target cell suspension was added. Target cells were incubated 
for 30 min on ice, centrifuged (1400 rpm, 5min, RT) and washed twice with 20 ml of 
complete DMEM medium. After the last centrifugation, supernatant was discarded and 
the concentration of target cells adjusted in complete X-Vivo 10 rTF to 5 x 105 cells/ml. 
NK-92/5.28.z and parental NK-92 were harvested by centrifugation (1600 rpm, 5 min, 
RT) and resuspended in complete X-Vivo 10 rTF. Effector cells were counted and 
concentration was adjusted to 5 x 106 cells/ml in complete X-Vivo 10 rTF. 
Co-incubation of target and effector cells was performed in triplicates at a 10:1 effector 
to target (E:T) ratio in 96-well Ultra Low Attachment plates (Corning, New York, 
USA). 100 µl/well of target cell suspension (5 x 104 cells) and 100 µl/well of effector 
cells (5 x 105 cells) were pipetted into wells and incubated for 2 hours in a cell culture 
incubator. To determine spontaneous lysis, target cells were incubated in assay medium 
without effector cells. After incubation time the content of each well was transferred to 
an appropriately labeled FACS tube. Cells were labeled with 7-AAD (BD Pharmingen) 
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viability dye at 0.5 µg/test and 3 µl/sample of anti-human CD56-APC (BD Biosciences) 
and incubated for 15 minutes on ice. Samples were measured with the FACSCanto II 
flow cytometer and data were analyzed using FACSDiva software version 6.1.3. 
Percentage of 7-AAD and calcein violet AM double positive cells measured in the test 
tube were considered as sample lysis and used for calculation of specific cytotoxicity 
according to the equation:  
% Specific cytotoxicity = [(sample lysis - spontaneous lysis)/(100 - spontaneous lysis)] 
x 100 
2.7.3 Europium TDA (EuTDA) cytotoxicity assay 
In addition to a FACS-based killing assay, europium release cytotoxicity assay was 
established. Adherent target cells were harvested and washed as described in chapter 
2.7.2. Target cells were counted and concentration was adjusted to 1 x 106 cells/ml. 
Subsequently, loading of target cells with the acetoxymethyl ester of the fluorescence 
enhancing ligand (BATDA) (Perkin Elmer) was performed. A volume of 1µl of 
BATDA reagent per 1 x 106 of target cells was added. Target cells were incubated for 
30 min at 37 °C in cell culture incubator, thereafter cells were pelleted by centrifugation 
(1100 rpm, 4 min, RT), washed twice with 20 ml of washing buffer (PBS + 2.5 mM 
Probenecid + 20 mM HEPES) and counted using NucleoCounter NC-100 
(Chemometec) device. Target cell concentration was adjusted to 1 x 105 in assay 
medium (X-Vivo 10 rTF + 5 % of human plasma + 500 U/ml of IL-2 + 2.5 mM 
Probenecid). NK-92/5.28.z and parental NK-92 were harvested by centrifugation  
(1700 rpm, 5 min, RT), supernatant was discarded and the cell pellet was resuspended 
in assay medium. Effector cells were counted and concentration was adjusted to 
1 x 106 cells/ml in assay medium. Co-incubation of target and effector cells was 
performed in triplicates at 10:1 effector to target (E:T) ratio in 96-well V-bottom plate 
(Greiner Bio-One, Kremsmünster, Austria): 50 µl/well of target cell suspension 
(5 x 103 cells) and 50 µl/well of effector cells (5 x 104 cells) were pipetted into wells and 
incubated for 2 hours in a cell culture incubator. To determine spontaneous lysis, 
50 µl/well of target cells were incubated with 50 µl/well of assay medium without 
effector cells. To determine the background derived from BATDA reagent, target cell 
2 Materials and Methods 36 
suspension was centrifuged and 50 µl/well of supernatant was mixed with 50 µl/well of 
assay medium. Maximal lysis was assessed by treatment of target cells with 20 µl/well 
of Lysis buffer (Perkin Elmer) mixed with 30 µl/well of assay medium. After incubation 
time, 20 µl of supernatant was transferred from each well to a 96-well Flat bottom Optic 
Plate. Next, 200 µl of europium solution was added to each well and the plate was 
incubated for 15 min on a rocker-shaker protected from light. After this time, 
measurement of the fluorescent signal using Victor X4 (Perkin Elmer) set on Delfia 
Europium Protocol was performed. Specific lysis was calculated according to 
the following formula:  
% Specific release = [(Sample release - Spontaneous release)/(Maximal release -
 Spontaneous release)] x 100 
Spontaneous release was calculated as follows: 
% Spontaneous release = [(Spontaneous release - Background)/(Maximal release -
 Background)] x 100 
2.7.4 Cytometric bead array 
Release of soluble factors by NK-92/5.28.z and parental NK-92 upon stimulation with 
target cells was analyzed using the FACS-based Cytometric Bead Array  
(BD Biosciences). 5 x 105 effector cells per sample were co-incubated with tumor cells 
at 10:1 effector to target (E/T) ratio for 2 hours at 37 °C. Unstimulated effector and 
target cells, as well as cells stimulated with PMA (50 ng/ml)/Ionomycin (500 ng/ml), 
were included for determination of basal release and maximal release respectively. 
After incubation, the assay plate was centrifuged and 50 µl of supernatant was collected 
from each assay well and further analyzed for the presence and concentration of soluble 
factors according to the manufacturer’s protocol. Briefly, samples were incubated with 
capture beads specific to a defined set of analytes (Flex Set). Next, a master mix of 
PE-conjugated antibodies (detection reagent) was added forming FACS-detectable 
complexes (capture bead-analyte-detection reagent). Qualitative and quantitative 
analysis of the sample was based on the fluorescence signal characteristic for bead and 
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detector, respectively (Figure 2.3). Data were collected using BD LSRFortessa flow 
cytometer and analyzed with FCAP Array software version 3.0. 
 
2.7.5 Isolation of human primary NK cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of 
3 random healthy donors by centrifugation over a density gradient lymphocyte 
separation medium (BioWhittaker, Lonza). Subsequently, purification of human 
primary NK cells from the PBMC fraction was performed using the EasySepTM 
Negative Human NK cell Enrichment kit (STEMCELL Technologies) according to the 
manufacturer’s protocol. Briefly, 2 ml of PBMC resuspended in PBS/EDTA 
(CliniMACS, MiltenyiBiotec) at a concentration of 5 x 107 cells/ml were placed in 
a polystyrene tube (1 x 108 cells/tube). 50 µl/ml of EasySepTM Human NK cell 
Enrichment Cocktail containing bispecific antibody complexes targeted against non-NK 
cell surface antigens and against dextran were added. Samples were mixed by vortexing 
and incubated for 10 min at RT. After incubation, 100 µl/ml of dextran-coated 
EasySepTM D magnetic particles were added and samples were incubated for a further 
5 min. Afterwards, tubes were placed into an EasySepTM magnet. After 2.5 min, 
the desired fraction of unbound NK cells was poured off into a new tube. 
To increase the purity, the selection step was repeated. After isolation, positive fraction 
of NK cells was centrifuged (1400 rpm, 5 min, RT) resuspended in complete X-Vivo 10 
medium and conditioned in a cell culture incubator for 60 min. To assess the purity and 
viability of the isolated NK cell population, FACS staining for the detection of CD3 and 
CD56 was performed. Cells were stained with 3 µl/sample of anti-human CD56-APC 
Figure 2.3 Cytometric bead array assay. Modified from bdbiosciences.com 
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(BD Biosciences), 5 µl/sample CD3-V450 (BD Horizon) and 5 µl/sample 7-AAD  
(BD Pharmingen) and incubated for 15 min at RT protected from light. 
Afterwards, samples were washed with 2 ml of FACS wash buffer and measured using 
a BD LSRFortessa flow cytometer. 
2.7.6 Human stem cell colony formation assay after NK-cell treatment 
Peripheral blood stem cells (PBSCs) from G-CSF mobilized donors (n=3) were 
resuspended in complete X-Vivo 10 rTF medium. Based on the analysis of apheresis 
product provided by Cell Separation Department of Blood Transfusion Centre, 
Frankfurt, the concentration of CD34+ cells was adjusted to 3000/ml.  NK-92 and 
NK-92/5.28.z were harvested by centrifugation (1600 rpm, 5 min, RT) and the 
concentration of the cells was adjusted in fresh complete X-Vivo 10 rTF to the 
concentration resulting in a 10:1 ratio between effector cells and PBSCs.  
Conditioned medium of NK cells was performed as follows. NK-92 and NK-92/5.28.z 
cells were seeded at a concentration of 1 x 105 cells/ml in complete X-Vivo 10 rTF 
medium and cultured for 48 hours. After this time, cell suspensions were transferred to 
50 ml falcon tubes and centrifuged at 2000 rpm for 10 min at RT. 
Supernatant was harvested and used as conditioned medium for treatment of PBSCs. 
Co-incubation of PBSCs and effector cells/conditioned medium was performed in 
triplicates in 96-well Ultra Low Attachment plates (Corning, New York, USA): 
100 µl/well of PBSCs suspension (300 CD34+ cells/well) and 200 µl/well of effector 
cells or conditioned medium were pipetted into wells and incubated for 15 hours in 
a cell culture incubator at 37 °C. After incubation, the content of each well was seeded 
into a tube containing 3 ml of methylcellulose medium (StemMACS HSC-CFU lite 
with Epo, MiltenyiBiotec). Samples were vortexed and 1.1 ml of methylcellulose 
containing approximately 100 CD34+ cells was transferred into one 35-mm culture 
plate in duplicates (Greiner Bio-One, Kremsmünster, Austria). Controls included 
NK-92, NK-92/5.28.z and PBSC incubated alone in assay medium (X-Vivo 10 
containing recombinant transferrin, supplemented with 500 U/ml of IL-2 and 5 % of 
heat inactivated human plasma). After 14 days, colonies of myeloid and erythroid 
linages were enumerated (colony definition ≥ 30 cells) (Figure 2.4).  
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2.7.7 Enumeration of ErbB2 molecules on target cells 
The average number of ErbB2 molecules per target cell was determined using 
QuantiBRITE-PE beads (BD Biosciences). 1 x 105 target cells/tube were stained with 
5 µl of anti-human ErbB2-PE antibody (R&D Systems) and incubated for 30 min 
at room temperature in dark. After incubation, samples were washed twice with 2 ml of 
FACS wash buffer (PBS + 0.5% FCS). After the last centrifugation, supernatant was 
discarded and the cell pellet resuspended in 300 µl of FACS wash buffer. 
A ready-to-use tubes containing four populations of QuantiBRITE-PE beads with 
various, defined MFI of PE signal served as a standard sample and was run at the same 
instrument setting as tested samples. Samples were measured using BD LSRFortessa 
flow cytometer. Data derived from the standard sample were used for generation of the 
standard curve and further calculation. The MFI signal, derived from PE conjugated 
antibodies bound to the tested population, was converted into the average number of 
Figure 2.4 Scheme of the CFU-C assay. Modified from rndsystems.com 
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ErbB2 molecules per cell. Isotype control was included to eliminate background derived 
from unspecific binding. Calculations were performed according to the manufacturer’s 
instructions. 
2.7.8 Effect of corticosteroids on cytotoxicity 
NK-92/5.28.z were seeded in complete X-Vivo 10 rTF medium at a concentration 
of 2 x 105/ml in triplicates and treated with 4 different doses of Natrium (prednisolone-
21-succinat) (Solu-Decortin H1000mg, Merck Serono GmbH) ranging from 
0-200 µg/ml (0 µg/ml, 0.2 µg/ml, 2 µg/ml, 20 µg/ml, 200 µg/ml) of culture medium. 
Prednisolone powder was dissolved in culture medium and 1:10 serial dilution was 
performed. 100 µl of diluted stock solutions were pipetted into respective culture flask. 
Cells were cultured for 24 hours in a cell culture incubator. Subsequently, specific 
cytotoxicity toward ErbB2-positive MDA-MB-453 cells and natural killing ability 
toward a HLA-negative K562 cell line were tested using EuTDA cytotoxicity assay 
(described in chapter 2.7.3).  
2.8 Statistical analysis 
Statistical analysis of data was performed using GraphPad Prism software version 5.02. 
Results are presented as mean ± SEM. Two-tailed Student’s t-test was used for 
comparison of two groups. For multiple comparisons one way analysis of variance 
(ANOVA) was carried out. Statistical differences were considered significant 
at a P < 0.05. 
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3.1 Development of a GMP-compliant manufacturing processes 
3.1.1 GMP-grade culture media 
NK-92 cell line was adapted to GMP-grade X-Vivo 10 culture medium in order to make 
it suitable for clinical application [35]. Due to its high human serum albumin (HSA) 
content (approximately 30 %), X-vivo 10 medium is intended to promote cell growth 
without the need for further human plasma substitution. Nevertheless, NK-92 cells 
cultured in X-Vivo 10 medium still require human plasma supplementation for efficient 
cell expansion. Therefore, commercially available GMP grade cell culture media:  
2 variants of X-Vivo 10 (Lonza, Basel, Switzerland) and CellGro (CellGenix, Freiburg, 
Germany) were compared with regard to their ability to promote growth of 
NK-92.5.28.z cells as plasma-free and plasma-supplemented formulation. 
The first assessment was made between X-Vivo 10 containing human holo-transferrin 
and X-Vivo 10 containing recombinant transferrin (X-Vivo 10 rTF). Both media were 
supplemented with 500 U/ml of IL-2 and 5 % of heat inactivated human plasma. 
Although up to day six a difference in cell proliferation was not detected, the presence 
of recombinant transferrin seemed to improve cell growth in long-term culture. 
The most pronounced difference was observed at day 7 with fold expansion of 
20.73 ± 0.33 and 15 ± 0.6 for X-Vivo 10 rTF and X-Vivo 10 containing human 
holo-transferrin (P<0.0011), respectively. These data suggest that X-Vivo 10 rTF gives 
the opportunity to reach higher cell concentrations in batch culture, without medium 
exchange or further supplementation (Figure 3.1A) when compared to X-Vivo 10 
containing human-derived transferrin with maximal cell concentrations/ml of 
12.49 x 105 ± 0.32 x 105 and 7.5 x 105 ± 0.3 x 105, respectively. 
Subsequently, X-Vivo 10 rTF was compared with CellGro (SCGM) giving equivalent 
results in terms of supporting cell proliferation as plasma-supplemented composition 
with fold expansion of 21.08 ± 0.1 (X-Vivo 10 rTF) and 20.07 ± 0.37 (CellGro) at day 
six. However, CellGro was not able to promote cell expansion in plasma-free conditions 
(max. conc./ml in batch culture 1.52 x 105 ± 0.1 x 105), whereas 
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X-Vivo 10 containing rTF maintained gradual cell growth (max. conc./ml in batch 
culture 2.65 x 105 ± 0.09 x 105) (Figure 3.1B), thus facilitating acclimation to 
plasma-free culture conditions. Summary of the cell growth rates obtained in tested 
conditions are presented in Table 3.1. 
 
Figure 3.1 Comparison of NK-92/5.28.z cell growth in GMP-compliant serum-free culture media. 
(A) Comparison of two variants of X-Vivo 10 media containing transferrin from two different sources. 
(B) Growth of NK-92/5.28.z cells in X-Vivo 10 rTF and CellGro. Solid lines represent 
plasma-supplemented culture. Dotted lines represent plasma-free cultures.  
3.1.2 Serum/plasma-free culture 
To eliminate undefined, donor-derived supplements, NK-92/5.28.z cells were subjected 
to the 32-day process of acclimation to serum/plasma-free conditions. An applied 
feeding regimen enabled maintenance of cell viability over ≥ 80 % during the whole 
acclimation course and maximal concentration in batch culture of 
10.2 x 105 ± 0.85 x 105 cells/ml (Mean ± SEM) at day 30 (Figure 3.2A). At the end of 
the acclimation procedure, the quality of the cells was evaluated with the following 
results for tested parameters: CAR expression > 99 %, identity (CD56+ CD16-) > 99 % 
and specific cytotoxicity against ErbB2(+) targets with the mean value of 94.4 %. 
NK-92/5.28.z cells cultured in plasma-supplemented medium were included for 
comparison (Figure 3.2B). Established plasma-free culture was further maintained and 
analyzed providing favorable results in terms of cell proliferation when compared to not 
acclimated control cells cultured in plasma-free medium with doubling time of 
47.37 h ± 2.75 h and 83.11 h ± 3.08 h (P < 0.001), respectively. Cell growth parameters 
obtained in all tested culture conditions were summarized in Table 3.1. 
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Significantly shorter doubling time of the cells subjected to acclimation demonstrated 
the importance of the performed procedure. CAR expression and phenotype of 
NK-92/5.28.z were further investigated and remained stable over the 28-week analysis 
period with values > 99 % (Figure 3.2C).  
 
Figure 3.2 Acclimation of NK-92/5.28.z cells to serum/plasma-free culture. (A) Cells were seeded at an 
initial concentration of 5 x 104/ml in X-Vivo 10 rTF supplemented with 500 U/ml of IL-2 without 
addition of plasma/serum. Every second day, half the culture supernatant was removed and culture was 
replenished with fresh plasma-free medium. Subsequently, cells were resuspended and cell number and 
viability were determined. Cells were kept in batch culture for 32 days until reaching confluency defined 
as 1 x 106/ml. (B) At the end of the batch culture, identity (CD56+CD16-), CAR expression 
(7AAD-CAR+) and specific cytotoxicity against ErbB2(+) targets were tested and compared with the 
results obtained with cells cultured in plasma-supplemented medium (with plasma). (C) CAR expression 
and identity were further tested up to 28 weeks. Experiments were performed in triplicates. 
Data are presented as Mean ± SEM 
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3.1.3 Impact of IL-2 concentration on cell proliferation and functionality 
Natural killer cells can reach optimal potency and expansion capacity only in an 
optimized cytokine milieu where IL-2 plays a crucial role and, in the case of NK-92, 
seems to be sufficient to reach satisfactory levels of cell activation. 
Therefore, finding an optimal concentration of this cytokine for ex vivo cell expansion 
was an important issue investigated in this study. Cell proliferation of NK-92 and 
NK-92/5.28.z cells was tested at five different concentrations of IL-2: 0 U/ml, 10 U/ml, 
100 U/ml, 500 U/ml and 1000 U/ml. Obtained results show that IL-2 is essential 
for proliferation of NK-92 and NK-92/5.28.z cells. Low concentration of this cytokine 
(10 U/ml) is able to maintain cell proliferation with maximal fold expansion in batch 
culture of 8.85 ± 0.53 and 10.53 ± 1.64 (Mean ± SEM) for NK-92 and NK-92/5.28.z 
cells, respectively, but it is not sufficient to promote robust cell expansion. 
Increase of IL-2 concentration in culture medium leads to more efficient cell expansion, 
however, there were no significant differences in fold expansion of NK-92 and 
NK-92/5.28.z cells when cultured in 100 U/ml, 500 U/ml, 1000 U/ml. 500 U/ml was 
indicated as the optimal IL-2 concentration giving slightly better results than 100 U/ml. 
In addition, doubling this concentration (1000 U/ml) did not promote further cell 
expansion (Figure 3.3A). Interestingly, CAR-mediated specific cytotoxicity seems not 
to be strictly dependent on the IL-2 concentration in culture media. All three tested 
concentrations (50 U/ml, 100 U/ml, 500 U/ml) resulted in specific cytotoxicity 
of NK-92/5.28.z against ErbB2-positive targets of more than 90 % with values 
of 97.26 % ± 0.19 % for 50 U/ml, 96.84 % ± 0.14 % for 100 U/ml and 
91.98 % ± 0.83 % for 500 U/ml. As expected, increasing levels of IL-2 supported 
natural killing when tested against K562 cells, of both genetically modified and parental 
NK-92 cells (Figure 3.3B). Furthermore, stability of cell potency in IL-2-free culture 
was tested over time, up to 72 hours. An instantaneous, significant decrease in natural 
killing of both NK-92 and NK-92/5.28.z amounting 17.59 % ± 2.5 % and 
19.27 % ± 4.57 % after 24 hours, respectively, was observed. Conversely, retargeted 
killing of NK-92/5.28.z toward ErbB2-positive targets was decreasing gradually with 
cytotoxicity values of more than 50 % up to 48 h (67.77 % ± 3.16 % at 24 h;  
59.02 % ± 5.16 % at 48 h) and 45.50 % ± 5.99 % after 72 hours (Figure 3.3C). 
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Figure 3.3 Expansion and functionality of NK-92 and NK-92/5.28.z cultured in medium supplemented 
with various IL-2 concentrations. (A) Proliferation of parental (NK-92 WT) and genetically modified 
NK-92 cells (NK-92/5.28.z) in X-Vivo 10 rTF supplemented with 5 % of human plasma and various 
concentrations of IL-2 up to 10 days. (B) Natural killing of NK-92 (white bars) and NK-92/5.28.z 
(light grey bars) and retargeted killing of NK-92/5.28.z (dark grey bars) cultured for 5 days 
in X-Vivo 10 rTF supplemented with 5 % of human plasma and 50 U/ml, 100 U/ml, 500 U/ml of IL-2. 
(C) Stability of natural killing of NK-92 (white symbol) and NK-92/5.28.z (light grey symbol) 
and retargeted killing of NK-92/5.28.z (dark grey symbol) in IL-2-free culture was tested up to 72 hours.  
3.1.4 Influence of human platelet lysate on NK-92/5.28.z proliferation and 
functionality 
Promising data on expansion of other cell types (e.g. MSCs, osteoblasts) cultured 
in media supplemented with platelet lysate encouraged us to test the proliferation 
of NK-92/5.28.z in a similar setting and to replace the serum substitution by platelet 
lysate. Therefore, platelet lysate from two different companies/sources (hPL1 and 
hPL2) in comparison with human plasma was assessed for its ability to promote cell 
expansion and cytotoxicity. However, there was no advantageous influence of 
cultivation in medium supplemented with 5 % of hPL in terms of natural killing (human 
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plasma: 47.97 % ± 4.12 %; hPL1: 62.44 % ± 5.5 %; hPL2: 54.6 % ± 4.24 %) and 
specific killing of ErbB2-positive (MDA-MB-453) targets (human plasma:  
95.1 % ± 3.08 %; hPL1: 91.42 % ± 4.62 %; hPL2: 92.65 % ± 4.7 %) (Figure 3.4A). 
What is more, cells cultured in medium supplemented with 5 % of human plasma 
proliferated significantly better (P < 0.05) when compared to hPL2 with fold expansion 
of 23.87 ± 0.22 and 17.37 ± 0.67 (Mean ± SEM), respectively at day 9 (Figure 3.4B). 
 
 
Figure 3.4 Comparison of functionality and proliferation of NK-92/5.28.z cells cultured in human plasma 
and platelet lysate (hPL) supplemented medium. (A) NK-92/5.28.z cells were cultured in X-Vivo 10 rTF 
supplemented with 500 U/ml of IL-2 and 5 % of either human plasma (white bars) or hPL1 (grey bars) 
or hPL2 (dark grey bars). After 72 hours natural killing against K562 and CAR-mediated killing against 
ErbB2-overexpressing MDA-MB-453 cell line were tested in EuTDA killing assay. 
(B) Proliferation of NK-92/5.28.z cultured in X-Vivo 10 rTF supplemented with 500 U/ml of IL-2 
and 5 % of either human plasma (white symbols) or hPL1 (grey symbols) or hPL2 (dark grey symbols) 
was measured up to 9 days.  
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Table 3.1 Impact of different serum substitutes in GMP-compliant, albumin containing culture media supplemented with 500 U/ml of IL-2 on NK-92/5.28.z cells 
proliferation 
 
 
 
Culture medium Human serum substitute Doubling time [h] Maximal fold 
expansion 
Maximal concentration/ml 
in batch culture [x105] 
X-Vivo 10 w/o Phenol red 
and Gentamycin containing 
recombinant Transferrin 
(Lonza, #BE02-055Q) 
5 % of heat inactivated 
human plasma 28.84 ± 0.5 24.97 ± 0.65 12.49 ± 0.32 
5 % of human platelet lysate 1 35.6 ± 1.38 21.37 ± 1.01 10.7 ± 0.52 
5 % of human platelet lysate 2 37.48 ± 1.89 18.07 ± 3.04 9.01 ± 1.52 
serum-free culture 
w/o acclimation 83.11 ± 3.08 5.3 ± 0.18 2.65 ± 0.09 
serum-free culture 
post-acclimation 47.37 ± 2.75 20.4 ± 1.71 10.2 ± 0.85 
X-Vivo 10 w/o Phenol red 
and Gentamycin 
(Lonza, #BE04-743Q) 
5 % of heat inactivated 
human plasma 34.39 ± 0.63 15 ± 0.6 7.5 ± 0.3 
CellGro SCGM (CellGenix) 
5 % of heat inactivated 
human plasma 33.29 ± 0.2 21.23 ± 2.34 10.62 ± 1.17 
serum-free culture 90.97 ± 5.47 3.03 ± 0.2 1.52 ± 0.1 
Grey field indicates optimal formulation and respective growth parameters. Results shown as Mean ± SEM 
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3.1.5 Establishment of cryopreservation protocols 
The freeze/thaw cycle is the first, and most stressful, step for the cells in the whole 
course of expansion, due to it impacting the quality and quantity of the starting cell 
population, thereby determining efficiency of the expansion procedure. In order to 
evaluate the best cryopreservation and thawing protocol for NK-92/.528.z cells, the 
recovery of parental and retargeted NK-92 cells was analyzed directly and 24 hours 
after thawing following freezing in HSA, commercially available CryoStor CS 10 or 
a combination of both containing various concentrations of DMSO (5 %, 7.5 %, 10 %, 
12.5 %, 15 %). Obtained results demonstrate that HSA supplemented with 7.5 % of 
DMSO gave the most beneficial results for NK-92/5.28.z with recovery of 
68.84 % ± 5.07 % and 23.91 % ± 9.05 % directly post-thaw and 24 hours after thawing, 
respectively. In the case of parental NK-92 cells, recovery values at 0 h and 24 h were 
not sufficient to determine the optimal cryopreservation solution (Figure 3.5A). 
Therefore, an additional measurement of cell concentration was performed 7 days 
post-thaw (Figure 3.5B) showing the best results for the cells frozen in HSA + 7.5 % of 
DMSO (5.47 x 105 ± 0.44 x 105 cells/ml) confirming the optimal character of this 
combination to cryopreserve parental and genetically modified NK-92 cells. 
Hoping to further improve the quality of NK-92/5.28.z cells after thawing,  
HSA + 7.5 % DMSO was supplemented with 20 % of NK-92/5.28.z conditioned 
medium (CM) from 72-hour culture. There was no significant difference detected: 
neither directly post-thaw with recovery values of 73.06 % ± 2.66 % for 
cryopreservation solution without CM (w/o CM) and 61.11 % ± 5.79 % for 
cryopreservation solution supplemented with CM (+20% CM), nor in recovery 
measured after 24 hours (w/o CM: 48.06 % ± 6.16 %; +20% CM: 53.61 % ± 4.19 %) 
(Figure 3.6A). Further analysis of cell growth also did not show any differences 
between solution without or with CM (day 6 w/o CM: 10.73 x 105 ± 0.57 x 105; day 6 
+20% CM: 11.86 x 105 ± 0.57 x 105) (Figure 3.6B).  
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Figure 3.5 Influence of cryopreservation solutions on NK-92 and NK-92/5.28.z cells post-thaw recovery. 
(A) Recovery of parental NK-92 and NK-92/5.28.z was measured directly (0 h; white bars) and 24 h 
(grey bars) after thawing. (B) An additional measurement of concentration of viable NK-92 cells after 
7 days in culture was performed. 
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Figure 3.6 Influence of the presence of NK-92/5.28.z.-derived conditioned medium (CM) 
in cryopreservation solution on (A) post-thaw recovery and (B) cell growth of NK-92/5.28.z. Graphs 
show the data obtained from the analysis of 4 independent vials. Results shown as Mean ± SEM 
 
 
Table 3.2 Summary of tested cryopreservation solutions for freezing of NK-92/5.28.z  
 
 
 
 
Cryopreservation solution DMSO 
concentration 
Direct post-thaw recovery 
[%] 
Recovery after 24h 
[%] 
Human Serum Albumin (HSA) 
5 % 63.05 ± 6.64 8.7 ± 0.0 
7.5 % 68.84 ± 5.07 23.91 ± 9.05 
10 % 66.67 ± 4.03 15.94 ± 4.03 
CryoStor CS10 10 % 53.62 ± 2.90 14.49 ± 1.92 
Human Serum Albumin (HSA) 
+ CryoStor CS10 
5 % 
10 % 
12.5 % 
15 % 
65.22 ± 10.94 
25.36 ± 8.54 
15.94 ± 4.75 
13.04 ± 4.53 
15.94 ± 1.45 
0.72 ± 0.72 
0.72 ± 0.72 
3.62 ± 2.62 
Grey field indicates the optimal combination. Results shown as Mean ± SEM 
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3.1.6 Impact of gamma irradiation on proliferation and potency of NK-92/5.28.z 
In all clinical trials performed hitherto, NK-92 cells were subjected to γ-irradiation 
exposure to prevent permanent engraftment in patient. In this study, proliferation and 
viability of NK-92 and NK-92/5.28.z following γ-irradiation with 5 doses (0 Gy, 2 Gy, 
5 Gy, 10 Gy, 30 Gy) every 24 h up to 5 days were analyzed. Figure 3.7A shows that 
30 Gy, 10 Gy and 5 Gy, but not 2 Gy, caused complete inhibition of cell proliferation 
when compared to the non-irradiated control. It resulted in a significant decline in 
viability that was first observed 48 h post-irradiation of parental NK-92 cells with the 
dose of 30 Gy with a viability value of 59.33 % ± 7.27 % versus 98.79 % ± 0.3 % for 
non-irradiated cells. Treatment with 2 Gy significantly retarded cell growth but did not 
affect cell viability which exceeded 80% for both cell lines over the entire analysis 
period. Moreover, genetically modified NK-92 were markedly less radiosensitive;  
an effect that first became visible 48 h after irradiation with 30 Gy (92.4 % ± 0.1 %) 
when compared to parental cells (59.33 % ± 7.27 %) (Figure 3.7 B). 
Subsequently, potency of NK-92 and genetically modified NK-92 was examined 
2 hours post-exposure where no significant decrease, in either specific cytotoxicity 
against ErbB2-positive targets of NK-92/5.28.z cells (0 Gy: 97.7 % ± 0.1 %; 10 Gy: 
96.7 % ± 0.36 %; 30 Gy: 94.8 % ± 1.39 %; Mean ± SEM) or natural killing ability of 
both cell lines, was detected (Figure 3.7C). In addition, differences in the secretion of 
soluble factors between non-irradiated and irradiated NK-92/5.28.z cells upon 
stimulation with three cell lines routinely used as targets in previously performed 
experiments were investigated. GZMB, IFN-γ, IL-10, TNF, and MIP-1α were produced 
at similar levels by irradiated and non-irradiated NK-92/5.28.z cells while IL-6 was not 
detected. There was a significant drop in sFasL production upon stimulation with 
MDA-MB-453 following irradiation with 30 Gy from 385.02 pg/ml ± 4.04 pg/ml (0 Gy) 
to 202.69 pg/ml ± 9.95 pg/ml (30 Gy) (Mean ± SEM) and a significant increase in IL-8 
secretion following irradiation with 10 Gy from 479.38 pg/ml ± 112.77 pg/ml (0 Gy) to 
1433.01 pg/ml ± 135.12 pg/ml (10 Gy) (Mean ± SEM) but not with 30 Gy 
(768.58 pg/ml ± 105.09 pg/ml) compared to the non-irradiated control (Figure 3.8). 
Taken together, the above results suggest that 10 Gy is the optimal irradiation dose for 
NK-92/5.28.z, inhibiting cell proliferation with satisfactory viability values of 
87.6 ± 4.61 % versus 99.86 ± 0.14 % for non-irradiated cells at the 72 hour time point. 
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Figure 3.7 Impact of γ-irradiation on the proliferation, viability and potency of NK-92 and NK-92/5.28.z. 
Cells were exposed to various irradiation doses (0 Gy, 2 Gy, 5 Gy, 10 Gy, 30 Gy) washed and seeded 
at an initial concentration of 1 x 105/ml. (A) Cell concentration and (B) viability were tested every 24 
hours up to 5 days. (C) Specific cytotoxicity and natural killing ability of parental and genetically 
modified NK-92 cells were measured 2 hours post-irradiation using an EuTDA killing assay. 
Results are presented as Mean ± SEM; n=3 
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Figure 3.8 Influence of irradiation dose on soluble factors release by stimulated NK-92/5.28.z.  
NK-92/5.28.z were irradiated with 10 Gy (grey bars) and 30 Gy (black bars) and co-cultured with target 
cells at E/T ratio of 10:1. NK-92/5.28.z cells cultured in the absence of target cells, as well non-irradiated 
NK-92/5.28.z (0 Gy, white bars) were included as controls. Concentrations of soluble proteins in test 
supernatants were measured using a cytometric bead array. 
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3.2 Qualification of a GMP-compliant master cell bank of NK-92/5.28.z 
3.2.1 Testing of manufacturing related parameters 
A representative sample (5%) of the cryopreserved master cell bank was allocated to 
qualification and testing. Results of the analysis of safety parameters (e.g. sterility 
testing by direct inoculation method, LAL test for endotoxin, presence of viral 
contaminants, presence of mycoplasma and DNA fingerprinting) performed 
in accordance with the principles of good manufacturing practice by the contract 
research organization (CRO) (BioReliance Inc., Glasgow, UK) confirmed the identity 
and biological safety of the MCB. Additionally, according to established methods 
(method section), manufacturing related parameters like purity (% of CD56+ CD16-), 
stability of CAR expression, potency and the post-thaw recovery were tested. 
Results of the cell recovery from 6 independent vials enable determination of actual vial 
content, which is crucial information for the master cell bank qualification  
(Figure 3.9A). A vial, in average, contained a total number of 2.06 x 107 ± 0.14 x 107 
cells (Mean ± SEM) (range: 1.51-2.53 x 107/vial) with a mean viability post-thaw of 
65.65 % ± 3.08 % (range: 54.27 %-74.28 %). Cells thawed from MCB demonstrated 
a satisfactory post-thaw recovery with the mean value of 57.25 % ± 7.06 
(Mean ± SEM), with maximal and minimal recovery of 84.52 % and 39 %, respectively 
(Figure 3.9B). Moreover, cells expanded from 3 (n=3) independent vials exhibited 
reproducible post-thaw growth in VueLife 750-C1 culture bags prefilled with 1 L of 
culture medium, with an evident recovery phase between day 0 and 7 and exponential 
growth phase from day 7 to 12 (Figure 3.9C). What is more, the freeze/thaw procedure 
did not attenuate stability of the cells defined as CAR expression level, phenotype and 
functionality with the values obtained 1-3 weeks post-thaw of 99.11 % ± 0.18 % 
(percentage of CAR+ 7AAD- cells analyzed 1 week post-thaw), 99.42 % ± 0.12 % 
(percentage of CD56+ CD16- cells analyzed 1 week post-thaw), 88.7 % ± 1.65 % 
(specific cytotoxicity against ErbB2-positive targets analyzed 3 weeks post-thaw), 
respectively, when comparted to results, obtained shortly before freezing 
(CAR+ 7AAD-: 99.17 % ± 0.15 %; CD56+ CD16-: 99.6 % ± 0.06 %; specific 
cytotoxicity: 63.59 ± 1.15 %). The analysis period was extended to 12 months showing 
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no decrease in values of stability parameters (CAR+ 7AAD-: 99.77 ± 0.03 %; 
CD56+ CD16-: 100 %; specific cytotoxicity: 89.75 ± 3.77 %) (Figure 3.9D). 
 
 
Figure 3.9 Master cell bank qualification with regard to manufacturing parameters. (A) Mean vial content 
analyzed directly post-thaw (n=6). (B) Post-thaw recovery of NK-92/5.28.z cells derived from 
6 independent vials (each dot represents 1 vial). (C) Post-thaw growth of NK-92/5.28.z cells thawed from 
3 independent vials inoculated directly into VueLife 750-C1 culture bags prefilled with 1 L 
of X-Vivo 10 rTF supplemented with 5 % of human plasma and 500 U/ml of IL-2. (D) Analysis 
of stability parameters before freezing of MCB and after thawing (n=3). Results shown as Mean ± SEM. 
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3.3 Manufacturing and release testing of therapeutic patient doses, 
expanded from the master cell bank 
3.3.1 Establishment of shipment/injection solution (excipient)  
To find the optimal excipient for shipment and subsequent infusion, which will preserve 
cell viability and cytotoxicity, 6 different buffered solutions, including 4 routinely used 
for storage and/or the application of blood products, were evaluated. Testing included: 
saline-adenine-glucose-mannitol hypertonic solution (SAG-M; 376 mOsm/l; Fresenius 
Kabi, Bad Homburg, Germany), phosphate-adenine-glucose-guanosin-saline-mannitol 
isotonic solution (PAGGS-M; 285 mOsm/l; Fresenius Kabi, Bad Homburg, Germany), 
SSP (Macopharma, Langen, Germany) and PBS/EDTA (MiltenyiBiotec, Bergisch 
Gladbach, Germany). All buffers were supplemented with 1 % of human serum 
albumin. In addition, pure HSA (200 g/1L) and X-Vivo 10 rTF medium as pure 
or complete (supplemented with 5% heat inactivated human plasma and 500 U/ml IL-2) 
formulation were tested. X-Vivo 10 rTF, HSA, PBS/EDTA + 1 % HSA and 
SSP + 1 % HSA maintained a stable pH between 7.0 and 8.0 over the 48-hour analysis 
period, whereas SAG-M and PAGGS-M showed an acidic pH (<6.5) characteristic for 
erythrocyte storage buffers. All tested storage solutions except for SSP + 1 % HSA and 
PBS/EDTA + 1 % HSA, were able to maintain cell viability at satisfactory levels 
(> 85 %) for up to 48 hours. Viability of the cells stored in SSP + 1 % HSA and 
PBS/EDTA + 1 % HSA declined significantly (65.12 % ± 1.26 % and 47.3 % ± 1.38 %, 
respectively) despite having a stable, near-physiological pH of these buffers (SSP min. 
and max pH: 7.00 ± 0.11 and 7.46 ± 0.02; PBS/EDTA min. and max pH: 7.07 ± 0.04 
and 7.15 ± 0.01). Interestingly, three solutions with different pH: slightly basic pure 
X-Vivo 10 rTF (min. pH: 7.33 ± 0.01 and max. pH: 8.14 ± 0.02), neutral pure HSA 
(min. pH: 7.3 ± 0.03 and max pH: 7.63 ± 0.03) and acidic PAGGS-M + 1 % HSA 
(min. pH: 5.89 ± 0.01 and max pH: 6.39 ± 0.04) gave comparable results and were 
indicated as optimal for cell viability measured after 48-hour storage under ambient 
conditions (pure X-Vivo 10 rTF: 90.27 % ± 0.18 %; pure HSA: 86.24 ± 0.33 %; 
PAGGS-M + 1 % HSA: 86.0 ± 0.16 %), suggesting a marginal importance of pH values 
for cell viability in this experiment. There was no difference in cell viability between 
supplemented X-Vivo 10 rTF and pure X-Vivo 10 rTF with viability values at 
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the 48-hour time point of 91.49 % ± 0.62 % and 90.27 % ± 0.18 %, respectively.  
Furthermore, irradiation of the cells stored in X-Vivo 10 rTF with 10 Gy did not impair 
cell viability in the analyzed time range when compared to a non-irradiated control with 
viability values of 91.49 % ± 0.62 % and 93.24 % ± 0.07 %, respectively 
(Figure 3.10A). Subsequently, three selected solutions (pure X-Vivo 10, pure HSA 
and PAGGS-M + 1 % HSA) were tested for their ability to preserve cell cytotoxicity 
during 6 hours of storage under ambient conditions. Pure X-Vivo 10 rTF and 
PAGGS-M + 1 % HSA provided comparable results in the specific cytotoxicity of 
NK-92/5.28.z against ErbB2-positive targets, amounting to 86.18 % ± 2.58 % and 
81.31 % ± 1.07 % (Mean ± SEM), respectively. Storage in HSA significantly 
(P<0.0001) diminished the potency of NK-92/5.28.z cells, when compared to 
X-Vivo 10 rTF and PAGGS-M + 1 % HSA, with a specific cytotoxicity value of 
63.38 % ± 0.99 % (Figure 3.10B). Obtained data suggest that pure X-Vivo 10 rTF 
culture medium with its slightly basic pH and ability to preserve cell viability and 
potency at satisfactory levels may be used for final formulation of the cellular product 
and thereby serve as storage/injection solution. 
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Figure 3.10 Impact of storage buffers on the stability of NK-92/5.28.z. (A) pH and viability values of cell 
suspensions prepared in 6 tested buffers measured over 48-hour storage under ambient conditions. 
(B) Specific cytotoxicity against ErbB2(+) targets of NK-92/5.28.z cells stored in 3 preselected buffered 
solutions under ambient conditions, analyzed 6 hours post-preparation. NK-92/5.28.z. cells stored 
in complete X-Vivo 10 rTF in cell culture incubator were included as a control (control cells). 
3.3.2 Stability of NK-92/5.28.z at high cell densities  
The intended route of administration affects the final formulation of the cellular 
product. Thus local intratumoral or peritumoral injection limits the injection volume and 
consequently demands high cell densities in the final product. To evaluate the 
maximally feasible cell density in a potential patient dose, viability and potency of 
irradiated (10 Gy) NK-92/5.28.z in high density cell suspensions (2 x 107/ml;  
4 x 107/ml; 6 x 107/ml), stored under ambient conditions, were tested to model patient 
dose potency and stability. The data demonstrated high stability of the irradiated cells 
with a viability of > 90 % for 24 hours (96.41 % ± 0.36 % for 2 x 107/ml; 
94.84 % ± 0.22 % for 4 x 107/ml; 92.83 % ± 0.63 % for 6 x 107/ml) and specific 
cytotoxicity against ErbB2(+) targets of > 50 % up to 18 hours for all three tested 
concentrations. However, cytotoxicity of NK-92/5.28.z at the density of 6 x 107/ml after 
18 hours was significantly lower (51.48 % ± 1.5 %) when compared to 4 x 107/ml 
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(67.01 % ± 1.89 %; P<0.0001) and 2 x 107/ml (75.36 % ± 2.44 %; P<0.0001)  
(Figure 3.11), implying cell concentration as a factor potentially limiting the stability of 
patient doses in the clinically relevant period of time. Based on the obtained results, the 
concentration of 5 x 107/ml was indicated as feasible and used as a concentration of the 
final product in 3 subsequent validation runs (chapter 3.3.3). 
 
 
Figure 3.11 Stability of γ-irradiated NK-92/5.28.z cells in high density cell suspensions during storage 
under ambient conditions in X-Vivo 10 + 100 U/ml of IL-2. Viability (left panel) and specific 
cytotoxicity against ErbB2(+) targets (right panel) were analyzed at the indicated time points using 
EuTDA cytotoxicity assay; n=3. 
3.3.3 Generation of a therapeutic doses of NK-92/5.28.z 
To confirm the feasibility of established clinical scale manufacturing protocol covering 
the following issues: efficient cell expansion, optimal irradiation dose, cell density in 
the final product and optimal transport solution; three independent validation runs 
of patient dose generation were performed under full GMP conditions with subsequent 
testing of final product. Three independent batches of NK-92/5.28.z cells seeded at the 
concentration of 5 x 104 cells/ml in VueLife 750-C1 culture bags prefilled with 
complete X-Vivo 10 rTF showed stable and reproducible growth with the average 
doubling time of 32.76 h ± 0.32 h over a 5-day culturing period (Figure 3.12A). 
Cells were harvested at a concentration of approximately 6 x 105 cells/ml 
(batch 1: 6.5 x 105 cells/ml; batch 2: 6.6 x 105 cells/ml; batch 3: 5.94 x 105 cells/ml). 
All three patient doses fulfilled predefined specification in terms of cell viability 
(specification > 80 %; result: 92.16 % ± 0.74 %; Mean ± SEM of 3 independent 
products), CAR expression (specification > 95 %; result: 97.67 % ± 0.4 %;  
Mean ± SEM of 3 independent products) and specific cytotoxicity  
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(specification > 50 %; result: 83.43 % ± 2.48 %; Mean ± SEM of 3 independent 
products) post-preparation. Moreover, the stability of generated products in terms 
of viability and potency was further tested up to 24 hours showing high viability values 
of > 85 % for three products over the whole analysis period (viability values 
24 hours post-preparation: product 1: 87.4 %; product 2: 87.7 %; product 3: 87.35%) 
and potency of more than 70 % at 6 hours post-preparation (specific cytotoxicity: 
product 1: 86.13 % ± 5.08 %; product 2: 84.78 % ± 0.39 %; product 3: 
73.67 % ± 4.55 %; Mean ± SEM of triplicates) (Figure 3.12B). Importantly, the 
generated cellular products were negative for culturable microbes (BacT/Alert) and free 
of mycoplasma and endotoxin and thus within specification for these outcomes as well. 
 
Figure 3.12 Expansion of individual patient dose and testing of final product stability. (A) 3 independent 
batches of NK-92/5.28.z cells were expanded to a concentration > 5 x 105 cells/ml in VueLife 750-C1 
culture bags. Subsequently, cells were harvested, irradiated and, after serial centrifugation and washing 
steps, 3 final products were formulated. (B) Specific cytotoxicity against ErbB2(+) targets and viability 
of the cells in final formulation were tested for up to 24 hours. 
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3.4 Patient related issues in the context of clinical application 
3.4.1 Impact of corticosteroid treatment on NK-92/5.28.z cytotoxicity 
Corticosteroids are potent immunosuppressive agents used in cancer patients to mitigate  
the side effects caused by first line anticancer therapies [99]. The mechanisms of action 
include, inter alia, inhibition of natural killer cell cytotoxicity. For that reason, 
the impact of 4 clinically relevant concentrations (0.2 µg/ml, 2 µg/ml, 20 µg/ml, 
200 µg/ml) of corticosteroids on the potency of NK-92/5.28.z. was assessed. 
The dose of 200 µg per milliliter of culture medium corresponds with the highest 
clinical dose of prednisolone applied intravenously (1000 mg of prednisolone) in the 
case of pulmonary edema. 24-hour prednisolone treatment did not significantly 
attenuate CAR-dependent cytotoxicity of genetically modified NK-92 cells against 
ErbB2-overexpressing targets with the following results: 0.2 µg/ml: 95.56 % ± 1.1 %;  
2 µg/ml: 93.05 % ± 2.87 %; 20 µg/ml: 91.43 % ± 2.62 %; 200 µg/ml:  
86.86 % ± 3.48 %, when compared to non-treated control (0 µg/ml): 90.07 % ± 2.78 %. 
Natural killing ability was significantly reduced in a dose-dependent manner with 
twofold difference between the untreated control (57.84 % ± 2.8 %) and cells treated 
with the highest tested prednisolone dose (29.76 % ± 1.37 %; Mean ± SEM) 
(Figure 3.13).  
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Figure 3.13 Impact of 24-hour prednisolone treatment on CAR-mediated cytotoxicity against ErbB2(+) 
cells (grey bars) and natural killing against K562 cells (white bars) of NK-92/5.28.z. Results presented 
as Mean ± SEM of triplicates from 3 independent experiments. 
3.4.2 Analysis of soluble factors secreted by target stimulated NK-92 cells, 
NK-92/5.28.z and primary NK cells 
The profile of soluble factors, including effector molecules, secreted upon short-term 
stimulation was determined in order to test cell potency as well as to predict potential 
(systemic) side effects of the cell therapy. Release of GZMB, IFN-γ, sFasL, TNF, IL-2, 
IL-6, IL-8, IL-10, G-CSF and GM-CSF by parental NK-92 and NK-92/5.28.z was 
measured after 2-hour stimulation with target cells. Adequate controls of unstimulated 
and PMA/Ionomycin stimulated effector cells as well as PMA/Ionomycin stimulated 
target cells were included (Table 3.3). Secretion of GZMB, IFN-γ, sFasL, IL-8 and 
IL-10 by NK-92/5.28.z was distinctly higher compared to parental cells, not only when 
stimulated with K562, but also in unstimulated controls. However, in the case of soluble 
Fas ligand the differences did not reach statistical significance (P=0.1692 and P=0.2110 
for unstimulated and K562 stimulated cells, respectively). These data demonstrate 
a specific and significant increase in GZMB (2-fold; P<0.05), IFN-γ (4-fold; P<0.001), 
IL-8 (24-fold; P<0.01) and IL-10 (5-fold; P<0.01) production by NK-92/5.28.z, 
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co-cultured with ErbB2-overexpressing targets (MDA-MB-453), when compared to 
baseline secretion (unstimulated NK-92/5.28.z). This phenomenon was not observed in 
the case of parental NK-92 cells, indicating resistance of our ErbB2(+) target cell line to 
natural killing mechanisms, which can be overcome by specific CAR-mediated 
activation (Figure 3.14). TNF and GM-CSF were detected only upon strong stimulation 
with PMA/Ionomycin, but not in test samples. Secretion of IL-6, G-CSF and IL-2 by 
target stimulated effector cells was not detected (data not shown). 
In addition, the profile of soluble factors secreted by primary NK (pNK) cells was 
tested, where the experimental setting was comparable to the one applied to NK cell 
lines. Primary NK cells stimulated with K562 target cells secreted higher amounts of 
effector molecules like GZMB (1.8-fold), IFN-γ (31.8-fold) and sFasL (2.7-fold), when 
compared to unstimulated controls. Increased concentrations of effector molecule 
secreted by pNK cells stimulated with MDA-MB-453 and MDA-MB-468 were not 
detected, indicating resistance of these target cell lines to the pNK cell-mediated lysis 
(Figure 3.15). As expected, unstimulated peripheral blood primary NK cells secreted 
significantly lower amounts of effector molecules (GZMB, IFN-γ, sFasL), when 
compared to unstimulated parental NK-92 (GZMB: 61-fold more, IFN-γ: 
67.4-fold more, sFasL: 12-fold more) and NK-92/5.28.z cells (GZMB: 277-fold more, 
IFN-γ: 934.6-fold more, sFasL: 21.6-fold more). Table 3.4 shows the concentrations of 
soluble factors secreted by unstimulated and K562 stimulated primary NK cells in 
comparison to NK-92 and NK-92/5.28.z. IL-10 was not detected in the supernatants of 
primary NK cells, whereas abundant amounts of this cytokine were secreted by NK cell 
lines. 
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Table 3.3 Cytokine profile of PMA (50ng/ml)/Ionomycin (500ng/ml) stimulated target cells. 
 
Results shown as Mean ± SEM 
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Figure 3.14 Influence of second generation ErbB2-CAR expression on the release of soluble factors by 
stimulated NK-92 cells. NK-92 (white bars) or NK-92/5.28.z (grey bars) were incubated for 2 hours with 
ErbB2(+) MDA-MB-453, ErbB2(-) MDA-MB-468 or K562 cells at 10:1 E/T ratio. Effector cells 
incubated without target cells (unstimulated), as well as stimulated with PMA/Ionomycin served as 
negative and positive controls, respectively. 
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Figure 3.15 Release of soluble factors by target stimulated primary NK cells isolated from buffy coats of 
normal peripheral blood from 3 independent donors. NK cells were incubated for 2 hours with ErbB2(+) 
MDA-MB-453, ErbB2(-) MDA-MB-468 or K562 cells at 10:1 E/T ratio. NK cells incubated without 
target cells (unstimulated), as well as stimulated with PMA/Ionomycin served as negative and positive 
controls, respectively. 
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Table 3.4 Secretion of soluble factors by unstimulated and K562 stimulated primary NK cells (pNK) and NK cell lines.
Soluble factor 
unstimulated +K562 
pNK NK-92 NK-92/5.28.z pNK NK-92 NK-92/5.28.z 
GZMB 272.07 ± 59.07 16584 ± 990.3 75331 ± 5963 504.29 ± 119.65 26718 ± 5066 104881 ± 6329 
IFN-γ 0.83 ± 0.49 55.97 ± 19.52 775.7 ± 107 26.4 ± 3.96 82.97 ± 31.36 1146 ± 177.3 
sFasL 15.65 ± 2.73 187.6 ± 35.32 338.2 ± 95.29 42 ± 4.9 261.3 ± 50.22 429.9 ± 115.7 
TNF BDL BDL BDL 9.59 ± 2.87 BDL BDL 
IL-10 BDL 1735 ± 46.51 2671 ± 58.15 BDL 2659 ± 406.2 4587 ± 206.5 
IL-8 3.65 ± 0.94 BDL 93.25 ± 11.39 79.12 ± 20.05 27.63 ± 4.41 442.2 ± 23.63 
BDL, below detection limit. Results shown as Mean ± SEM. Concentrations of soluble factors secreted by primary NK cells are presented as mean values 
of 3 independent donors. 
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3.4.3 NK-92/5.28.z activation depends on ErbB2 expression on target cells.  
To investigate the specificity of NK-92/5.28.z. and evaluate a threshold level of ErbB2 
on the target cell surface required for effector cell activation, three breast cancer cell 
lines (MDA-MB-361, MDA-MB-453 and MDA-MB-468), human hepatocellular 
carcinoma cell line (HepG2) and a glioblastoma cell line (G55T2) were tested for their 
ErbB2 status, showing expression ranging from negative (< 300 ErbB2 molecules/cell 
for MDA-MB-468 and G55T2) to highly positive (> 1 x 105 ErbB2 molecules/cell for 
MDA-MB-453). A subsequently conducted EuTDA cytotoxicity assay, showed that all 
target cells expressing ErbB2 protein (MDA-MB-453: 1.06 x 105 ± 0.03 x 105 
molecules/cell, MDA-MB-361: 6.99 x 104 ± 0.23 x 104 molecules/cell, HepG2: 
11.59 x 103 ± 0.29 x 103 molecules/cell; Mean ± SEM) were efficiently and selectively 
killed by NK-92/5.28.z (MDA-MB-453: 89.94 % ± 1.95 %, MDA-MB-361: 
77.04 % ± 1.34 %, HepG2: 71.7 % ± 3.97 %) confirming the dependency of 
NK-92/5.28.z cell activation on an ErbB2 presence on target cell surface (Figure 3.16). 
However, even in the case of ErbB2-negative targets a certain amount of specific lysis 
mediated by CAR-expressing NK-92 cells was observed (MDA-MB-468: 
13.34 % ± 3.05 %, G55T2: 17.72 % ± 1.55 %).  
 
Figure 3.16 Specific cytotoxicity of NK-92/5.28.z depends on ErbB2 expression on target cells. 
Number of ErbB2 molecules per target cell (white) was analyzed using QuantiBRITE-PE beads. 
Specific cytotoxicity of NK-92/5.28.z toward target cells was measured in EuTDA killing assay. 
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3.4.4 Impact of NK-92/NK-92/5.28.z on colony forming capacity of peripheral 
blood stem cells 
The possibility of off-tumor effects of the CAR-modified NK-92 cells, either through 
NK-receptor mediated mechanisms or through CAR-mediated on- or off-target effects 
must be considered, although previous work has not suggested such. Therefore, to test 
the impact of NK-cell treatment on normal hematopoietic cells, the colony forming 
capacity of peripheral blood stem cells (PBSCs) after co-incubation with NK-92, 
NK-92/5.28.z and conditioned medium (CM) derived from both NK cell lines was 
analyzed. There was no difference in myeloid colony number in any of the analyzed 
treatment combinations (+NK-92: 107.89 ± 5.73, +NK-92/5.28.z: 102.67 ± 2.66, 
+CM-NK-92: 95 ± 3.79, +CM-NK-92/5.28.z: 93.33 ± 5.47) when compared to 
an untreated control (PBSC: 97.63 ± 4.15). Interestingly, a slight but reproducible 
increase in the number of erythroid colonies post-treatment with conditioned medium of 
NK-92 (+CM-NK-92: 87.33 ± 3.28) and NK-92/5.28.z (+CM-NK-92/5.28.z: 
74.67 ± 2.06) from 48-hour culture was found, when compared to untreated control 
(PBSC: 64.88 ± 2.14) giving statistically significant differences of P<0.0001 and 
P=0.005 for CM-NK-92 and CM-NK-92/5.28.z, respectively. However, an increase in 
the frequency of erythroid colonies was not observed when PBSCs were treated with 
NK-92 (+NK-92: 72.44 ± 4.89) or NK-92/5.28.z cells (+NK-92/5.28.z: 64.56 ± 4.65), 
implicating soluble factors rather than direct cell-cell interaction in the observed 
phenomenon (Figure 3.17). 
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Figure 3.17 Colony forming capacity of peripheral blood stem cells post-treatment with NK-92 
(NK-92 10:1) and NK-92/5.28.z (NK-92/5.28.z 10:1) cells, as well as with conditioned medium derived 
from both NK cell lines (NK-92 CM and NK-92/5.28.z CM). Myeloid (grey bars) and erythroid 
(white bars) derived colonies were enumerated. Peripheral blood stem cells incubated in assay medium 
without effector cells were included as a control (PBSC). 
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4 Discussion 
To meet the regulatory requirements for clinical-grade cell expansion, reagents and 
protocols have to be well-defined so as to enable manufacturing of a cellular product in 
a reliable, safe and reproducible way. Elimination of components causing undue 
variability in cell quality or cell growth parameters is highly expected [100]. 
Three GMP-grade culture media were assessed for their ability to support cell 
proliferation in plasma-free and plasma-supplemented cultures. X-Vivo 10 containing 
recombinant transferrin (X-Vivo rTF) became our gold standard for the cultivation of 
parental and retargeted NK-92 cells, even as a plasma-free formulation, maintaining cell 
growth, phenotype and functionality at satisfactory levels. However, significantly 
longer doubling time of the cells cultivated in plasma-free (DT post-acclimation: 
47.37 h ± 2.75 h, Mean ± SEM) when compared to plasma-supplemented conditions 
(DT: 28.84 h ± 0.5 h, Mean ± SEM), stresses the need for further supplementation with 
human plasma in order to reach the required cell dose in a time-effective manner.  
CAR expressing NK-92, same as the parental cell line, is dependent on exogenous IL-2 
for cell survival, proliferation and potency. Although, other cytokines like IL-7, IL-12 
and IL-18 were tested as alternatives, only IL-2 was able to efficiently maintain 
the long-term growth and functionality of NK-92 cells [101,102]. In the current study, 
the optimal saturating concentration of this cytokine (500 U/ml of culture medium), 
efficiently supporting cell proliferation and cytotoxicity was successfully established. 
However, it is worth mentioning that genetically modified variants of NK-92 with 
ectopic expression of IL-2 (NK-92MI and NK-92 CI) and IL-15 (NK-92/IL-15-EGFP) 
have been generated and proved to be independent from exogenous cytokine support 
[42,43]. Although, the aforementioned cell lines are available only in their 
research-grade formats, the strategy seems to be promising and may simplify and 
economize established GMP-compliant protocols for the large-scale expansion 
of NK-92 cells. A growing body of literature stresses the beneficial effect of human 
platelet lysate (hPL) on the growth and function of various cell types, albeit mostly for 
primary, adherent cells [103,104]. We demonstrated a decreased proliferation rate of 
NK-92/5.28.z cells cultured in medium supplemented with platelet lysate when 
compared to cells cultured in human plasma supplemented medium. Moreover, an 
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inhibitory effect of TGF-beta, which is one of the main components of platelet alpha 
granules, on the functionality of primary NK cells and NK-92 cell line by 
downmodulation of NKp30 and NKG2D was reported [105,106]. Adverse effects on 
cytotoxicity were not observed in our studies, probably due to relatively low 
concentration (5 %) of platelet lysate (and hence, TGF-beta) in the culture medium and 
the short cultivation time (72 h). Indeed, the possibility that long-term culturing of 
NK-92/5.28.z cells in hPL supplemented medium could lead to loss of cytotoxicity 
should be considered. Based on the data obtained by the other researchers on TGF-beta 
concentration in human platelet lysate [107], we calculated that concentration of 
TGF-beta in our culture medium supplemented with 5 % of hPL (approximately 
7 ng/ml) might, be sufficient to attenuate the natural killing of NK-92 and NK-92/5.28.z 
if culturing period was extended. 
Long-term culturing and cell passaging may lead to the accumulation of genetic and 
epigenetic changes and as a consequence to alterations in phenotype and/or functional 
properties [108]. It also carries a potential risk for microbial or viral contaminations, 
as well as cross-contamination by other cell lines. To prevent these incidents, cryogenic 
preservation of valuable cell lines and generation of frozen stocks is widely used. 
However, in this approach, poor viability of NK cells following thawing may be 
an important factor, potentially limiting the clinical application by prolongation of the 
recovery phase, and thus the cell expansion period [109-111]. Therefore, finding 
optimal cryopreservation conditions appears to be substantial for efficiency of patient 
dose generation of NK-92/5.28.z cells. In the freezing/thawing cycle, the cryoprotective 
agent (CPA) plays an important role. The most extensively used CPA is DMSO, 
probably due to its ability to efficiently permeate most cell types and hence provide 
better recovery values, when compared to other CPAs. Moreover, concerning 
the clinical purpose of NK-92/5.28.z cells cryopreserved as master cell bank, it is of 
importance to use CPAs available at pharmacopeia-grade. DMSO from certified 
suppliers meets these standards. DMSO at suboptimal, low concentrations is not able to 
prevent ice crystal formation during the freezing process which, as a consequence, leads 
to rapid membrane rupture and cell death, whereas too high of a DMSO concentration 
might be cytotoxic [112]. The second important task in developing a cryopreservation 
process is selection of a base media used for CPA preparation. At the research scale, 
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animal sera were widely used with a great success due to their high content of lipids and 
proteins. Obviously, upgrading a cell line to the clinical grade-product renders the usage 
of animal derived components obsolete because of regulatory reasons, stressing 
the need of investigation of human derived (or, better yet, synthetic) alternatives [113]. 
Therefore, in this study, several combinations of GMP-compliant cryopreservation 
solutions with different DMSO content and human serum albumin (HSA) as a base 
medium were tested. After systematic testing, human serum albumin (HSA) 
supplemented with 7.5% of DMSO was identified as the optimal cryopreservation 
solution for recovery of CAR-expressing and parental NK-92 cells, after a freeze/thaw 
cycle, with post-thaw recovery values of 68.84 % ± 5.07 % and 49.51 % ± 5.12 %, 
respectively. Furthermore, results obtained in this study showed a significant decrease 
in recovery values of NK-92 (40.69 % ± 10.2 %) and NK-92/5.28.z (23.91 % ± 9.5 %) 
cells 24 hours after thawing when compared to measurements performed directly 
post-thaw. One possible reason could be freezing-induced damage of metabolic 
organelles, which resulted in cell death within a couple of hours post-thaw. 
This finding suggests that testing cell recovery only directly post-thaw may be 
insufficient for the establishment of optimal cryopreservation conditions. 
Extension of recovery analysis and comparisons of growth parameters of the cells 
frozen in different cryopreservation solutions, within the first few days post-thaw, may 
be necessary. Establishment of optimal expansion and cryopreservation protocols 
enabled the generation of a GMP-compliant master cell bank (MCB) of NK-92/5.28.z 
cells. Post-thaw analysis of manufacturing parameters confirmed the suitability of the 
procedure, as it resulted in a high quality of thawed NK-92/5.28.z cells with predictable 
cell growth, which ensures reproducible expansion of individual patient dose. 
The generation of a GMP-compliant MCB was an important part of the current study, 
providing an "on demand" well characterized platform for the expansion of therapeutic 
doses.  
Although NK-92 cells never engrafted in immunocompromised SCID mice, the few 
clinical trials that were done so far, always included γ-irradiation of the cell product 
prior to transfusion as a definitive safeguard against proliferation and engraftment in the 
patient. In clinical trials, employing parental NK-92 cells irradiated with 10 Gy, rapid 
clearance was reported, where NK-92 cells were detected in the patient’s blood up to 
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48 hours post-infusion [35,36]. For that reason, radiation sensitivity and maintenance of 
functionality after irradiation were investigated over time with the main focus on high 
density cell suspensions imitating therapeutic doses of NK-92/5.28.z. 
Our data confirmed irradiation dose of 10 Gy as the optimal treatment of genetically 
modified NK-92 cells intended for clinical application, offering a convenient balance 
between effector cell stability/efficacy (cell viability > 90 % for 24 hours; specific 
cytotoxicity > 50 % up to 18 hours) and definitive proliferation arrest. Additionally, the 
release of soluble factors by effector cells as a stress response to γ-irradiation was 
tested. As described for other cell types, we expected elevated levels of 
pro-inflammatory cytokines: IL-8 and IL-6 after exposure [114]. However, there was 
significant increase only in IL-8 production, whereas the release of IL-6 was not 
induced upon irradiation. This confirms the results of other experiments where IL-6 was 
not detected even after stimulation with ErbB2-positive targets.  
Formulation of the cellular product depends on the clinical application, where local 
injection into the vital body organs seems the most challenging. A good example of 
such an approach is an imminent clinical trial employing NK-92/5.28.z cells for the 
treatment of patients with ErbB2-overexpressing GBM, where intracranial injection of 
cell suspension will be performed through a Rickham reservoir implanted during 
resection surgery. This route of administration is associated with several limitations, for 
instance: the restricted injection volume which necessitates high cell densities in the 
final product in order to achieve clinically relevant doses. Another issue is the clinically 
applicable injection medium (excipient) optimal to preserve cell quality [115,116]. 
In this study, the concentration of 5 x 107 cells/ml was determined as a maximal stable 
cell concentration in the final product. Performed experiments showed that, too high of 
a concentration of the cells could be a limiting factor especially in the case of NK-92 
cells, which are particularly sensitive to overgrowth and hence rapidly lose their 
cytotoxic properties when stored in high densities. Moreover, prolonged storage in 
a closed system leads to nutrient and cytokine exhaustion and an accumulation of toxic 
metabolites like lactate, which may additionally impair the quality of the cells as well as 
cause a pH acidic shift of the storage/shipment solution. Therefore, to ensure clinical 
efficacy of NK-92/5.28.z, several buffers were tested to serve as an excipient for 
shipment and injection. X-Vivo 10 containing recombinant transferrin gave the most 
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promising results in terms of cell viability and potency over 6-hour storage 
(91.49 % ± 0.62 % and 86.18 % ± 2.58 %, respectively), indicating that the combination 
of supplements contained in this medium is optimal not only for NK-cell culturing but 
also for cell storage/shipment. The manufacturing of cellular products is associated with 
numerous limitations specific to the particular cell type. The aim of this study, 
therefore, was to solve the issues of reproducible and efficient cell expansion, optimal 
irradiation dose and maximal cell concentration in final product, which resulted in the 
establishment of a clinical grade manufacturing procedures enabling generation of 
sufficient numbers of functional cells to form a stable patient dose. Three independent 
cellular therapy product processing of NK-92/5.28.z cells were successfully completed. 
Post-preparation analysis of viability and cell potency revealed that the stability of 
generated patient doses was satisfactory in the context of clinical application, proving 
the optimal character of established conditions. 
In some ErbB2-overexpressing tumors potentially eligible for NK-92/5.28.z treatment, 
corticosteroids are part of the standard of care, used to reduce tumor-related symptoms 
or side effects of first line antitumor therapies (e.g. vasogenic edema in patients with 
malignant brain tumors) [117]. Considering the numerous studies reporting inhibitory 
effects of corticosteroids on NK-cell cytotoxicity [118,119], analysis of a potential 
impact of prednisolone treatment on CAR-mediated and natural killing by genetically 
modified NK-92 cells was of importance. As expected based on published reports, 
the natural killing ability against HLA-negative targets was strongly reduced in 
a dose-dependent manner. The effect is probably due to a downregulation of natural 
cytotoxicity receptors (NCR) as reported by other researchers [97]. 
Remarkably, retargeted cytotoxicity of NK-92/5.28.z was not affected, showing high 
potency in killing ErbB2-positive targets even after prednisolone treatment with the 
highest tested dose of 200 µg/ml of culture medium, which corresponds with the highest 
clinical dose applied intravenously (1000 mg). This interesting finding indicates the 
feasibility of NK-92/5.28.z as a combined or second line therapy and confirmed the 
independence of CAR-mediated cell activation from natural cytotoxicity mechanisms. 
Consequently, it may suggest the resistance of NK-92/5.28.z to common tumor-escape 
mechanisms utilizing the downregulation/exhaustion of natural cytotoxicity receptors 
by tumor cells (e.g. downregulation of NKp30 by soluble variants of its ligand B7-H6 in 
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ovarian carcinoma patients [120] or down-modulation of NKG2D by soluble MIC 
ligands [121-123]). 
Cytokine release syndrome (CRS) is the most common and most severe complication 
observed in patients subjected to immune-based therapies (e.g. CAR-engineered T cells 
or therapeutic antibodies).  In most cases CRS is fully reversible and manageable with 
a combination of supportive care and the IL-6 receptor-blocking antibody, tocilizumab. 
This indicates IL-6 is a major player at least in the early, acute phase of the syndrome. 
Moreover, IL-6 and TNF-α were the first inflammatory cytokines highly elevated in 
the serum of pediatric ALL patients suffering from grade 3 CRS after 
CD19-CAR T cells infusion [124,125]. In performed experiments, with CAR-armed 
NK-92 cells IL-6 was not produced by effector cells and TNF was secreted at very low 
levels, even upon strong stimulation. This suggests the superiority of engineered 
NK cells over T cells in this pivotal safety aspect. Therapies employing NK and T cells 
as effectors are diametrically opposed strategies where manipulated T cells are 
intended to persist in the patient’s circulation as memory cells and after tumor clearance 
serve as cancer immunosurveillance, while NK-cell based therapies preconceive 
effector cell degradation after rapid tumor elimination (with rather classical 
pharmacokinetics similar to conventional drugs), thus reducing the risk of long-term 
side effects [126]. On the other hand, intensified secretion of pro-inflammatory 
cytokines (IFN-γ, MIP-1α) by NK-92/5.28.z cells upon stimulation with ErbB2-positive 
targets, may contribute to the enhancement of endogenous antitumor immunity by 
stimulation of the host immune system, as recently explored by Zhang et al in mouse 
models of GMB [96]. Possible mechanisms of this phenomenon could be 
natural killer-dendritic cell (DC) interaction resulting in the conversion of DC into 
type-1 polarized DCs (DC1); demonstrating resistance to tumor-related suppressive 
mechanisms and endowed with the ability to induce Th1 and CTL antitumor responses 
[127,128]. Moreover, IFN-γ, secreted by tumor stimulated NK-92/5.28.z, may promote 
tumor-specific antibody production by B cells and activation of CD4+ T cells to secrete 
Th1 cytokines which lead to further CTL and B cell induction. 
The obtained results confirmed that ErbB2 expression on target cells is essential for 
robust activation of retargeted killing mediated by genetically modified NK-92 cells. 
However, it should be noted that all targets utilized in our experiments were of tumor 
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origin, expressing stress molecules and other factors inducing the activation of 
NK-92/5.28.z cells via natural killer receptors. Therefore, even in the case of 
ErbB2-negative targets (MDA-MB-468, G55T2) a certain amount of cell lysis was 
observed. The fact, that even low expression of the target molecule is sufficient to 
trigger potent and rapid activation of CAR-expressing NK-92 cells should be considered 
in terms of potential on-target/off-tumor effects and associated side effects. ErbB2 is not 
only overexpressed by cancer cells but also expressed at low levels by normal human 
tissues of epithelial origin [88]. In this safety aspect, the ErbB2-specific original 
monoclonal antibody from which the antigen binding domain is derived plays a critical 
role. A phase I clinical study utilizing immunotoxin (erb-38) consisting of the 
Fv portion of ErbB2-specific monoclonal antibody e23 fused to a truncated form of 
Pseudomonas exotoxin A, demonstrated hepatotoxicity in all treated patients [129]. 
Whereas in a similar approach with the recombinant antibody toxin scFv(FRP5)-ETA 
(binding domain derived from FRP5 mAb), administered at therapeutic doses, no 
induction of toxicity was reported [130]. Trastuzumab is an ErbB2-specific monoclonal 
antibody showing great potential as a therapy for the ErbB2-overexpressing breast 
cancers either alone or in combination with chemotherapy regimens; however, it is 
associated with a risk of cardiac dysfunction, due to a recognition of low levels of 
ErbB2 protein on adult human cardiomyocytes [91]. Conversely, the safety of 
the FRP5-based binding domain used for generation of the CAR applied in 
NK-92/5.28.z was recently confirmed. In that study, which included a group of 
recurrent/refractory sarcoma patients who were treated with ErbB2-specific CAR-T 
cells equipped with targeting domain, derived from FRP5, severe toxicities were not 
observed [131]. The few available clinical reports suggest, that the position of the 
binding epitope relative to the target cell membrane plays a crucial role in the safety 
issue. The FRP5 antibody recognizes the membrane distal domain of ErbB2 (epitope on 
subdomain I) distant from the trastuzumab-binding domain (epitope on subdomain IV) 
[130,132]. Furthermore, no cytotoxicity above background values was observed in 
in vitro killing assays against normal human cardiomyocytes, lung epithelial cells and 
PBMCs, as reported by Schonfeld et al [95]. In this work, analysis of potential adverse 
reactions caused by NK-treatment was extended to the investigation of colony-forming 
capacity of peripheral blood progenitor cells (apheresis material from G-CSF mobilized 
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donors) treated in vitro with NK-92, NK-92/5.28.z or CM of both, where no reduction 
in clonogenic potential was observed. Interestingly, there was a slight but significant 
increase in the number of erythroid colonies suggesting the presence of growth factors 
in NK-conditioned medium [133] which in combination with the erythropoietin present 
in the cytokine-replete methylcellulose medium used for our studies could induce 
modest erythroid skewing [134]. 
In this study, GMP-compliant procedures enabling the production of therapeutic doses 
of NK-92/5.28.z were successfully established. Moreover, crucial factors concerning 
safety and efficacy in the context of imminent clinical trials were discussed. 
In summary, it was shown that NK-92 is not only a very good candidate to become 
a potent, standard therapy for treatment of tumors, but it is also a perfect platform for 
further modification. Its CAR-expressing derivative NK-92/5.28.z. retains main features 
of parental cells (phenotype, doubling time, the same optimal culture and 
cryopreservation conditions) while exhibiting superior, selective potency against 
ErbB2-positive targets normally resistant to NK-cell cytotoxicity. 
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5 Summary 
5.1 Abstract 
The NK-92/5.28.z cell line is an ErbB2 (HER2) specific, CAR-expressing continuously 
growing derivative of the clinically applicable NK-92 line, and exhibits profound and 
highly specific cytotoxicity against ErbB2-expressing tumor targets which are resistant 
to parental NK-92 cells. This study aimed to establish good manufacturing practice 
procedures enabling the generation of therapeutic doses of ErbB2-CAR expressing 
NK-92 cells for upcoming phase I/II clinical trials in ErbB2-overexpressing 
malignancies. The concept of patient dose manufacturing presented here encompasses 
the generation of a GMP-compliant master cell bank, which serves as a well-defined 
source of NK-92/5.28.z cells for further expansion of individual patient doses. 
To reach sufficient numbers of genetically modified NK-92 cells, expansion protocols 
were developed by systematic testing of culture conditions including GMP-grade 
culture media (X-Vivo 10 with human holo-transferrin, X-Vivo 10 with recombinant 
transferrin, CellGro) and human serum substitutes (human serum albumin, platelet 
lysate, heat inactivated human plasma). Since growth and potency of NK-92/5.28.z cells 
are IL-2 dependent, identification of a suitable concentration of this cytokine was an 
important issue addressed in this work. As a result of performed analyses, X-Vivo 10 
containing recombinant transferrin supplemented with 5 % of heat inactivated human 
plasma and 500 U/ml IL-2 was selected as the culture medium for clinical expansions. 
This combination supported reproducible cell growth with doubling time 
of 28.84 h ± 0.5 h ±, maximal -fold expansion in batch culture of 
24.97 ± 0.65 (max. conc.: 12.49 x 105 ± 0.32 x 105 cells/ml ) stable CAR expression and 
potency of the cells, even in long-term culture (CAR expression: 99.77 % ± 0.03 %; 
specific cytotoxicity: 89.75 % ± 3.77 % after 12 months of culturing). Considering the 
sensitivity of NK-92 and its CAR-expressing derivative to cryopreservation procedures, 
a part of this thesis focused on selection of cryopreservation solutions providing 
satisfactory post-thaw recovery of frozen cells, where human serum albumin as a base 
medium supplemented with 7.5 % DMSO gave the best results (post-thaw recovery of 
5 Summary 80 
NK-92/5.28.z cells: 68.84 % ± 5.07 %). Following established GMP-compliant culture 
and cryopreservation procedures, a master cell bank comprising 200 vials of 
NK-92/5.28.z cells was generated. By means of concurrently developed quality control 
methods, 6 representative vials from the master cell bank were tested in terms of 
manufacturing related parameters (mean cryovial content, post-thaw recovery and cell 
growth, cell identity, specific cytotoxicity) confirming the high quality of the cells and 
thereby the validity of the performed process. Multiparameter analysis revealed that 
therapeutic doses of 5 x 109 NK-92/5.28.z cells can be expanded from a master cell 
bank within 5 days. Application of X-Vivo 10 rTF medium supplemented with 
100 U/ml of IL-2 as an excipient, supported 6-hour shelf life of irradiated (10 Gy) 
NK-92/5.28.z cells formulated as a final product at the density of 5 x 107/ml. 
This concentration translates to the final dosage form of 1 x 108 cells/dose in 2 ml, 
a volume which is suitable for intracranial injection in the upcoming clinical trial in 
glioblastoma. The systemic (intravenous) route of administration planned in 
an upcoming breast cancer trial will allow the infusion of even higher volumes of up to 
100 ml, and thereby higher cell numbers up to 5 x 109 cells/dose. In addition, 
investigation of factors impacting the efficacy and safety of clinical application was 
another important part of this thesis. Analysis of soluble factors released by target 
stimulated NK-92/5.28.z cells showed selective and significant increase in the secretion 
of GZMB (2-fold), IFN-γ (4-fold), IL-8 (24-fold) and IL-10 (5-fold) NK-92/5.28.z upon 
stimulation with ErbB2(+) targets. This phenomenon was not observed in the case of 
parental NK-92 cells and primary NK cells, indicating resistance of ErbB2(+) target cell 
line to natural killing mechanism, which can be overcome by specific CAR-mediated 
activation. Abundant amounts of immunomodulatory cytokines secreted by tumor 
activated NK-92/5.28.z may stimulate the host immune system by interaction with 
dendritic cells, induction of CTL and tumor-specific antibody production by B cells. 
Of possible relevance for clinical tolerability, IL-6 which plays the leading role in 
cytokine release syndrome was not detected. Treatment with clinically relevant doses of 
corticosteroids (maximal dose of 200 µg/ml corresponds with the highest dose of 
prednisolone applied clinically) did not affect retargeted killing of ErbB2(+) targets by 
NK-92/5.28.z cells, while natural killing against K562 cells was attenuated in 
a dose-dependent manner, as expected. Colony forming assays with mobilized 
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peripheral blood progenitor cells pretreated with NK-92 or NK-92/5.28.z showed no 
evidence of NK cell impact on the colony forming capacity of PBSCs. In this study, 
GMP-compliant procedure enabling production of therapeutic doses of NK-92/5.28.z 
was successfully established. The data identify genetically modified, CAR-expressing 
NK-92 cells as a powerful, clinically feasible candidate for efficient and safe adoptive 
immunotherapy of ErbB2-overexpressing malignancies like breast cancer or 
glioblastoma. 
5.2 Zusammenfassung 
Die NK-92/5.28.z-Zelllinie ist unter optimalen Zellkulturbedingungen eine 
kontinuierlich wachsende, ErbB2 (Her2) Tumorantigen spezifische CAR-exprimierende 
Variante der klinisch einsetzbaren NK-92-Zellen. Sie zeichnet sich durch ihre hohe 
Zytotoxizität gegenüber ErbB2-positiven Tumorzellen aus, die gegen parentale NK-92-
Zellen resistent sind. Das Ziel dieser Arbeit war die Etablierung von GMP-konformen 
Protokollen zur Herstellung von therapeutischen Dosen ErbB2-CAR-exprimierender 
NK-92/5.28.z-Zellen für bevorstehende klinische Phase I/II Studien zur Therapie 
ErbB2-überexprimierender Tumore. Das in dieser Arbeit vorgestellte Konzept zur 
Herstellung therapeutischer Dosen schließt die Erstellung einer GMP-konformen 
Masterzellbank ein, die als qualifizierte Ausgangsbasis für die Herstellung von 
individuellen Patientendosen der NK-92/5.28.z-Zelllinie dienen soll. 
Um eine ausreichende Anzahl genetisch modifizierter NK-92/5.28.z-Zellen zu erhalten, 
wurden optimale Expansionsprotokolle entwickelt, indem systematisch die 
Kulturbedingungen getestet wurden. Insbesondere wurde die Eignung verschiedener 
Zellkulturmedien (X-Vivo 10 mit humanem holo-Transferrin, X-Vivo 10 mit 
rekombinantem Transferrin (rTF), CellGro) sowie humaner Serumsubstitute (humanes 
Serumalbumin, humanes Plättchenlysat, hitzeinaktiviertes humanes Plasma) hinsichtlich 
einer GMP-konformen Zellexpansion untersucht. Da Zellproliferation und 
Funktionalität von NK-92/5.28.z-Zellen IL-2-abhängig sind, war die Findung einer 
optimalen Konzentration dieses Zytokins ein wichtiger Aspekt dieser Arbeit. Es zeigte 
sich, dass das Zellkulturmedium X-Vivo 10 mit rTF, supplementiert mit 5% 
hitzeinaktiviertem humanem Plasma und 500 IU/ml rekombinantem IL-2, ein 
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reproduzierbares Zellwachstum und gleichbleibende Funktionalität mit stabilen 
Zelldopplungszeiten (28,84 h ± 0,50 h), einer 24,97 ± 0,65 –fachen maximalen 
Expansion (max. Zellkonzentration: 12,49 x 105 ± 0,32 x 105 Zellen/ml) sowie einer 
stabilen CAR-Expression und funktionellen Aktivität (CAR-Expression: 
99.77 % ± 0.03 %; spezifische Zytotoxizität: 89.75 % ± 3.77 %) auch in einer 
Langzeitkultur bis 12 Monate garantiert. In Anbetracht der Empfindlichkeit von NK-92-
Zellen und der davon abgeleiteten genetisch modifizierten Variante wurde ein 
besonderer Schwerpunkt auf die Optimierung der Kryokonservierungsmedien 
hinsichtlich der erzielbaren Zellausbeuten nach dem Auftauprozess gelegt. Hier zeigte 
sich 7,5% DMSO in humanem Serumalbumin als am besten geeignet (Rate vitaler NK-
92/5.28.z-Zellen nach dem Auftauen: 68.84 % ± 5.07 %). Auf Basis dieser GMP-
konformen Zellkultur und Kryokonservierung wurde eine Masterzellbank von NK-
92/5.28.z-Zellen mit 200 Ampullen angelegt. Entsprechend der entwickelten 
Qualitätskontrollprotokolle konnte bei allen 6 repräsentativ untersuchten Ampullen der 
Masterzellbank die Einhaltung von herstellungsrelevanten Aspekten, wie 
Gesamtzellzahl, Zellkonzentration, Zellausbeute nach dem Auftauen, Zellwachstum, 
Zellidentität und spezifische Zytotoxizität bestätigt werden. Anschließend wurden 
Faktoren untersucht, die hinsichtlich der Herstellung einer Patientendosis essentiell 
sind. Dies umfasste Transportbedingungen, Injektionsmedium, Bestrahlungsdosis und 
die maximale Zellkonzentration des finalen Produktes. Therapeutische Patientendosen 
von 5 x 109 NK-92/5.28.z-Zellen konnten innerhalb von 5 Tagen aus der 
Masterzellbank generiert werden. Die Verwendung von X-Vivo 10 rTF,  supplementiert 
mit 100 IU/ml rekombinantem IL-2 als Exzipient erlaubte für die Formulierung des 
Endproduktes eine Zelldichte von 5 x 107/ml bestrahlter (10Gy) NK-92/5.28.z-Zellen 
und ermöglichte eine Haltbarkeit des Produktes von 6 Stunden. Zur intrakranialen 
Applikation der NK-92/5.28.z-Zellen in der geplanten Glioblastom-Studie  können 
maximal 2 ml Zelldispersion verwendet werden, so dass als maximale finale Dosis 
1 x 108 Zellen injiziert werden können. Die systemische Gabe in der geplanten 
klinischen Studie für Brustkrebspatienten ermöglicht die Injektion von bis zu 100 ml 
Zelldispersion, wodurch bei diesen Patienten bis zu 5 x 109 NK-92/5.28.z-Zellen pro 
Injektion appliziert werden können. Zusätzlich wurden weitere Faktoren untersucht, die 
wesentliche Auswirkungen auf die Effizienz und Sicherheit einer klinischen 
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Anwendung von NK-92/5.28.z-Zellen haben. So konnte nach Zellkontakt mit 
Tumorantigen-exprimierenden Zielzellen mit NK-92/5.28.z-Zellen ein signifikanter 
Anstieg der Sekretion von Granzyme B (2-fach), IFN-γ (4-fach), IL-8 (24-fach) und 
IL-10 (5-fach) durch NK-92/5.28.z-Zellen bestimmt werden. Diese Sekretion war 
spezifisch für NK-92/5.28.z-Zellen und konnte sowohl für parentale NK-92-Zellen als 
auch für primäre NK-Zellen nicht beobachtet werden, was die Resistenz 
ErbB2(+)-Zielzellen gegenüber der natürlichen Zytotoxizität nahe legt. Große Mengen 
immunmodulatorischer Zytokine, die durch aktivierte NK-92/5.28.z-Zellen sekretiert 
werden, können durch Interaktionen mit dendritischen Zellen, Induktion von CTL und 
tumor-spezifischen Antikörper produzierenden B-Zellen Einfluss auf das 
Wirtsimmunsystem nehmen. IL-6, ein pro-inflammatorisches Zytokin, dem eine 
entscheidende Rolle beim sogenannten „cytokine-release syndrom“ zukommt, konnte 
nicht nachgewiesen werden. Weiterhin konnte gezeigt werden, dass klinisch relevante 
Dosen von Kortikosteroiden (die maximale eingesetzte Dosis von 200 µg/ml entspricht 
der höchsten verabreichten Prednisolonmenge, die klinisch appliziert wird) keinen 
Einfluss auf die spezifische Zytotoxizität von  NK-92/5.28.z-Zellen haben, während die 
natürliche Zytotxizität gegenüber K562-Zellen dosisabhängig inhibiert wurde. 
Schließlich konnte auch kein Einfluss der parentalen NK-92-Zellen sowie der 
NK-92/5.28.z-Zellen auf die Koloniebildungsfähigkeit von humanen peripheren 
Blutstammzellen in sogenannten CFU- (colony forming units) Assays nachgewiesen 
werden.   
In dieser Arbeit wurde ein GMP-konformer Prozess zur Herstellung therapeutischer 
Dosen von NK-92/5.28.z-Zellen erfolgreich etabliert und validiert. Die Ergebnisse 
demonstrieren, dass gegen das Tumorantigen ErbB2 gerichtete CAR-exprimierende 
NK-92-Zellen ein wirkungsvolles, klinisch anwendbares Therapeutikum für die 
Behandlung ErbB2-überexprimierender Tumore, wie Brustkrebs und Glioblastom, 
darstellt. 
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6.1 Abbreviations 
° C Degree Celsius 
ADCC Antibody-dependent cell-mediated cytotoxicity 
ALL Acute lymphoblastic leukemia 
APC Allophycocyanin 
CAIX Carbonic anhydrase IX 
CAR Chimeric antigen receptor 
CD Cluster of differentiation 
CLL Chronic lymphatic leukemia 
CM Conditioned medium 
Conc. Concentration 
CR Complete remission 
CRS Cytokine release syndrome 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DT Doubling time 
E/T Effector to target ratio 
EBV Epstein–Barr virus 
EGFR Epidermal growth factor receptor 
EpCAM Epithelial cell adhesion molecule 
Eu Europium 
FACS Fluorescence-activated cell sorting 
FasL  Fas ligand 
FBS Fetal bovine serum 
FDA Food and drug administration 
FFP Fresh frozen plasma 
FITC Fluorescein isothiocyanate 
G-CSF Granulocyte-colony stimulating factor 
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GD2 Disialoganglioside 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GMP Good manufacturing practice 
GvHD Graft versus host disease 
Gy Gray 
GZMB Granzyme B 
h Hour 
HER2 Human epidermal growth factor receptor 2 
HER2taNK HER2 specific target activated natural killer cells 
HI Heat inactivated 
HLA Human leukocyte antigen 
hPL Human platelet lysate 
HSA Human serum albumin 
IFN Interferon 
IL Interleukin 
kDa Kilodalton 
L Liter 
LGL Large granular lymphocyte 
Max. Maximal 
min Minute 
Min. Minimal 
ml Milliliter 
mM Millimolar 
mOS Median overall survival 
mOsm Milliosmole 
NCR Natural cytotoxicity receptor 
NHL Non-Hodgkin lymphoma 
NK Natural killer cells 
PBSC Peripheral blood stem cells 
PE Phycoerythrin 
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PFS Progression free survival 
PMA Phorbol 12-myristate 13-acetate 
pNK Primary natural killer cell 
R Receptor 
r Recombinant 
RCC Renal cell carcinoma 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
scFv Single chain variable fragment 
SCGM Stem cell growth medium 
SEM Standard error of the mean 
TF Transferrin 
TNF Tumor necrosis factor 
TRAIL TNF–related apoptosis-inducing ligand 
TRF Time-resolved fluorometry 
TWEAK TNF-like weak inducer of apoptosis 
WT Wild-type cells 
6 Addendum 87 
 
6.2 List of figures 
Figure 1.1 Distribution of NK cell populations. ............................................................... 2 
Figure 1.2 Model of human NK cell maturation .............................................................. 3 
Figure 1.3 Balance between activating and inhibitory signals regulates the interaction 
between NK cell and target cell. ....................................................................................... 5 
Figure 1.4 Role of NK cells in antitumor immunity. ........................................................ 6 
Figure 1.5 Lack of KIR expression increases the cytolytic activity of NK-92 cells. ....... 8 
Figure 1.6 Generations of chimeric antigen receptors. ................................................... 12 
Figure 1.7 Immunoglobulin-derived regions utilized in CAR construct ........................ 13 
Figure 1.8 Mechanism of action of ErbB2 targeted therapeutic agents. ......................... 20 
Figure 1.9 ErbB2 specific 2nd generation CAR expressed by NK-92/5.28.z .................. 21 
Figure 2.1 Generation of a master cell bank ................................................................... 32 
Figure 2.2 Principle of CAR staining ............................................................................. 34 
Figure 2.3 Cytometric bead array assay. ......................................................................... 37 
Figure 2.4 Scheme of CFU-C assay. ............................................................................... 39 
Figure 3.1 Comparison of NK-92/5.28.z cell growth in GMP-compliant serum-free 
culture media. .................................................................................................................. 42 
Figure 3.2 Acclimation of NK-92/5.28.z cells to serum/plasma-free culture. ................ 43 
Figure 3.3 Expansion and functionality of NK-92 and NK-92/5.28.z cultured in medium 
supplemented with various IL-2 concentrations. ............................................................ 45 
Figure 3.4 Comparison of functionality and proliferation of NK-92/5.28.z cells cultured 
in human plasma and platelet lysate (hPL) supplemented medium. ............................... 46 
Figure 3.5 Influence of cryopreservation solutions on NK-92 and NK-92/5.28.z cells 
post-thaw recovery.  ........................................................................................................ 49 
Figure 3.6 Influence of presence of NK-92/5.28.z.-derived conditioned medium (CM) in 
cryopreservation solution on post-thaw recovery and cell growth of NK-92/5.28.z. ..... 50 
Figure 3.7 Impact of γ-irradiation on the proliferation, viability and potency of NK-92 
and NK-92/5.28.z. ........................................................................................................... 52 
Figure 3.8 Influence of irradiation dose on soluble factors release by stimulated 
NK-92/5.28.z. ................................................................................................................. 53 
Figure 3.9 Master cell bank qualification with regard to manufacturing parameters. .... 55 
Figure 3.10 Impact of storage buffers on the stability of NK-92/5.28.z. ........................ 58 
7 Addendum 88 
Figure 3.11 Stability of γ-irradiated NK-92/5.28.z cells in high density cell suspensions 
over storage under ambient conditions in X-Vivo 10 + 100 U/ml of IL-2. .................... 59 
Figure 3.12 Expansion of individual patient dose and testing of final product stability. 
 ........................................................................................................................................ 60 
Figure 3.13 Impact of 24-hour prednisolone treatment on CAR-mediated cytotoxicity 
against ErbB2(+) cells and natural killing against K562 cells. .....................................  62 
Figure 3.14 Influence of second generation ErbB2-CAR expression on the release of 
soluble factors by stimulated NK-92 cells. ..................................................................... 65 
Figure 3.15 Release of soluble factors by target stimulated primary NK cells isolated 
from buffy coats of normal peripheral blood from 3 independent donors. ..................... 66 
Figure 3.16 Specific cytotoxicity of NK-92/5.28.z depends on ErbB2 expression on 
target cells. ...................................................................................................................... 68 
Figure 3.17 Colony forming capacity of peripheral blood stem cells post-treatment with 
NK-92 and NK-92/5.28.z cells, as well as with conditioned medium derived from both 
NK cell lines. .................................................................................................................. 70 
 
6.3 List of tables 
Table 1.1 NK cell lines ..................................................................................................... 7 
Table 1.2 ErbB2 overexpression in different types of tumors ........................................ 17 
Table 2.1 List of chemicals ............................................................................................. 24 
Table 2.2 List of cell culture reagents ............................................................................. 24 
Table 2.3 List of buffers ................................................................................................. 25 
Table 2.4 List of antibodies ............................................................................................ 26 
Table 2.5 List of kits ....................................................................................................... 26 
Table 3.1 Impact of different serum substitutes in GMP-compliant, albumin containing 
culture media supplemented with 500 U/ml of IL-2 on NK-92/5.28.z cells proliferation 
 ........................................................................................................................................ 47 
Table 3.2 Summary of tested cryopreservation solutions for freezing of NK-92/5.28.z 50 
Table 3.3 Cytokine profile of PMA (50ng/ml)/Ionomycin (500ng/ml) stimulated target 
cells. ................................................................................................................................ 64 
7 Addendum 89 
Table 3.4 Secretion of soluble factors by unstimulated and K562 stimulated primary NK 
cells (pNK) and NK cell lines. ........................................................................................ 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 References 90 
7 References 
Reference List 
 
 [1] M. A. Caligiuri, Human natural killer cells, Blood, 112 (2008) 461-469. 
 [2] J. E. Melsen, G. Lugthart, A. C. Lankester, and M. W. Schilham, Human 
Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations, 
Front Immunol., 7 (2016) 262. 
 [3] G. Ferlazzo, D. Thomas, S. L. Lin, K. Goodman, B. Morandi, W. A. Muller, A. 
Moretta, and C. Munz, The abundant NK cells in human secondary lymphoid 
tissues require activation to express killer cell Ig-like receptors and become 
cytolytic, J. Immunol., 172 (2004) 1455-1462. 
 [4] A. G. Freud, B. Becknell, S. Roychowdhury, H. C. Mao, A. K. Ferketich, G. J. 
Nuovo, T. L. Hughes, T. B. Marburger, J. Sung, R. A. Baiocchi, M. Guimond, 
and M. A. Caligiuri, A human CD34(+) subset resides in lymph nodes and 
differentiates into CD56bright natural killer cells, Immunity., 22 (2005) 295-
304. 
 [5] A. Moretta, C. Bottino, M. Vitale, D. Pende, R. Biassoni, M. C. Mingari, and L. 
Moretta, Receptors for HLA class-I molecules in human natural killer cells, 
Annu. Rev. Immunol., 14 (1996) 619-648. 
 [6] D. H. Raulet and R. E. Vance, Self-tolerance of natural killer cells, Nat. Rev. 
Immunol., 6 (2006) 520-531. 
 [7] Y. T. Bryceson, M. E. March, H. G. Ljunggren, and E. O. Long, Activation, 
coactivation, and costimulation of resting human natural killer cells, Immunol. 
Rev., 214 (2006) 73-91. 
 [8] E. Vivier, S. Ugolini, D. Blaise, C. Chabannon, and L. Brossay, Targeting 
natural killer cells and natural killer T cells in cancer, Nat. Rev. Immunol., 12 
(2012) 239-252. 
 [9] L. L. Lanier, NK cell recognition, Annu. Rev. Immunol., 23 (2005) 225-274. 
 [10] D. Pende, S. Parolini, A. Pessino, S. Sivori, R. Augugliaro, L. Morelli, E. 
Marcenaro, L. Accame, A. Malaspina, R. Biassoni, C. Bottino, L. Moretta, and 
A. Moretta, Identification and molecular characterization of NKp30, a novel 
triggering receptor involved in natural cytotoxicity mediated by human natural 
killer cells, J. Exp. Med., 190 (1999) 1505-1516. 
 [11] M. Vitale, C. Bottino, S. Sivori, L. Sanseverino, R. Castriconi, E. Marcenaro, R. 
Augugliaro, L. Moretta, and A. Moretta, NKp44, a novel triggering surface 
molecule specifically expressed by activated natural killer cells, is involved in 
7 References 91 
non-major histocompatibility complex-restricted tumor cell lysis, J. Exp. Med., 
187 (1998) 2065-2072. 
 [12] S. Sivori, M. Vitale, L. Morelli, L. Sanseverino, R. Augugliaro, C. Bottino, L. 
Moretta, and A. Moretta, p46, a novel natural killer cell-specific surface 
molecule that mediates cell activation, J. Exp. Med., 186 (1997) 1129-1136. 
 [13] M. J. Smyth, Y. Hayakawa, K. Takeda, and H. Yagita, New aspects of natural-
killer-cell surveillance and therapy of cancer, Nat. Rev. Cancer, 2 (2002) 850-
861. 
 [14] S. Bauer, V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies, 
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible 
MICA, Science, 285 (1999) 727-729. 
 [15] D. Cosman, J. Mullberg, C. L. Sutherland, W. Chin, R. Armitage, W. Fanslow, 
M. Kubin, and N. J. Chalupny, ULBPs, novel MHC class I-related molecules, 
bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the 
NKG2D receptor, Immunity., 14 (2001) 123-133. 
 [16] P. H. Kruse, J. Matta, S. Ugolini, and E. Vivier, Natural cytotoxicity receptors 
and their ligands, Immunol. Cell Biol., 92 (2014) 221-229. 
 [17] C. S. Brandt, M. Baratin, E. C. Yi, J. Kennedy, Z. Gao, B. Fox, B. Haldeman, C. 
D. Ostrander, T. Kaifu, C. Chabannon, A. Moretta, R. West, W. Xu, E. Vivier, 
and S. D. Levin, The B7 family member B7-H6 is a tumor cell ligand for the 
activating natural killer cell receptor NKp30 in humans, J. Exp. Med., 206 
(2009) 1495-1503. 
 [18] M. J. Smyth, E. Cretney, J. M. Kelly, J. A. Westwood, S. E. Street, H. Yagita, K. 
Takeda, S. L. van Dommelen, M. A. Degli-Esposti, and Y. Hayakawa, 
Activation of NK cell cytotoxicity, Mol. Immunol., 42 (2005) 501-510. 
 [19] R. B. Herberman and H. T. Holden, Natural cell-mediated immunity, Adv. 
Cancer Res., 27 (1978) 305-377. 
 [20] Y. Hayakawa and M. J. Smyth, Innate immune recognition and suppression of 
tumors, Adv. Cancer Res., 95 (2006) 293-322. 
 [21] S. E. Street, E. Cretney, and M. J. Smyth, Perforin and interferon-gamma 
activities independently control tumor initiation, growth, and metastasis, Blood, 
97 (2001) 192-197. 
 [22] E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, Functions of 
natural killer cells, Nat. Immunol., 9 (2008) 503-510. 
 [23] A. Martin-Fontecha, L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. 
Lanzavecchia, and F. Sallusto, Induced recruitment of NK cells to lymph nodes 
provides IFN-gamma for T(H)1 priming, Nat. Immunol., 5 (2004) 1260-1265. 
7 References 92 
 [24] R. Mocikat, H. Braumuller, A. Gumy, O. Egeter, H. Ziegler, U. Reusch, A. 
Bubeck, J. Louis, R. Mailhammer, G. Riethmuller, U. Koszinowski, and M. 
Rocken, Natural killer cells activated by MHC class I(low) targets prime 
dendritic cells to induce protective CD8 T cell responses, Immunity., 19 (2003) 
561-569. 
 [25] J. M. Kelly, P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, and 
M. J. Smyth, Induction of tumor-specific T cell memory by NK cell-mediated 
tumor rejection, Nat. Immunol., 3 (2002) 83-90. 
 [26] Y. Matsuo and H. G. Drexler, Immunoprofiling of cell lines derived from 
natural killer-cell and natural killer-like T-cell leukemia-lymphoma, Leuk. Res., 
27 (2003) 935-945. 
 [27] P. Trempat, J. Tabiasco, P. Andre, N. Faumont, F. Meggetto, G. Delsol, R. D. 
Gascoyne, J. J. Fournie, E. Vivier, and P. Brousset, Evidence for early infection 
of nonneoplastic natural killer cells by Epstein-Barr virus, J. Virol., 76 (2002) 
11139-11142. 
 [28] J. H. Gong, G. Maki, and H. G. Klingemann, Characterization of a human cell 
line (NK-92) with phenotypical and functional characteristics of activated 
natural killer cells, Leukemia, 8 (1994) 652-658. 
 [29] H. G. Klingemann, E. Wong, and G. Maki, A cytotoxic NK-cell line (NK-92) 
for ex vivo purging of leukemia from blood, Biol. Blood Marrow Transplant., 2 
(1996) 68-75. 
 [30] Y. Yan, P. Steinherz, H. G. Klingemann, D. Dennig, B. H. Childs, J. McGuirk, 
and R. J. O'Reilly, Antileukemia activity of a natural killer cell line against 
human leukemias, Clin. Cancer Res., 4 (1998) 2859-2868. 
 [31] Y. K. Tam, J. A. Martinson, K. Doligosa, and H. G. Klingemann, Ex vivo 
expansion of the highly cytotoxic human natural killer-92 cell-line under current 
good manufacturing practice conditions for clinical adoptive cellular 
immunotherapy, Cytotherapy., 5 (2003) 259-272. 
 [32] G. Maki, H. G. Klingemann, J. A. Martinson, and Y. K. Tam, Factors regulating 
the cytotoxic activity of the human natural killer cell line, NK-92, J. 
Hematother. Stem Cell Res., 10 (2001) 369-383. 
 [33] S. Rajagopalan and E. O. Long, KIR2DL4 (CD158d): An activation receptor for 
HLA-G, Front Immunol., 3 (2012) 258. 
 [34] S. Arai, R. Meagher, M. Swearingen, H. Myint, E. Rich, J. Martinson, and H. 
Klingemann, Infusion of the allogeneic cell line NK-92 in patients with 
advanced renal cell cancer or melanoma: a phase I trial, Cytotherapy., 10 (2008) 
625-632. 
7 References 93 
 [35] T. Tonn, S. Becker, R. Esser, D. Schwabe, and E. Seifried, Cellular 
immunotherapy of malignancies using the clonal natural killer cell line NK-92, 
J. Hematother. Stem Cell Res., 10 (2001) 535-544. 
 [36] T. Tonn, D. Schwabe, H. G. Klingemann, S. Becker, R. Esser, U. Koehl, M. 
Suttorp, E. Seifried, O. G. Ottmann, and G. Bug, Treatment of patients with 
advanced cancer with the natural killer cell line NK-92, Cytotherapy., 15 (2013) 
1563-1570. 
 [37] L. Boissel, M. Betancur, W. Lu, W. S. Wels, T. Marino, R. A. Van Etten, and H. 
Klingemann, Comparison of mRNA and lentiviral based transfection of natural 
killer cells with chimeric antigen receptors recognizing lymphoid antigens, 
Leuk. Lymphoma, 53 (2012) 958-965. 
 [38] L. Binyamin, R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. 
M. Weiner, Blocking NK cell inhibitory self-recognition promotes antibody-
dependent cellular cytotoxicity in a model of anti-lymphoma therapy, J. 
Immunol., 180 (2008) 6392-6401. 
 [39] G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, 
and H. Watier, Therapeutic activity of humanized anti-CD20 monoclonal 
antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, 99 
(2002) 754-758. 
 [40] L. Boissel, M. Betancur-Boissel, W. Lu, D. S. Krause, R. A. Van Etten, W. S. 
Wels, and H. Klingemann, Retargeting NK-92 cells by means of, 
Oncoimmunology., 2 (2013) e26527. 
 [41] C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, H. G. Klingemann, and 
W. Wels, Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing 
cancer cells results in efficient and selective tumor cell destruction, Blood, 100 
(2002) 1265-1273. 
 [42] C. Sahm, K. Schonfeld, and W. S. Wels, Expression of IL-15 in NK cells results 
in rapid enrichment and selective cytotoxicity of gene-modified effectors that 
carry a tumor-specific antigen receptor, Cancer Immunol. Immunother., 61 
(2012) 1451-1461. 
 [43] Y. K. Tam, G. Maki, B. Miyagawa, B. Hennemann, T. Tonn, and H. G. 
Klingemann, Characterization of genetically altered, interleukin 2-independent 
natural killer cell lines suitable for adoptive cellular immunotherapy, Hum. Gene 
Ther., 10 (1999) 1359-1373. 
 [44] A. Romanski, G. Bug, S. Becker, M. Kampfmann, E. Seifried, D. Hoelzer, O. G. 
Ottmann, and T. Tonn, Mechanisms of resistance to natural killer cell-mediated 
cytotoxicity in acute lymphoblastic leukemia, Exp. Hematol., 33 (2005) 344-
352. 
7 References 94 
 [45] R. Esser, T. Muller, D. Stefes, S. Kloess, D. Seidel, S. D. Gillies, C. Aperlo-
Iffland, J. S. Huston, C. Uherek, K. Schonfeld, T. Tonn, N. Huebener, H. N. 
Lode, U. Koehl, and W. S. Wels, NK cells engineered to express a GD2 -
specific antigen receptor display built-in ADCC-like activity against tumour 
cells of neuroectodermal origin, J. Cell Mol. Med., 16 (2012) 569-581. 
 [46] S. Genssler, M. C. Burger, C. Zhang, S. Oelsner, I. Mildenberger, M. Wagner, J. 
P. Steinbach, and W. S. Wels, Dual targeting of glioblastoma with chimeric 
antigen receptor-engineered natural killer cells overcomes heterogeneity of 
target antigen expression and enhances antitumor activity and survival, 
Oncoimmunology., 5 (2016) e1119354. 
 [47] T. Muller, C. Uherek, G. Maki, K. U. Chow, A. Schimpf, H. G. Klingemann, T. 
Tonn, and W. S. Wels, Expression of a CD20-specific chimeric antigen receptor 
enhances cytotoxic activity of NK cells and overcomes NK-resistance of 
lymphoma and leukemia cells, Cancer Immunol. Immunother., 57 (2008) 411-
423. 
 [48] A. Romanski, C. Uherek, G. Bug, E. Seifried, H. Klingemann, W. S. Wels, O. 
G. Ottmann, and T. Tonn, CD19-CAR engineered NK-92 cells are sufficient to 
overcome NK cell resistance in B-cell malignancies, J. Cell Mol. Med., 20 
(2016) 1287-1294. 
 [49] G. Gross, T. Waks, and Z. Eshhar, Expression of immunoglobulin-T-cell 
receptor chimeric molecules as functional receptors with antibody-type 
specificity, Proc. Natl. Acad. Sci. U. S. A, 86 (1989) 10024-10028. 
 [50] G. M. Bendle, C. Linnemann, A. I. Hooijkaas, L. Bies, M. A. de Witte, A. 
Jorritsma, A. D. Kaiser, N. Pouw, R. Debets, E. Kieback, W. Uckert, J. Y. Song, 
J. B. Haanen, and T. N. Schumacher, Lethal graft-versus-host disease in mouse 
models of T cell receptor gene therapy, Nat. Med., 16 (2010) 565-70, 1p. 
 [51] D. Abate-Daga and M. L. Davila, CAR models: next-generation CAR 
modifications for enhanced T-cell function, Mol. Ther. Oncolytics., 3 (2016) 
16014. 
 [52] W. Haso, D. W. Lee, N. N. Shah, M. Stetler-Stevenson, C. M. Yuan, I. H. 
Pastan, D. S. Dimitrov, R. A. Morgan, D. J. FitzGerald, D. M. Barrett, A. S. 
Wayne, C. L. Mackall, and R. J. Orentas, Anti-CD22-chimeric antigen receptors 
targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121 (2013) 
1165-1174. 
 [53] H. G. Caruso, L. V. Hurton, A. Najjar, D. Rushworth, S. Ang, S. Olivares, T. 
Mi, K. Switzer, H. Singh, H. Huls, D. A. Lee, A. B. Heimberger, R. E. 
Champlin, and L. J. Cooper, Tuning Sensitivity of CAR to EGFR Density 
Limits Recognition of Normal Tissue While Maintaining Potent Antitumor 
Activity, Cancer Res., 75 (2015) 3505-3518. 
7 References 95 
 [54] R. D. Guest, R. E. Hawkins, N. Kirillova, E. J. Cheadle, J. Arnold, A. O'Neill, J. 
Irlam, K. A. Chester, J. T. Kemshead, D. M. Shaw, M. J. Embleton, P. L. Stern, 
and D. E. Gilham, The role of extracellular spacer regions in the optimal design 
of chimeric immune receptors: evaluation of four different scFvs and antigens, J. 
Immunother., 28 (2005) 203-211. 
 [55] M. Chmielewski, G. Rappl, A. A. Hombach, and H. Abken, T cells redirected by 
a CD3zeta chimeric antigen receptor can establish self-antigen-specific tumour 
protection in the long term, Gene Ther., 20 (2013) 177-186. 
 [56] N. M. Haynes, J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, 
M. H. Kershaw, M. J. Smyth, and P. K. Darcy, Single-chain antigen recognition 
receptors that costimulate potent rejection of established experimental tumors, 
Blood, 100 (2002) 3155-3163. 
 [57] B. Savoldo, C. A. Ramos, E. Liu, M. P. Mims, M. J. Keating, G. Carrum, R. T. 
Kamble, C. M. Bollard, A. P. Gee, Z. Mei, H. Liu, B. Grilley, C. M. Rooney, H. 
E. Heslop, M. K. Brenner, and G. Dotti, CD28 costimulation improves 
expansion and persistence of chimeric antigen receptor-modified T cells in 
lymphoma patients, J. Clin. Invest, 121 (2011) 1822-1826. 
 [58] H. M. Finney, A. N. Akbar, and A. D. Lawson, Activation of resting human 
primary T cells with chimeric receptors: costimulation from CD28, inducible 
costimulator, CD134, and CD137 in series with signals from the TCR zeta 
chain, J. Immunol., 172 (2004) 104-113. 
 [59] A. H. Long, W. M. Haso, J. F. Shern, K. M. Wanhainen, M. Murgai, M. 
Ingaramo, J. P. Smith, A. J. Walker, M. E. Kohler, V. R. Venkateshwara, R. N. 
Kaplan, G. H. Patterson, T. J. Fry, R. J. Orentas, and C. L. Mackall, 4-1BB 
costimulation ameliorates T cell exhaustion induced by tonic signaling of 
chimeric antigen receptors, Nat. Med., 21 (2015) 581-590. 
 [60] A. A. Hombach and H. Abken, Costimulation by chimeric antigen receptors 
revisited the T cell antitumor response benefits from combined CD28-OX40 
signalling, Int. J. Cancer, 129 (2011) 2935-2944. 
 [61] J. H. Park, M. B. Geyer, and R. J. Brentjens, CD19-targeted CAR T-cell 
therapeutics for hematologic malignancies: interpreting clinical outcomes to 
date, Blood, 127 (2016) 3312-3320. 
 [62] E. Sotillo, D. M. Barrett, K. L. Black, A. Bagashev, D. Oldridge, G. Wu, R. 
Sussman, C. Lanauze, M. Ruella, M. R. Gazzara, N. M. Martinez, C. T. 
Harrington, E. Y. Chung, J. Perazzelli, T. J. Hofmann, S. L. Maude, P. Raman, 
A. Barrera, S. Gill, S. F. Lacey, J. J. Melenhorst, D. Allman, E. Jacoby, T. Fry, 
C. Mackall, Y. Barash, K. W. Lynch, J. M. Maris, S. A. Grupp, and A. Thomas-
Tikhonenko, Convergence of Acquired Mutations and Alternative Splicing of 
CD19 Enables Resistance to CART-19 Immunotherapy, Cancer Discov., 5 
(2015) 1282-1295. 
7 References 96 
 [63] D. L. Porter, W. T. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw, A. W. Loren, 
A. Bagg, K. T. Marcucci, A. Shen, V. Gonzalez, D. Ambrose, S. A. Grupp, A. 
Chew, Z. Zheng, M. C. Milone, B. L. Levine, J. J. Melenhorst, and C. H. June, 
Chimeric antigen receptor T cells persist and induce sustained remissions in 
relapsed refractory chronic lymphocytic leukemia, Sci. Transl. Med., 7 (2015) 
303ra139. 
 [64] S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. 
Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, 
S. R. Rheingold, A. Shen, D. T. Teachey, B. L. Levine, C. H. June, D. L. Porter, 
and S. A. Grupp, Chimeric antigen receptor T cells for sustained remissions in 
leukemia, N. Engl. J. Med., 371 (2014) 1507-1517. 
 [65] D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. 
A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, S. M. Steinberg, D. 
Stroncek, N. Tschernia, C. Yuan, H. Zhang, L. Zhang, S. A. Rosenberg, A. S. 
Wayne, and C. L. Mackall, T cells expressing CD19 chimeric antigen receptors 
for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-
escalation trial, Lancet, 385 (2015) 517-528. 
 [66] Y. Guo, Y. Wang, and W. Han, Chimeric Antigen Receptor-Modified T Cells 
for Solid Tumors: Challenges and Prospects, J. Immunol. Res., 2016 (2016) 
3850839. 
 [67] C. U. Louis, B. Savoldo, G. Dotti, M. Pule, E. Yvon, G. D. Myers, C. Rossig, H. 
V. Russell, O. Diouf, E. Liu, H. Liu, M. F. Wu, A. P. Gee, Z. Mei, C. M. 
Rooney, H. E. Heslop, and M. K. Brenner, Antitumor activity and long-term fate 
of chimeric antigen receptor-positive T cells in patients with neuroblastoma, 
Blood, 118 (2011) 6050-6056. 
 [68] J. R. Park, D. L. Digiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B. 
Meechoovet, C. Bautista, W. C. Chang, J. R. Ostberg, and M. C. Jensen, 
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T 
lymphocyte clones in patients with neuroblastoma, Mol. Ther., 15 (2007) 825-
833. 
 [69] C. H. Lamers, S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. 
Gratama, G. Stoter, and E. Oosterwijk, Treatment of metastatic renal cell 
carcinoma with autologous T-lymphocytes genetically retargeted against 
carbonic anhydrase IX: first clinical experience, J. Clin. Oncol., 24 (2006) e20-
e22. 
 [70] L. Coussens, T. L. Yang-Feng, Y. C. Liao, E. Chen, A. Gray, J. McGrath, P. H. 
Seeburg, T. A. Libermann, J. Schlessinger, U. Francke, and ., Tyrosine kinase 
receptor with extensive homology to EGF receptor shares chromosomal location 
with neu oncogene, Science, 230 (1985) 1132-1139. 
7 References 97 
 [71] P. J. Brennan, T. Kumagai, A. Berezov, R. Murali, and M. I. Greene, 
HER2/Neu: mechanisms of dimerization/oligomerization, Oncogene, 21 (2002) 
328. 
 [72] H. A. Lane, I. Beuvink, A. B. Motoyama, J. M. Daly, R. M. Neve, and N. E. 
Hynes, ErbB2 potentiates breast tumor proliferation through modulation of 
p27(Kip1)-Cdk2 complex formation: receptor overexpression does not 
determine growth dependency, Mol. Cell Biol., 20 (2000) 3210-3223. 
 [73] R. M. Neve, H. A. Lane, and N. E. Hynes, The role of overexpressed HER2 in 
transformation, Ann. Oncol., 12 Suppl 1 (2001) S9-13. 
 [74] M. M. Moasser, The oncogene HER2: its signaling and transforming functions 
and its role in human cancer pathogenesis, Oncogene, 26 (2007) 6469-6487. 
 [75] R. Gorlick, A. G. Huvos, G. Heller, A. Aledo, G. P. Beardsley, J. H. Healey, and 
P. A. Meyers, Expression of HER2/erbB-2 correlates with survival in 
osteosarcoma, J. Clin. Oncol., 17 (1999) 2781-2788. 
 [76] V. Koka, A. Potti, S. E. Forseen, H. Pervez, G. N. Fraiman, M. Koch, and R. 
Levitt, Role of Her-2/neu overexpression and clinical determinants of early 
mortality in glioblastoma multiforme, Am. J. Clin. Oncol., 26 (2003) 332-335. 
 [77] C. Gravalos and A. Jimeno, HER2 in gastric cancer: a new prognostic factor and 
a novel therapeutic target, Ann. Oncol., 19 (2008) 1523-1529. 
 [78] T. Kameda, W. Yasui, K. Yoshida, T. Tsujino, H. Nakayama, M. Ito, H. Ito, and 
E. Tahara, Expression of ERBB2 in human gastric carcinomas: relationship 
between p185ERBB2 expression and the gene amplification, Cancer Res., 50 
(1990) 8002-8009. 
 [79] J. Schlegel, G. Stumm, K. Brandle, A. Merdes, G. Mechtersheimer, N. E. Hynes, 
and M. Kiessling, Amplification and differential expression of members of the 
erbB-gene family in human glioblastoma, J. Neurooncol., 22 (1994) 201-207. 
 [80] A. Nassar, A. Khoor, R. Radhakrishnan, A. Radhakrishnan, and C. Cohen, 
Correlation of HER2 overexpression with gene amplification and its relation to 
chromosome 17 aneuploidy: a 5-year experience with invasive ductal and 
lobular carcinomas, Int. J. Clin. Exp. Pathol., 7 (2014) 6254-6261. 
 [81] R. J. Gilbertson, A. D. Pearson, R. H. Perry, E. Jaros, and P. J. Kelly, Prognostic 
significance of the c-erbB-2 oncogene product in childhood medulloblastoma, 
Br. J. Cancer, 71 (1995) 473-477. 
 [82] N. Buza, D. M. Roque, and A. D. Santin, HER2/neu in Endometrial Cancer: A 
Promising Therapeutic Target With Diagnostic Challenges, Arch. Pathol. Lab 
Med., 138 (2014) 343-350. 
7 References 98 
 [83] M. Babashahi, M. Mehrazma, S. J. Nasiri, J. F. Azizi, and M. Rezaei-Tavirani, 
Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic 
Findings, Iran J. Cancer Prev., 6 (2013) 160-164. 
 [84] S. Menard, P. Casalini, M. Campiglio, S. Pupa, R. Agresti, and E. Tagliabue, 
HER2 overexpression in various tumor types, focussing on its relationship to the 
development of invasive breast cancer, Ann. Oncol., 12 Suppl 1 (2001) S15-
S19. 
 [85] T. Takehana, K. Kunitomo, K. Kono, F. Kitahara, H. Iizuka, Y. Matsumoto, M. 
A. Fujino, and A. Ooi, Status of c-erbB-2 in gastric adenocarcinoma: a 
comparative study of immunohistochemistry, fluorescence in situ hybridization 
and enzyme-linked immuno-sorbent assay, Int. J. Cancer, 98 (2002) 833-837. 
 [86] M. Bayrak, O. F. Olmez, E. Kurt, E. Cubukcu, T. Evrensel, O. Kanat, and O. 
Manavoglu, Prognostic significance of c-erbB2 overexpression in patients with 
metastatic gastric cancer, Clin. Transl. Oncol., 15 (2013) 307-312. 
 [87] H. Meden and W. Kuhn, Overexpression of the oncogene c-erbB-2 (HER2/neu) 
in ovarian cancer: a new prognostic factor, Eur. J. Obstet. Gynecol. Reprod. 
Biol., 71 (1997) 173-179. 
 [88] M. F. Press, C. Cordon-Cardo, and D. J. Slamon, Expression of the HER-2/neu 
proto-oncogene in normal human adult and fetal tissues, Oncogene, 5 (1990) 
953-962. 
 [89] J. Baselga and J. Albanell, Mechanism of action of anti-HER2 monoclonal 
antibodies, Ann. Oncol., 12 Suppl 1 (2001) S35-S41. 
 [90] R. D. Mass, M. F. Press, S. Anderson, M. A. Cobleigh, C. L. Vogel, N. Dybdal, 
G. Leiberman, and D. J. Slamon, Evaluation of clinical outcomes according to 
HER2 detection by fluorescence in situ hybridization in women with metastatic 
breast cancer treated with trastuzumab, Clin. Breast Cancer, 6 (2005) 240-246. 
 [91] A. Seidman, C. Hudis, M. K. Pierri, S. Shak, V. Paton, M. Ashby, M. Murphy, 
S. J. Stewart, and D. Keefe, Cardiac dysfunction in the trastuzumab clinical 
trials experience, J. Clin. Oncol., 20 (2002) 1215-1221. 
 [92] Y. J. Bang, C. E. Van, A. Feyereislova, H. C. Chung, L. Shen, A. Sawaki, F. 
Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, 
J. Ruschoff, and Y. K. Kang, Trastuzumab in combination with chemotherapy 
versus chemotherapy alone for treatment of HER2-positive advanced gastric or 
gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised 
controlled trial, Lancet, 376 (2010) 687-697. 
 [93] Y. Park, T. Kitahara, R. Takagi, and R. Kato, Current status of therapy for breast 
cancer worldwide and in Japan, World J. Clin. Oncol., 2 (2011) 125-134. 
 [94] L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. 
Posati, D. Rogaia, F. Frassoni, F. Aversa, M. F. Martelli, and A. Velardi, 
7 References 99 
Effectiveness of donor natural killer cell alloreactivity in mismatched 
hematopoietic transplants, Science, 295 (2002) 2097-2100. 
 [95] K. Schonfeld, C. Sahm, C. Zhang, S. Naundorf, C. Brendel, M. Odendahl, P. 
Nowakowska, H. Bonig, U. Kohl, S. Kloess, S. Kohler, H. Holtgreve-Grez, A. 
Jauch, M. Schmidt, R. Schubert, K. Kuhlcke, E. Seifried, H. G. Klingemann, M. 
A. Rieger, T. Tonn, M. Grez, and W. S. Wels, Selective inhibition of tumor 
growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen 
receptor, Mol. Ther., 23 (2015) 330-338. 
 [96] C. Zhang, M. C. Burger, L. Jennewein, S. Genssler, K. Schonfeld, P. Zeiner, E. 
Hattingen, P. N. Harter, M. Mittelbronn, T. Tonn, J. P. Steinbach, and W. S. 
Wels, ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma, J. 
Natl. Cancer Inst., 108 (2016). 
 [97] C. Vitale, L. Chiossone, C. Cantoni, G. Morreale, F. Cottalasso, S. Moretti, A. 
Pistorio, R. Haupt, E. Lanino, G. Dini, L. Moretta, and M. C. Mingari, The 
corticosteroid-induced inhibitory effect on NK cell function reflects down-
regulation and/or dysfunction of triggering receptors involved in natural 
cytotoxicity, Eur. J. Immunol., 34 (2004) 3028-3038. 
 [98] C. H. June, M. V. Maus, G. Plesa, L. A. Johnson, Y. Zhao, B. L. Levine, S. A. 
Grupp, and D. L. Porter, Engineered T cells for cancer therapy, Cancer 
Immunol. Immunother., 63 (2014) 969-975. 
 [99] J. E. Wooldridge, C. M. Anderson, and M. C. Perry, Corticosteroids in advanced 
cancer, Oncology (Williston. Park), 15 (2001) 225-234. 
 [100] Y. K. Tam, J. A. Martinson, K. Doligosa, and H. G. Klingemann, Ex vivo 
expansion of the highly cytotoxic human natural killer-92 cell-line under current 
good manufacturing practice conditions for clinical adoptive cellular 
immunotherapy, Cytotherapy., 5 (2003) 259-272. 
 [101] J. H. Gong, G. Maki, and H. G. Klingemann, Characterization of a human cell 
line (NK-92) with phenotypical and functional characteristics of activated 
natural killer cells, Leukemia, 8 (1994) 652-658. 
 [102] U. Kalina, D. Kauschat, N. Koyama, H. Nuernberger, K. Ballas, S. 
Koschmieder, G. Bug, W. K. Hofmann, D. Hoelzer, and O. G. Ottmann, IL-18 
activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, 
and mediates IFN-gamma production by the stress kinase p38 and by the 
extracellular regulated kinases p44erk-1 and p42erk-21, J. Immunol., 165 (2000) 
1307-1313. 
 [103] K. Bieback, Platelet lysate as replacement for fetal bovine serum in 
mesenchymal stromal cell cultures, Transfus. Med. Hemother., 40 (2013) 326-
335. 
7 References 100 
 [104] A. Ruggiu, V. Ulivi, F. Sanguineti, R. Cancedda, and F. Descalzi, The effect of 
Platelet Lysate on osteoblast proliferation associated with a transient increase of 
the inflammatory response in bone regeneration, Biomaterials, 34 (2013) 9318-
9330. 
 [105] B. Yang, H. Liu, W. Shi, Z. Wang, S. Sun, G. Zhang, Y. Hu, T. Liu, and S. Jiao, 
Blocking transforming growth factor-beta signaling pathway augments 
antitumor effect of adoptive NK-92 cell therapy, Int. Immunopharmacol., 17 
(2013) 198-204. 
 [106] R. Castriconi, C. Cantoni, C. M. Della, M. Vitale, E. Marcenaro, R. Conte, R. 
Biassoni, C. Bottino, L. Moretta, and A. Moretta, Transforming growth factor 
beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for 
the NK-mediated killing of dendritic cells, Proc. Natl. Acad. Sci. U. S. A, 100 
(2003) 4120-4125. 
 [107] N. Fekete, M. Gadelorge, D. Furst, C. Maurer, J. Dausend, S. Fleury-
Cappellesso, V. Mailander, R. Lotfi, A. Ignatius, L. Sensebe, P. Bourin, H. 
Schrezenmeier, and M. T. Rojewski, Platelet lysate from whole blood-derived 
pooled platelet concentrates and apheresis-derived platelet concentrates for the 
isolation and expansion of human bone marrow mesenchymal stromal cells: 
production process, content and identification of active components, 
Cytotherapy., 14 (2012) 540-554. 
 [108] S. Bork, S. Pfister, H. Witt, P. Horn, B. Korn, A. D. Ho, and W. Wagner, DNA 
methylation pattern changes upon long-term culture and aging of human 
mesenchymal stromal cells, Aging Cell, 9 (2010) 54-63. 
 [109] N. Lapteva, A. G. Durett, J. Sun, L. A. Rollins, L. L. Huye, J. Fang, V. 
Dandekar, Z. Mei, K. Jackson, J. Vera, J. Ando, M. C. Ngo, E. Coustan-Smith, 
D. Campana, S. Szmania, T. Garg, A. Moreno-Bost, F. Vanrhee, A. P. Gee, and 
C. M. Rooney, Large-scale ex vivo expansion and characterization of natural 
killer cells for clinical applications, Cytotherapy., 14 (2012) 1131-1143. 
 [110] R. W. Childs and M. Berg, Bringing natural killer cells to the clinic: ex vivo 
manipulation, Hematology. Am. Soc. Hematol. Educ. Program., 2013 (2013) 
234-246. 
 [111] G. Suck and M. B. Koh, Emerging natural killer cell immunotherapies: large-
scale ex vivo production of highly potent anticancer effectors, Hematol. Oncol. 
Stem Cell Ther., 3 (2010) 135-142. 
 [112] V. G. Da, N. Zerrouk, I. Richard, G. Provot, J. C. Chaumeil, and P. Arnaud, 
Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on 
Caco2/TC7 colon tumor cell cultures, Biol. Pharm. Bull., 25 (2002) 1600-1603. 
 [113] E. J. Woods, S. Thirumala, S. S. Badhe-Buchanan, D. Clarke, and A. J. Mathew, 
Off the shelf cellular therapeutics: Factors to consider during cryopreservation 
and storage of human cells for clinical use, Cytotherapy., 18 (2016) 697-711. 
7 References 101 
 [114] F. Pasi, A. Facoetti, and R. Nano, IL-8 and IL-6 bystander signalling in human 
glioblastoma cells exposed to gamma radiation, Anticancer Res., 30 (2010) 
2769-2772. 
 [115] R. O. Dillman, C. M. Duma, P. M. Schiltz, C. DePriest, R. A. Ellis, K. Okamoto, 
L. D. Beutel, L. C. de, and S. Chico, Intracavitary placement of autologous 
lymphokine-activated killer (LAK) cells after resection of recurrent 
glioblastoma, J. Immunother., 27 (2004) 398-404. 
 [116] K. B. Quattrocchi, C. H. Miller, S. Cush, S. A. Bernard, S. T. Dull, M. Smith, S. 
Gudeman, and M. A. Varia, Pilot study of local autologous tumor infiltrating 
lymphocytes for the treatment of recurrent malignant gliomas, J. Neurooncol., 
45 (1999) 141-157. 
 [117] J. Dietrich, K. Rao, S. Pastorino, and S. Kesari, Corticosteroids in brain cancer 
patients: benefits and pitfalls, Expert. Rev. Clin. Pharmacol., 4 (2011) 233-242. 
 [118] D. M. Callewaert, V. K. Moudgil, G. Radcliff, and R. Waite, Hormone specific 
regulation of natural killer cells by cortisol. Direct inactivation of the cytotoxic 
function of cloned human NK cells without an effect on cellular proliferation, 
FEBS Lett., 285 (1991) 108-110. 
 [119] M. P. Nair and S. A. Schwartz, Immunomodulatory effects of corticosteroids on 
natural killer and antibody-dependent cellular cytotoxic activities of human 
lymphocytes, J. Immunol., 132 (1984) 2876-2882. 
 [120] S. Pesce, G. Tabellini, C. Cantoni, O. Patrizi, D. Coltrini, F. Rampinelli, J. 
Matta, E. Vivier, A. Moretta, S. Parolini, and E. Marcenaro, B7-H6-mediated 
downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune 
escape, Oncoimmunology., 4 (2015) e1001224. 
 [121] E. S. Doubrovina, M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. 
Dupont, and Y. M. Vyas, Evasion from NK cell immunity by MHC class I 
chain-related molecules expressing colon adenocarcinoma, J. Immunol., 171 
(2003) 6891-6899. 
 [122] V. Groh, J. Wu, C. Yee, and T. Spies, Tumour-derived soluble MIC ligands 
impair expression of NKG2D and T-cell activation, Nature, 419 (2002) 734-738. 
 [123] H. R. Salih, H. G. Rammensee, and A. Steinle, Cutting edge: down-regulation of 
MICA on human tumors by proteolytic shedding, J. Immunol., 169 (2002) 4098-
4102. 
 [124] D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. 
Grupp, and C. L. Mackall, Current concepts in the diagnosis and management of 
cytokine release syndrome, Blood, 124 (2014) 188-195. 
 [125] D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. 
A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, S. M. Steinberg, D. 
Stroncek, N. Tschernia, C. Yuan, H. Zhang, L. Zhang, S. A. Rosenberg, A. S. 
7 References 102 
Wayne, and C. L. Mackall, T cells expressing CD19 chimeric antigen receptors 
for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-
escalation trial, Lancet, 385 (2015) 517-528. 
 [126] M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. 
June, T cells with chimeric antigen receptors have potent antitumor effects and 
can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3 
(2011) 95ra73. 
 [127] P. Kalinski, A. Giermasz, Y. Nakamura, P. Basse, W. J. Storkus, J. M. 
Kirkwood, and R. B. Mailliard, Helper role of NK cells during the induction of 
anticancer responses by dendritic cells, Mol. Immunol., 42 (2005) 535-539. 
 [128] P. Kalinski, R. B. Mailliard, A. Giermasz, H. J. Zeh, P. Basse, D. L. Bartlett, J. 
M. Kirkwood, M. T. Lotze, and R. B. Herberman, Natural killer-dendritic cell 
cross-talk in cancer immunotherapy, Expert. Opin. Biol. Ther., 5 (2005) 1303-
1315. 
 [129] L. H. Pai-Scherf, J. Villa, D. Pearson, T. Watson, E. Liu, M. C. Willingham, and 
I. Pastan, Hepatotoxicity in cancer patients receiving erb-38, a recombinant 
immunotoxin that targets the erbB2 receptor, Clin. Cancer Res., 5 (1999) 2311-
2315. 
 [130] M. G. von, S. Harder, S. Hovelmann, E. Jager, S. E. Al-Batran, S. Loibl, A. 
Atmaca, C. Cimpoiasu, A. Neumann, A. Abera, A. Knuth, M. Kaufmann, D. 
Jager, A. B. Maurer, and W. S. Wels, Phase I clinical study of the recombinant 
antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in 
patients with advanced solid malignomas, Breast Cancer Res., 7 (2005) R617-
R626. 
 [131] N. Ahmed, V. S. Brawley, M. Hegde, C. Robertson, A. Ghazi, C. Gerken, E. 
Liu, O. Dakhova, A. Ashoori, A. Corder, T. Gray, M. F. Wu, H. Liu, J. Hicks, 
N. Rainusso, G. Dotti, Z. Mei, B. Grilley, A. Gee, C. M. Rooney, M. K. 
Brenner, H. E. Heslop, W. S. Wels, L. L. Wang, P. Anderson, and S. Gottschalk, 
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric 
Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive 
Sarcoma, J. Clin. Oncol., 33 (2015) 1688-1696. 
 [132] C. Ceran, M. Cokol, S. Cingoz, I. Tasan, M. Ozturk, and T. Yagci, Novel anti-
HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis 
factor-alpha, BMC. Cancer, 12 (2012) 450. 
 [133] L. J. Levitt, A. Nagler, F. Lee, J. Abrams, M. Shatsky, and D. Thompson, 
Production of granulocyte/macrophage-colony-stimulating factor by human 
natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor 
and by the CD2 receptor, J. Clin. Invest, 88 (1991) 67-75. 
7 References 103 
 [134] A. R. Migliaccio, M. Bruno, and G. Migliaccio, Evidence for direct action of 
human biosynthetic (recombinant) GM-CSF on erythroid progenitors in serum-
free culture, Blood, 70 (1987) 1867-1871. 
 
8 Acknowledgements 104 
 
8 Acknowledgements 
I would like to express my special appreciation and thanks to my advisor and mentor 
Prof. Dr. Torsten Tonn who found a place for me in his research group and gave me the 
opportunity to accomplish my PhD on such an important and interesting project.  
Besides my advisor, I would like to thank the rest of my research group, especially 
Dr. Marcus Odendahl and Dr. Annette Romanski for their advice, experience and 
support. 
I would like to thank Prof. Dr. Beatrix Süß for accepting me as an external student at the 
University of Darmstadt and for her effort and kindness. I also would like to thank 
Prof. Dr. Adam Bertl for his effort of being my second supervisor and referee of my 
thesis. 
A special thanks to Prof. Dr. Halvard Bönig for valuable suggestions and comments on 
my manuscript and thesis and for his willingness to help. 
My sincere thanks also go to Dr. Eliza Wiercinska and Dr. Patricia Quade-Lyssy, for the 
years of their priceless friendship, for the brilliant scientific discussions, all the 
invaluable advices and hints and all enjoyable moments also outside of work. 
I also want to thank my fellow labmates for the fantastic, family atmosphere and great 
support especially in the beginning of my work. A special thanks to Dr. Peter Milanov 
for introducing me into the secrets of molecular biology and for all the fun we had 
together during long, busy evenings. 
I would also like to thank my beloved boyfriend Radoslaw Suchocki for supporting me 
spiritually throughout the entire period of my studies and PhD.  
Lastly, and most importantly, I wish to thank my parents, Renata Nowakowska and 
Sylwester Nowakowski, who raised me, supported me and never doubted me. 
To them I dedicate this thesis. 
9 Word of honor 105 
 
9 Word of honor 
 
 
 
I assure herewith on my word of honor, that I wrote this thesis by myself. All quotes, 
whether word by word, or in my own words, have been put in quotation marks or 
otherwise identified as such. The thesis has not been published anywhere else or has 
been presented to any other examination board. 
 
Darmstadt, …………………….. 
 
     
 _________________________________ 
      (signature) 
 
 
 
 
 
 
 
10 Curriculum Vitae 106 
 
10 Curriculum Vitae 
Name:   Paulina Nowakowska 
Date and birthplace: 26.03.1987 in Malbork 
Nationality:  Polish 
 
Education 
09/2003 – 06/2006 High School No. II, Elblag Poland (Class with medical profile) 
Degree: High school graduation 
10/2006 – 04/2011 Studies on Medical University of Gdansk, 
Faculty of Pharmacy, Specialization-Laboratory Medicine 
10/2010 – 04/2011 Master thesis at the Department of Immunology of the Medical 
University of Gdansk (Head of research group: Prof. Dr. hab. 
med. Jolanta Mysliwska). „CD4+Foxp3+ regulatory T cells 
versus Th17 cells in type 1 diabetes“ 
   Degree: Master of Science in Medical Analysis 
since 09/2011 PhD Student at the German Red Cross Blood donor Service 
BaWü-Hessen, Institute of Transfusion Medicine and 
Immunohematology of the Goethe University Clinics, Frankfurt 
am Main (Head of Research group: Prof. Dr. med. Torsten Tonn)  
Scholarship 
07/2010 – 09/2010 The Erasmus International Traineeship, funded by Erasmus 
program in the Scientific Laboratory at the Department of 
Paediatric Cardiology, Cardiac Centre GmbH, University of 
Leipzig, Germany
11 Publications and congress contributions 107 
11 Publications and congress contributions 
11.1 Publications 
Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, Seifried E, 
Wels WS, Tonn T. Clinical grade manufacturing of genetically modified, CAR-
expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer 
Immunol.Immunother. (submitted) 
Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C. 
Selection and expansion of natural killer cells for NK cell-based immunotherapy. 
Cancer Immunol.Immunother.2016; DOI: 10.1007/s00262-016-1792-y 
Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. 
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer 
immunotherapy. Cancer Immunol.Immunother.2016; DOI: 10.1007/s00262-015-1761-
x. 
Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, 
Bonig H, Kohl U, Kloess S, Kohler S, Holtgreve-Grez H, Jauch A, Schmidt M, 
Schubert R, Kuhlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, 
Wels WS. Selective inhibition of tumor growth by clonal NK cells expressing an 
ErbB2/HER2-specific chimeric antigen receptor. Mol.Ther.2015; DOI: 
10.1038/mt.2014.219. 
 
 
 
11 Publications and congress contributions 108 
11.2 Congress contributions 
11.2.1 Oral presentation 
Nowakowska P, Odendahl M, Schonfeld K, Zhang C, Bonig H, Becker P, Grez M, 
Naundorf S, Seifried E, Wels WS, Tonn T. 2015. GMP-Process optimization to allow 
the clinical scale expansion of genetically modified, ErbB2-specific CAR expressing 
"off the shelf" natural killer (NK-92) cells. 48th Annual Meeting of Deutsche 
Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI), Basel, 
Switzerland 
11.2.2 Poster 
Nowakowska P, Odendahl M, Bonig H, Schonfeld K, Zhang C, Naundorf S, Becker P,  
Seifried E, Grez M, Wels WS, Tonn T. 2015. Optimization and validation of processes 
related to the GMP compliant manufacture of genetically modified CAR expressing 
NK-92 cells. 21st Annual Meeting of International Society for Cellular Therapy, Las 
Vegas, United States of America  
Nowakowska P, Odendahl M, Schonfeld K, Zhang C, Bonig H, Grez M, Naundorf S, 
Seifried E, Wels WS, Tonn T. 2014. Generation and qualification of a GMP compliant 
master cell stock of CAR expressing ErbB2-specific NK-92 cells for clinical trials. 47th 
Annual Meeting of Deutsche Gesellschaft für Transfusionsmedizin und 
Immunhämatologie (DGTI), Dresden, Germany 
Nowakowska P, Odendahl M, Bonig H, Wels WS, Seifried E, Tonn T. 2014. 
Establishment of GMP compliant process for the expansion of therapeutic doses of 
genetically modified NK-92 cells. 12th Annual Meeting of The Association for Cancer 
Immunotherapy, Mainz, Germany 
Nowakowska P, Odendahl M, Bonig H, Wels WS, Seifried E, Tonn T. 2014. 
Generation and qualification of a GMP compliant master cell stock of CAR expressing 
ErbB2-specific NK-92 cells for clinical trials. 20th Annual Meeting of International 
Society for Cellular Therapy, Paris, France  
 
